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Malignant gliomas represent a difficult therapeutic challenge due to the invasive nature of 
the tumor and limited tumoral delivery of therapeutic agents. Novel delivery systems 
capable of intracellular delivery, tumor targeting by specific interactions with tumor cells 
and permeable to blood brain barrier are highly desirable for improved gliomas therapies. 
Sulfatides, the sulfated derivates of galactosylceramide, are of the most abundant lipids in 
the central nervous system (CNS). Sulfatides are involved in a variety of biological 
processes such as cell adhesion, platelet aggregation, cell growth, protein trafficking, 
signal transduction, neuronal plasticity, cell morphogenesis and disease pathogenesis. 
More interestingly, sulfatides were found to interact with several extracellular matrix 
(ECM) glycoproteins including specially tenascin-c (TN-C). The over expression of TN-
C is related to the invasiveness of the gliomas and therefore serves as potential receptor 
for targeted anticancer drug or gene delivery. In this study, based on the specific 
interactions between sulfatides and TN-C, we aim to design a novel nano-sized sulfatides 
–containing-liposomes (SCLs) as a glioma targeting delivery system.   
Firstly, the molecular basis of SCLs-Gliomas interactions was investigated. 
Measurements of gliomas cell uptake of liposomes with different formulations showed 
that liposomes composed of sulfatides could effectively been taken up by the glioma cells 
compared to liposomes composed with DOPG, galactosylceramides or GM1. The uptake 
of sulfatides containing liposomes was affected by the molar ratio of the sulfatides in the 
liposomes. Perturbations by anti-sulfatides monoclonal antibodies and incorporations of 
PEG-DSPE on the liposome surface attenuated the SCLs uptake by gliomas cells, 
 x
suggesting that the sulfatides on the SCLs play a major role in liposome-gliomas cells 
interactions. Down regulation of TN-C which is overexpressed in cells by either chemical 
treatment or siRNA silencing, greatly attenuated the SCLs-glioma cell interaction 
resulted in reduced uptake of SCLs by the glioma cells. These results suggested that 
SCLs bind to the glioma cells by the specific recognition and interactions of sulfatides to 
the tenascins-C. 
Secondly, the mechanism of intracellular delivery of SCLs was studied. SCLs were found 
to be effectively internalized by glioma cells comparing with liposome composed with 
other formulations. Pre-treatment of the glioma cells with cytochalasin D (10 mg/ml) had 
no effect on the internalization of the sulfatides-containing liposomes, suggesting that 
macropinocytosis is unlikely to play a major role in uptake of the liposomes.  Cholesterol 
depletions and phosphatidylinositol-specific phospholipase C (PI-PLC) pretreatment 
caused 75% and 30% reduction in the uptake of the SCLs in gliomas suggested the 
caveolae/lipid rafts endocytosis involved in the SCLs internalizations. Sucrose and 
sphingosine pretreatments resulted in ~60% reduction in the SCLs uptake, suggesting 
SCLs could internalize the glioma cells via clathrin-dependent endocytosis. This was 
further confirmed by the overexpression of a dominant-negative Hub fragment of clathrin 
which inhibits coated pit formation in the glioma cells. It was clear that SCLs were 
internalized in the gliomas cells by both clathrin-dependent and caveolae/lipids rafts 
pathways.  
In the second part of this study, doxorubicin (DOX), a widely used antitumor drug, was 
adopted for the study of the efficacy of SCLs as a glioma targeted delivery system. DOX 
 xi
was effectively loaded into the SCLs to form a liposomal drug, SCL-DOX. The 
intracellular delivery of SCL-DOX was studied. SCL-DOX could effectively accumulate 
in the nuclei of glioma cells with a different pattern compared to those of free drug. The 
in vitro cytotoxicity studies showed that SCL-DOX is clearly superior (~6-fold drop in 
IC50) to that of DOX encapsulated in liposome formulation of (PEG-DSPE/Sulf/DOPE). 
In the subcutaneous xenografts animal model, SCL-DOX could effectively inhibit tumor 
growth and increase the mean life span by 33% compared to control groups (as  show by 
Kaplan-Meier survival analysis)  
In the last part of this study, an orthotopic tumor xenograft animal model was established. 
The compromised blood brain barrier (BBB) of tumor bearing animals enables the 
delivery of liposomes with a smaller size distribution. SCLs were found to effectively 
accumulate in the brain tumor compared to other liposome formulations without 
sulfatides in the composition. SCLs accumulated in the brain tumor site in a time- 
dependent manner, and exhibited a fast accumulation and diffusion followed by a slow 
dissipation. The diffusion of SCLs in the whole volume of the tumor after the first burst 
accumulation suggests the strong interactions of the SCLs-glioma had overcome the high 
interstitial fluid pressure. The colocalization of SCLs and TN-C immunostaining suggest 
the interactions between sulfatides and TN-C might play important roles in the diffusion 
and retention of SCLs in the tumor. 
 
We described here a novel nano size liposomal carrier system which the targeting to 
gliomas. The specific sulfatides-tenascin-C interactions enabled the targeting of SCLs to 
glioma. The effective intracellular delivery of the SCLs results in high antitumnor 
 xii
efficacy in both cell and animal models. The BBB permeability and the retention in the 
tumor volume suggest that SCLs is a promising brain delivery, glioma targeting novel 
carrier system. Since TN-C expression was highly up-regulated in many tumors,  SCLs 
may also be a useful ligand-targeted drug carriers for a wide spectrum of cancers in 
which sulfatide-binding ECM glycoproteins are expressed. 
 xiii
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Chapter 1 Introduction 
1.1. Briefing 
In this chapter, background information of this study such as glioma, the obstacles 
limiting glioma therapy, liposomes and the application of  liposomes as drug delivery 
systems to treat cancers, sulfatides and the applications of liposomes of sulfatides as 
carriers will be described and discussed. The objectives of our study would then be 
outlined. 
 
1.2. Glioma and its therapy 
1.2.1. Glioma and its classifications 
Gliomas are the commonest form (around 78%) of primary brain tumors in man 
(Sathornsumetee 2007). Malignant gliomas are histologically heterogeneous and could be 
divided into different subtypes according to their phenotype including astrocytomas, 
oligodendrogliomas, ependymomas and gangliogliomas. 
The astrocytomas are the most common form (more than 70%) of gliomas which are 
malignancy graded by the World Health Organization (WHO) from malignancy grade I 
(the least biologically aggressive) to grade IV (the most malignant). Some tumor types 
have only one grade, but others up to four (Kleihues 2000). The pilocytic astrocytomas 
(malignancy grade I) are the least malignant, occur mainly in children, only very rarely 
progress to more malignant tumors and have generally a good prognosis. The adult 
diffuse astrocytomas include the astrocytomas (malignancy grade II), the anaplastic 
astrocytomas (malignancy grade III) and the glioblastomas (malignancy grade IV). The 
average survival time of patients with an astrocytoma (malignancy grade II) is around 7 
 2
        
years (McCormack 1992), while patients with anaplastic astrocytomas have a median 
survival half that time (Winger 1989). Glioblastoma patients have a very poor prognosis 
with average survival reported between 9 and 11 months (Simpson 1993). 
Glioblastomas account for approximately 60 to 70% of malignant gliomas, anaplastic 
astrocytomas for 10 to 15%, and anaplastic oligodendrogliomas and anaplastic 
oligoastrocytomas for 10%. Less common tumors such as anaplastic ependymomas and 
anaplastic gangliogliomas account for the rest (CBTRUS report 2007). 
The cellular origins of malignant gliomas remain enigmatic. It was postulated that the 
gliomas cells arise from differential glia cell. There is increasing evidence that neural 
stem cells, or related progenitor cells, can be transformed into cancer stem cells and give 
rise to malignant gliomas (Lee 2007). 
Recently, there has been important progress in the understanding of the molecular 
pathogenesis of malignant gliomas (Wen 2008). Malignant transformation in gliomas 
results from the sequential accumulation of genetic aberrations and the deregulation of 
growth-factor signaling pathways (Furnari 2007).  
Malignant gliomas exhibit characteristics common to other cancers (Lious 2006). There 
are six aspects of alterations in cell physiology that collectively dictate the malignant 
growth of cancer cells: self-sufficiency in growth signals, insensitivity to growth-
inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis (Hanahan 2000).  
 
 3
        
1.2.2. Therapeutic strategies for malignant gliomas 
Conventional therapy frequently uses surgery to resect the tumor mass, followed by 
radiation and chemotherapy to eliminate residual tumor. Recent elucidation of molecular 
abnormalities underlying glioma pathogenesis has led to several novel therapeutic 
approaches, which include molecularly targeted therapy, immunotherapy, and gene 
therapy.  
In general, malignant gliomas represent a uniquely difficult therapeutic challenge 
compare to other cancers. Firstly, the blood brain barrier (BBB) limits most of the 
effective anti-cancer agents to reach the tumor. Secondly, the infiltrative nature of the 
malignant glioma precludes performance of a true total resection. Cell-cycle kinetic 
studies have shown that the glioma cells that migrate into the normal brain around the 
tumor are the most viable and have the highest capacity for proliferation (Tannock 1968, 
Baredsen 1969). For this reason, the tumors tend to recur after surgery or local radiation 
(Muller 1985, Kornblith 1988). 
 
1.3. Physiological barriers limiting the intracellular delivery of therapeutic agents to 
glioma cells 
One of the challenges for glioma therapy is the limited tumor delivery of therapeutic 
agents. The effective delivery of therapeutic agents to glioma cells is hindered by several 
factors such as: limited circulation and concentrations and poor drug retention, resulting 
from washout in hyperpermeable areas of tumor or from P-glycoprotein (Pgp)-mediated 
drug efflux across the blood-brain barrier, poor penetration of tumors and effective 
transcytosis. Dose escalation to overcome suboptimal pharmacokinetics and disposition is 
 4
        
usually not feasible because of drug toxicity. The factors affecting effective delivery at 
the glioma tumor sites are listed in the table 1.1. 
1. Concentration of therapeutic agents in the bloodstream 
2. Degree of protein and tissue binding 
3. Amount of therapeutic agents able to cross the blood brain barrier (BBB) 
4. Diffusion of therapeutic agents across the brain parenchyma 
5. Amount of free, unbound therapeutic agents crossing the tumor cell 
membrane (if the therapeutic agents need to take effect inside the cells) 
 
Table 1.1. Factors affecting the effective delivery of therapeutic agents to 
gliomas.  
 
1.3.1. Blood brain barrier (BBB)  
All systemically administered therapeutic agents must cross the capillary endothelial cells 
of the cerebral vasculature to gain access to tumor cells in the brain. This single layer of 
specialized vascular endothelial cells is known as the blood brain barrier (BBB). The 
blood brain barrier functions to maintain a precise neuronal environment by limiting the 
entry of molecules into the brain parenchyma. The endothelial cells comprising the BBB 
differ from other endothelial cells in that they have extended tight junctions, lack 
fenestrations and pinocytotic vesicles, and express specific transport mediators (Rapoport 
1986). The passage of substances across the BBB depends on their size, lipid solubility, 
and ionization state (Frenstermacher 1969). Most hydrophilic substances and large 
lipophilic substances (which include many chemotherapeutic compounds) are restricted 
 5
        
from entering the central nervous system (CNS). Smaller (< 180 MW [daltons]) 
lipophilic compounds are able to pass through the BBB, penetrating the lipid membranes 
by simple passive diffusion. Since the 1960s, only three drugs—temozolomide, BCNU, 
and CCNU—have been approved by the Food and Drug Administration (FDA) for 
specific use in brain tumor patients in the United States. 
Several different methods have been developed in attempts to circumvent the BBB 
limitation.  Firstly, BBB disruption by the hyperosmotic effects of mannitol has been 
studied in C6 glioma rats’ model (Inoue 1987). Secondly, chemical modifications could 
also increase the permeability of BBB. Bradykinin and bradykinin analogue (RMP-7) 
infusion were able to increase the permeability of BBB (Inamura et al 1994a; Inamura et 
al 1994b). The increased permeability by bradykinin and RMP-7 was mediated through 
bradykinin β2 receptors and dependent on nitric oxide synthase (NOS) (Elliott 1996). The 
third strategy is to make use of transporters across the vascular endothelial cells. 
Therapeutic agents linked to monoclonal antibodies against transferrin receptor (Zhang 
2005), insulin receptor (Boado 2007) or peptide interacting with low-density lipoprotein 
receptor-related protein-1 (Demeule 2008) could cross the BBB effectively. In addition, 
direct drug administration into and around the brain tumors were adopted in many studies 
which are often called convection-enhanced delivery (CED). Novel CED systems under 
investigations include the placement of drug-loaded wafers around a tumor resection bed, 
infusion of agents into or around a tumor resection cavity, or direct infusion of drugs into 
the tumor mass. 
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1.3.2 Interstitial fluid pressure 
Interstitial fluid pressure (IFP) was first described in a study of neoplastic tissue in rabbits 
(Young 1950). Boucher et al. (Boucher 1990) showed that IFP was increased in 
intracranial tumors in both patients and experimental rat tumor models. It is now 
recognized that most solid tumors have increased IFP (Heldin 2004).  
In the normal brain, the blood brain barrier solutes cross the BBB by passive diffusion. 
Because there is no lymphatic system in the brain, the extrachoroidal production of 
extracellular fluid removes excess interstitial fluid by diffusion in gray matter and bulk 
flow in white matter. Consequently, the IFP is close to 0 mmHg in normal brain tissue at 
steady state (Rosenberg 1980). In brain tumors, the mechanisms responsible for increased 
tumor IFP are not fully understood, but increased vascular permeability, coupled with 
high resistance to fluid flow in the distorted interstitial space of the surrounding gray and 
white matter is believed to be the main cause of increased IFP. In addition, although IFP 
is elevated, it is not uniform throughout a tumor (Boucher 1990). It is elevated at the 
center of a tumor and drops abruptly in the tumor periphery or in the surrounding normal 
tissue. The consequent pressure gradient drives interstitial fluid into the surrounding 
normal brain tissue, causing peritumoral edema (Baxter 1989). Based on solute 
distribution patterns, there is also marked heterogeneity of IFP within individual tumors 
(Vavra 2004). 
Increased IFP in brain tumors could be partially responsible for the poor delivery (besides 
BBB permeability) and distribution of both systemically administered and directly 
infused chemotherapeutic drugs to tumor sites (CED).   
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1.3.3 The plasma membrane of tumor cells inhibits the uptake of therapeutic agents 
The cell’s plasma membrane serves as barrier to prevent big molecules, such as peptides, 
proteins, and DNA, from spontaneously entering cells. Therapeutic agents, including 
various large molecules (proteins, enzymes, antibodies, plasmids) need to be delivered 
intracellularly to exert their therapeutic action. In certain circumstances, the therapeutic 
agents can be taken into cells by receptor-mediated endocytosis. The receptor-mediated 
endocytosis of therapeutic agents includes clathrin pit coated-dependent, caveolae and 
lipids rafts pathways. Depending on the mode of endocytosis; contents are transported to 
early endosomes or trafficked to organelles which include the lysosomes, Golgi, and 
mitochondria. Depending on their mode of action, most of the drugs need to exit the 
organelles to exert their pharmacological functions. 
The effective intracellular delivery of therapeutic agents requires overcome at least the 
above mentioned physiological barriers (schematically illustrated in Fig.1.1). 
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Fig.1.1 The physiological barriers limited effective intracellular delivery of 
therapeutic reagents to glioma cells. Systemically injected therapeutic agents (dark red 
dots) need to extravasate the blood vessels (in brain tumor, the blood brain barrier); and 
overcome the interstitial fluid pressure in the tumor volume. Finally, they need to pass 
through the plasma membrane before they could reach in the specific subcellular 
organelles or cytoplasm.  
        
1.3.3.1. Clathrin-coated pit dependent endocytosis pathways 
The major route for endocytosis in most cells, and the best-understood, is that mediated 
by the coat protein clathrin. This large protein assists in the formation of a coated pit on 
the inner surface of the plasma membrane of the cell. Coated pits cover 1–2% of the 
plasma membrane surface area (Brown 1999). In most cells, clathrin-coated pits (CCPs) 
dependent endocytosis serves as the main mechanism of internalization for different 
plasma membrane proteins and/or receptors and their ligands, including iron-containing 
particles (Bessis 1957), immunoglobulin G (Rodewald 1973), low-density lipoproteins 
[LDL; (Anderson 1978)], epidermal growth factor [EGF;(Gorden 1973)] and transferrin 
[Tf; (Hopkins 1983)].  
In CCP-dependent endocytosis, clathrin aids in vesicle formation. Assembly proteins, 
such as adaptins, dynamin, and numerous rab proteins, facilitate the binding, 
internalization, and post-internalization trafficking of vesicles. Adaptin acts to bind cell 
surface receptors on the extracellular face as well as binding clathrin heavy chains on the 
cytosolic side to allow for polymerization of clathrin subunits forming a polyhedral 
lattice scaffold. Proteins including amphiphysin and endophilin bring the surrounding 
membrane into close proximity. Following this, dynamin, a cystolic small GTPase, 
assembles around the neck of the budding vesicle and causes scission and intracellular 
release. Next, the vesicles fuse with early or sorting endosomes. At this stage, the 
intravesicular contents will either recycle back to the plasma membrane from sorting 
endosomes, or continue along the endolysosomal pathway for degradation in the 
lysosomes.  
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1.3.3.2. Lipid domains: lipid rafts and caveolae 
Lipid domains, which include caveolae and rafts, are high in cholesterol and 
sphingolipids, have a light buoyant density, and function in both endocytosis and cell 
signaling. Lipid domains were first detected in human and hamster fibroblasts as a 
detergent-insoluble glycoprotein matrix (Cater 1981) rich in glycosphingolipids (Okada 
1984). All of these membranes are detergent insoluble, rich in sphingomyelin and 
glycosphingolipids, and appear to contain similar molecules. Their function also depends 
on cholesterol (Rothberg 1990). 
The caveolae is a lipid domain that was first described more than 50 years ago as a 
membrane invagination on the surface of gallbladder epithelial cells (Yamada 1955) and 
endothelial cells (Palade 1953). Their unique physical features can include a distinctive 
membrane coat composed of caveolin-1 (Rothberg 1992), an absence of intramembrane 
particles in freeze fracture images, cholesterol concentrated around the rim of the domain 
(Montesano 1979), and a flask-shaped, invaginated morphology during internalization. 
The lower size limit appears to be the diameter of a flask-shaped caveolae (50 to 80 nm), 
while the upper limit is more variable. The cytoplasmic coat can occupy an area up to 
~150 nm in diameter (Rothberg 1990). Moreover, caveolin is associated in some cells 
with tubular invaginations that extend several micrometers into (Carozzi 2000), and even 
across , the cell (Dvorak 2001). A functional role for caveolae in endocytosis and signal 
transduction has been established (Anderson 1998). Finally, specific molecules have been 
identified that are dynamically associated with this membrane domain, including receptor 
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tyrosine kinases (Mineo 1996) and glycosylphosphatidylinositol (GPI)-anchored proteins 
(Mayor 1994) 
The term "lipid raft" (Simons 1997) is defined operationally by the procedures used to 
isolate a population of membranes from cells. Thus, rafts are a collection of membranes 
characterized by insolubility in nonionic detergents at 4°C; a special lipid composition 
that is rich in cholesterol, sphingomyelin, and glycolipids such as GM1 ganglioside 
(Smart 1999), and a light buoyant density (LBD) on sucrose gradients (Simons 1997). 
Those cells do not express caveolin and lack typical flask-shaped membrane 
invaginations (Fra 1995). LBD fractions from these cells are enriched in many of the 
same molecules found concentrated in the caveolae of caveolin-expressing cells (Wu 
1997).  
 
1.3.3.3. Intracellular delivery of therapeutic agents and the need to avoid lysosomal 
degradations. 
Having been taken up by the either of the pathways, the therapeutic agents need to be 
released at desired intracellular organelles or cytosol for exerts their therapeutic effects 
and avoid degradations. For example, in the clathrin-dependent pathways, those agents 
would become entrapped in endosomes and eventually ends in the lysosomes.  
Lysosomes are the endpoints of receptor-mediated endocytosis where active degradation 
by lysosomal enzymes takes place. As consequences, only a small portion of unaffected 
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therapeutic agents will be delivered to the desired subcellular organelles or cytoplasm to 
exert their therapeutic effects.  
 
1.4. Liposomes as carriers for intracellular drug delivery 
Fig.1.2 Scheme of liposomes formed in aqueous solution. Liposomes are self-
assembling colloid structures composed of  lipid bilayers surrounding aqueous 
compartments. 
 
Liposomes are self-assembling colloid structures composed of lipid bilayers surrounding 
(an) aqueous compartment(s). Liposomes were first described in the early 1960’s 
(Bangham 1965). The first suggested biological use of liposomes came from the group of 
Weismann in 1969 (Sessa 1969). Since then liposomes have been used as a versatile tool 
in biology, biochemistry and medicine.  
Liposome properties vary substantially with lipid composition, size, surface charge and 
the method of preparation. Based on size and number of bilayers, liposomes can be 
generally classified into three classes. Small unilamellar vesicles (SUV) are surrounded 
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by a single lipid layer and are 25–50 nm in diameter. Large unilamellar vesicles (LUV) 
are a heterogeneous group of vesicles similar to SUVs and are surrounded by a single 
lipid layer. Multilamellar vesicles (MLV), however, consist of several lipid layers 
separated from one another by a layer of aqueous solution. Based on surface charges, 
liposomes are classified as anionic, neutral or cationic liposomes. The cationic liposomes 
are widely used as carriers for DNA/RNA in the area of gene therapy.  
 
1.4.1. Liposomes as drug delivery systems  
Liposomes are small spherical vesicles that can be produced from natural non-toxic 
phospholipids and cholesterol. Because of their size, hydrophobic and hydrophilic 
character, as well as biocompatibility, liposomes are promising systems for drug delivery. 
Drugs associated with liposomes have markedly altered pharmacokinetic properties 
compared to drugs in solution. They are also effective in reducing systemic toxicity and 
preventing early degradation of the encapsulated drug after introduction into the target 
organism (Gabizon 1998). Liposome surfaces can be readily modified by attaching 
polyethylene glycol (PEG)-units to the bilayer (producing what is known as stealth 
liposomes) to enhance their circulation time in the bloodstream (Lasic 1999). 
Furthermore, liposomes can be conjugated to antibodies or ligands to enhance target-
specific drug therapy. 
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1.4.2. The applications of liposomes for gliomas therapy  
1.4.2.1. Enhanced BBB permeability in gliomas  
Both neovascularization and vascular hyperpermeability are integral characteristics for 
the growth of many tumors and represent potential points of therapeutic intervention. 
When primary tumors begin to grow beyond 1–2 mm in diameter within the brain 
parenchyma, the BBB becomes compromised both structurally and functionally (Fidler 
2002, Yuan 1994). Several groups have been able to show that tumors located in the 
brain also have a leaky microvasculature, although the pore sizes are significantly smaller 
(100-380 nm) than those seen with tumors located elsewhere in the body (200-780 nm) 
(Siegal 1995, Hobbs 1998). 
Liposomes have been shown to extravasate through the compromised vascular bed of 
many model tumors (Lasic 1991, Wu 1993, Yuan 1994, Monsky 1994), provided the 
liposome circulation time is adequate for sufficient tumor exposure to the liposomal 
formulation.  
 
1.4.2.2. Antivasculature effect of liposome encapsulated doxorubicin 
In a rat brain tumor model, Gabizon and coworkers were able to show that high levels of 
sterical stabilized liposomal doxorubicin (SSL-DOX) accumulated in the tumor (Siegal 
1995). Fischer rats injected with SSL-DOX at a dose of 6 mg/kg showed a maximal 
accumulation at 48 h at a level of 10 to 11 µg DOX/g of tumor tissue. This was 15-fold 
higher than the levels observed at the tumor site after the administration of an identical 
dose of free DOX (0.8 µg/g at 4 h), which were not different from levels found in the 
contralateral hemisphere. There was no accumulation of SSL-DOX in the contralateral 
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hemisphere, and in brain tissue immediately adjacent to the tumor, levels were <2 µg/g 
tissue for up to 70 h after injection but gradually increased to a maximum of 4 µg/g at 
120 h. 
In an intracranial 9L gliosarcomas animal model, Sharma and coworkers (1997) were 
able to show SSL-DOX enhances the median survival of rats by nearly 30% compared 
with saline controls or animals treated with unencapsulated DOX. In parallel, sterically 
stabilized liposomes labeled with fluorophores undergo deposition in a nonuniform, 
perivascular pattern in 9L tumors after i.v. injection (Sharma 1997). However, SSL-DOX 
liposomes show little propensity to interact directly with tumor cells in in vitro studies 
(Sharma 1997). Magnetic resonance and functional MR imaging were used for evaluation 
of intracranial 9L tumor responses to repetitive doses of free DOX or SSL-DOX. Those 
results suggest that the breakdown of tumor vasculature induced by SSL-DOX may arise 
from the perivascular accumulation of liposomes in tumor and cytotoxic effects on tumor 
vascular endothelium (Zhou 2002). 
These results suggest that even in the normally inaccessible central nervous system, a 
high tumor vascular permeability can be exploited for carrier-mediated drug delivery. 
However, to achieve higher and specific anti-tumor efficacy, these carrier must have a 
propensity to interact with the tumor cells.  
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1.5. Sulfatides and interacting molecules such as TN-C 
1.5.1 Sulfatides 
Sulfatides (Sulf) are sulfated derivatives of galactosylceramide (GalCer). Sulfatides make 
up one of the major classes of sulfoglycolipids that are distributed abundantly in the brain 
and kidney, and have been isolated from the gastrointestinal tract, erythrocytes, platelets 




Fig.1.3 Chemical Structure of galactosylceramide (GalCer) and its sulfated 
derivate: sulfatide (Sulf). The drawings for the above chemicals were obtained 
from the product data sheet (Avanti Polar Lipids, Inc).   
 
Sulfatides mediate diverse biological processes, including the regulation of cell growth; 
protein trafficking, signal transduction, cell adhesion, neuronal plasticity and cell 
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morphogenesis (see Refs. Vos. 1997, Ishizhka 1997, Merrill 1997 for reviews). Sulfatides 
are almost exclusively synthesized by oligodendrocytes in the central nervous system 
(CNS) are present predominantly in the myelin sheath surrounding axons and, thus, are 
present in both white matter and gray matter (Vos 1994). Altered levels of sulfatides in 
human brain tissues are involved in the pathogenesis of various human diseases. 
Accumulation of sulfatides, due to a sulfatidase deficiency, is responsible for 
metachromatic leukodystrophy, in which there is encephalopathy, long tract signs, and 
degeneration of myelin in the CNS (Kolon1995). Substantial sulfatides deficiency occurs 
at the very earliest stages of Alzheimer’s Disease, although the one or more causes of this 
deficiency remain unclear (Han 2002). Mice deficient in sulfatides and GalCer, generated 
by knocking out a ceramide galactosyltransferase, generally die by 3 months of age and 
demonstrate several abnormalities, including abnormal axonal function, dysmyelinosis, 
and loss of axonal conduction velocity (Bosio 1996, Coetzee 1996, Bosio 1998, Coezt 
1998). Recent studies suggesting sulfatides levels in the CNS are likely to be directly 
modulated by the same metabolic pathways that regulate levels of apoE-containing CNS 
lipoproteins. 
 
1.5.2. Sulfatides interaction with several molecules that are overexpressed in tumors 
To date, several adhesive proteins and coagulation proteins have been reported to bind to 
sulfatides. Sulfatides binding to these proteins may be involved in cell–substratum or 
cell–cell interaction (Pesheva 1997, Kobayashi 1994). 
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Several heparin-binding proteins have been shown to bind sulfatides including laminin 
(Roberts 1985, Hall 1995), thrombospondin (Roberts 1995), von Willebrand factor 
(Roberts 1996), tenascin-C (Crossin 1992), tenascin-R (Pesheva 1997), one 
approximately 30-kDa sulfoglucuronylglycolipid-binding protein (SBP-1) (Nair 1997) 
and midkine (Kurosawa 2000). Sulfatides can bind specifically to L-selectin (Suzuki 
1993) and to hepatocyte growth factor and serve as reservoirs for hepatocyte growth 
factor (Kobayashi 1994). Recent studies show that sulfatides can binding to lectin-c 
domain of  chondroitin sulfate proteoglycans (Miura 1999).  
 
1.5.2.1 Tenascin-C 
The distinct ability of gliomas to invade the normal surrounding tissue makes them 
difficult to control and nearly impossible to completely remove surgically. This accounts 
for the extraordinarily high lethality associated with malignant gliomas. The ability of 
tumor cells to interact with components of the surrounding extracellular matrix (ECM) 
affects numerous cellular processes, and inappropriate expression of these matrix 
components has been associated with glioma invasion, growth, and angiogenesis.  
The matrix protein tenascin-C appears to play an important role in angiogenesis. In 
glioblastoma tumors, tenascin-C is expressed at sites of neovascularisation by vascular 
cells, including those at the invasive edge of the tumor, but its levels are low in the 
normal brain (Zagzag 1996). Tenascin-C promotes brain microvascular endothelial cell 
migration and it is synthesised by migrating brain microvascular endothelial cells, 
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suggesting that endothelial cells can promote their own migration through an autocrine 
loop (ZagZag 2002). In addition, tenascin-C can promote FAK phosphorylation and 
upregulate VEGF expression (Huang 2001, Orend 2003), as well as induce proliferative 
signals that appear to be mediated through its interactions with integrin α5β1 and 
syndecan-4 (Huang 2001). These data suggest that the vascular cells in glioblastoma 
tumors and in other malignant tumors are induced or co-opted by the tumor to synthesize 
and secrete proangiogenic tenascin-C. 
Many studies suggest TN-C is a useful and effective target for glioma immunotherapy, 
radiotherapy, radioimaging and RNA interference therapy in clinical studies levels. In a 
Phase II study, intracavitary administration of 131I-labelled antitenascin-C monoclonal 
antibody (81C6) to patients with recurrent malignant glioma followed by chemotherapy, 
also resulted in a median survival that was greater than that of historical controls treated 
with surgery and 125I-brachytherapy (Reardon, 2002). In another Phase II clinical trial,  
131I-labelled 81C6 was injected into the surgical resection cavity of newly diagnosed 
glioblastoma patients, followed by conventional radiotherapy and chemotherapy. This 
treatment could significantly increase the median survival of the glioblastoma patients 
(Akabani 2005). RNA interference technology had been applied to suppress human brain 
tumors (glioblastoma multiforme, astrocytoma) through inhibition of the synthesis of 
tenascin-C (Zukiel 2006). 
As tenascin-C has multiple functional domains (Jones 2000), the physiological 
implications of targeting tenascin-C in glioblastoma tumors are probably multifactorial 
and are not completely understood. Nevertheless, the current and potential future use of 
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tenascin-C as a homing signal for conjugated cytotoxic agents or antiangiogenic agents 
for radiotherapy or for radioimaging, offers intriguing possibilities.  
 
1.5.2.2 Brevican 
Another ECM component that has been implicated in glioma biology is brevican, a 
hyaloronic acid-binding member of the lectican family of chondroitin sulfate 
proteoglycans.  mRNA for the brain-specific extracellular brevican is not detectable in 
normal adult human cortex or in any nonglioma tumor examined. Brevican is consistently 
overexpressed in surgical samples of glioma (n = 27). When grown as intracranial grafts, 
glioma cell lines that invade the brain express brevican, whereas noninvasive cell lines do 
not (Jaworski 1996). Animal studies of rats with intracranial grafts of brevican-
transfected CNS-1 cells displayed significantly shorter survival times than did rats with 
CNS-green fluorescent protein intracranial grafts (P < 0.001). Histological examination 
results suggest that up-regulation and proteolytic cleavage of brevican increase 
significantly the aggressiveness of gliomas (Nutt 2001). 
Brevican is a nervous system-specific chondroitin sulfate proteoglycan that belongs to the 
aggrecan family. Yamaguchi et al demonstrate that sulfatides act as cell surface receptors 
for brevican. The lectin domain of brevican binds sulfatides in a calcium-dependent 
manner (Mirua 1999). Intact, full-length brevican also binds both sulfatides. The lectin 
domain of brevican immobilized as a substrate supports adhesion of cells expressing 
sulfatides, and was inhibited by monoclonal antibodies against these glycolipids or by 
treatment of the substrate sulfatides. 
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 1.5.2.3. Midikine 
Angiogenesis is essential for tumor growth and progression. It has been demonstrated 
that tumor growth beyond a size 1 to 2 mm3 requires the induction of new blood vessels. 
Angiogenesis is regulated by several endogenous stimulators and inhibitors of endothelial 
cell migration, proliferation and tube formation. Malignant gliomas are among the most 
highly vascularized tumors in humans. There is growing evidence for the role of midkine 
as a paracrine and autocrine angiogenic factor (Kurosawa 2000, Mashour 1999). 
Together with pleiotrophin, midkine is a member of a family that is distinct from other 
heparin-binding growth factors. Midkine expression is augmented in advanced tumors at 
a very high frequency and in a non-tissue specific manner. Midkine is found 
overexpressed in primary bladder tumors, thyroid papillary carcinomas, hepatocellular 
carcinomas, Sternberg Reed cells of Hodgkin's disease and breast tumors, (reviewed in 
ref. Beecken 2000). In the studies of neurofibroma, immunohistochemistry revealed 
expression of midkine in endothelial cells of tumor blood vessels, but not in normal blood 
vessels (Mashour 2001).  
 
1.5.3. Sulfatides containing liposomes were applied as membrane model and carriers 
In the stability studies of small unilamellar vesicles (SUV) of sulfatides/ePC (NoDa 1994) 
and sulfatides/ DOPE (Wu 1996), sulfatides was shown to play an essential role in 
stabilizing liposomes. The hydration and partial dehydration of the head group of 
sulfatides determined the pH sensitivity of DOPE/sulfatide vesicles (Wu 1996). Using 
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mixing membrane lipids based on an assay of fluorescence resonance energy transfer, Li 
and coworkers elucidate the CaCl2 induced fusogenic properties of sulfatide-containing 
DOPE SUVs (Wu 1999). 
As membrane models, liposome composed of sulfatides were used to study the GalCer- 
sulfatides interactions and chemokines-sulfatides interactions (Bogges 2001, Sandoff  
2005). 
Liposomes containing sulfatides was found to be an effective carrier that could pass 
through BBB. It was found that sulfatides significantly improved the stability of reverse 
evaporation prepared vesicles (REVs) in vivo, and altered the brain preferential 
distribution of [125I]pCT encapsulated in liposomes in mice (Chen 1993 a). The brain 
delivery of liposomes composed of sulfatides was proved by other studies (Mora 2002). 
However, Sakamoto et al had proposed the argument that the brain delivery of liposome 
composed of sulfatides might be due to the osmotic disruption of BBB (Sakamoto 1993). 
In an experiment using ovarian tumor-bearing nude mice, it was found that doxorubicin 
encapsulated in the sulfatides-containing liposomes composed of phosphotidylcholine 
(PC) and cholesterol was maintained at a higher blood level, a lower concentration in the 
heart, and at a higher concentration in the tumor than the free drug. The antitumor 
activity of the liposome-entrapped doxorubicin also eliminated the free drug related body 
weight loss of the animals (Yagi 1989). 
Liposomes containing sulfatides that have been formulated with  different backbone 
lipids (ePC, DMPC, DPPC etc.) and with the final molar ratio of sulfatides in the 
liposomes varying from 4.9% to 30%. (Table 1.2) 
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Formulation molar ratio % of Sulf in liposome 
Applications of 
liposomes 
Drug ( other 
chemical) References 
DMPC/chol/Sulf     1:0.75:0.2 10.3 GalCer Sulf interaction NA Boggs 2001
DMPC/chol/GalCer/Sulf     
    
  
  
    
    
   
     
    
1:0.75:0.2:0.1 4.9 GalCer Sulf interaction NA Boggs 2001
ePC/chol/Sulf 55:20:25 25 Chemokine Sulf interaction NA Sandhoff 2005
ePC/Sulf 9:1 10 Sulf stablize liposome 
Carboxy-
flourescein Noda 1994 
ePC/Sulf 4:1 20 carrier, pH sensitivity 
Carboxy-
flourescein Viani 1993 
DOPE/Sulf 70:30 30 Sulf stablize liposome NA Wu 1996,1999
ePC/chol/Sulf 7:2:1 10 carrier for overian, cancer therapy Doxorubicin Yagi 1989
ePC/chol/sulf I0:5: 1 6.70 spleen delivery 
125I-labeled 
tyraminylinulin Liu 1991 
ePC/chol/Sulf 4:5:1 10 brain delivery Leupeptin Taka 1984 
ePC/Chol/sulfatide 7:10:3 15 brain delivery calcitonin Chen1993 a, b 
DPPC/chol/Sulf 7:2:1 10 brain delivery [14C]Cholesterol Sakamoto 1993
DMPC/chol/NPPE/Sulf 8:3:4:1.5 9.1 brain Delivery
3H-cholesteryl-
hexadecylether Mora 2002 
Table 1.2 Liposomes composed of sulfatides: the formulation, sulfatides molar ratio in different studies. 
Abbreviations: Chol: cholesterol; DMPC: 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine; DOPE: 1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine; DPPC: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine; ePC: egg L-a-Phosphatidylcholine; GalCer: 
galactosylceramide;  NPPE: N-palmitoylphosphatidylethanolamine;  Sulf: sulfatides. 
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1.6. Objectives of this study  
Malignant gliomas represent a difficult therapeutic challenge due to the invasive nature of 
the tumor and limited tumoral delivery of therapeutic agents. Liposomes as drug delivery 
systems are effective in treating solid tumors. However, to achieve better therapeutic 
effects, novel liposomes drug delivery systems able to specifically interact with the tumor 
cells are highly desired. 
Sulfatides have been proved to interact with many molecules which are overexpressed in 
the tumor as we have described earlier. Previous studies in our lab have also shown that 
liposomes composed sulfatides could pass through BBB (Chen 1993 a) which were 
consistent with results from other studies. However, the mechanism is still unclear. It is 
of great interest to investigate the possibility to use sulfatides to design novel liposome-
based delivery systems that may pass through BBB and specifically interact with the 
glioma cells.  
In this study, we have investigated the interactions of liposomes containing sulfatides 
with gliomas with both human glioma cell lines (CCF-STTG1 and U87-MG cells, 
respectively) and animal models transplantation. Firstly, we shall study whether 
sulfatides-containing liposomes could interact specifically with glioma cells. And 
whether those tumor overexpressed molecules could account for the specific interactions. 
Secondly, we shall study whether sulfatides-containing liposomes could be effectively 
taken up by the glioma cells. We shall attempt to probe the detail routes of liposomes 
entry into the cells. Thirdly, we shall choose doxorubicin as an antitumor drug to be 
encapsulated in the sulfatides-containing liposomes. We here optimized the liposomes for 
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DOX delivery and tested the anti-tumor effects using both cell culture and animal models. 
Finally, we shall establish intracranial tumor animal model to investigate tumor targeting 





Sulfatides-Containing Liposomes Targeting Glioma Cells 
Mediated by Sulfatides-Glioma Cells Interactions 
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Chapter 2. Sulfatides-Containing Liposomes Targeting Glioma Cells Mediated by 
Sulfatides-Glioma Cells Interactions 
2.1. Briefing 
The Sulfatides-containing liposomes (SCLs) were uptake by glioma cells via the specific 
interactions of sulfatides with the cells. The SCLs bind to the extracellular matrix (ECM) 
of glioma cells by the specific interactions between sulfatides and a glioma overexpressed 
ECM protein: tenascins C (TN-C).  
 
2.2. Materials and methods 
2.2.1. Chemicals  
Sulfatide (3'-sulfogalactosylceramide), galactosylceramide (GalCer), ganglioside GM1,  
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3- 
phosphorcholine (DOPC), cholera toxin B subunit (CTxB) and bodipy-lactosylceramide 
(Bodipy-LacCer) were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). 
Lissamine™ rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine  
(Rh-PE) was from Molecular Probes (Eugene, OR). Mouse anti-human TN-C monoclonal 
antibody, anti-O4 monoclonal antibody and the IgM negative control were from Chemicon 
(Temecula, CA). T7•Tag® monoclonal antibody was from Merck (Whitehouse Station, 
NJ). All other chemicals were from Sigma-Aldrich (St. Louis, MO). 
 
2.2.2. Human glioma cell lines and culture conditions  
Human U-87MG and CCF-STTG1 glioblastoma cell lines were obtained from American 
Type Culture Collection (Rockville, MD). U-87MG cells were grown in EMEM containing 
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2mM L-glutamine, 2.2 g/l NaHCO3, 110 mg/l sodium pyruvate, and 10% fetal calf serum 
(FCS). CCF-STTG1 cells were maintained in DMEM supplemented with 10% FCS. Cells 
were cultured in a humidified incubator containing 5% CO2 at 37°C.  
 
2.2.3. Liposome preparation  
All lipids were dissolved in chloroform: methanol (2:1, v/v), except GalCer which was 
dissolved in hot ethanol. Appropriate amounts of lipids were transferred from their 
respective stock solutions into glass tubes and dried by evaporation under a nitrogen stream, 
as described (Shao K 2006). For fluorescence microscopy studies, 0.5 mol % of Rh-PE was 
included. The samples were stored under vacuum for 24 hour at 4oC and the thin lipid film 
formed on the wall of the glass tubes was hydrated with PBS, briefly sonicated (1 minute), 
and extruded repeatedly through two layers of polycarbonate membranes with a pore size 
of 100 nm at room temperature (Avestin, Inc., Canada) (Olson F 1979).  
 
2.2.4. ECM binding and intracellular uptake of liposomes  
ECM binding and internalization of Rh-PE-labeled SCLs were examined using an inverted 
microscope (Olympus IX71) or a Zeiss laser scanning confocal microscope system (LSM 
510), respectively. Cells were seeded into 24-well plates containing glass coverslips for 24 
hour before co-incubation with the liposomes (final total lipid concentration: 80 µM) for 1 
hour. The cells were then washed three times with ice-cold PBS and immediately fixed 
with 3.7% paraformaldehyde (PFA). The coverslips were thoroughly rinsed with PBS and 
mounted on slides with anti-fade mounting media (Invitrogen, CA) before viewing. Rh-PE 
was excited at 543 nm and the emitted fluorescence was collected using a 560 nm 
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long-pass filter. For quantitative analysis, the images were processed with the Image-Pro 
Plus software (version 4.5.1, Media Cybernetics, Inc., USA), where cell contours or the 
ECM areas surrounding the cells for each set of the fields were traced out manually in the 
corresponding phase-contrast images and then used to mask the fluorescence images. The 
fluorescence intensities of 7-10 fields of ~10 cells/field/condition or 5 fields of ~10 ECM 
areas/field/condition were analyzed.  
 
2.2.5. Antibody perturbation: the effect of anti-O4 MAB on liposome uptake 
Sulfatide/DOPE/Rh-PE (30:69.5:0.5; mol/mol/mol) liposomes were incubated with 
anti-O4 monoclonal antibody (100 µg/ml) or mouse IgM (100 µg/ml) (Chemicon, CA) for 
30 min at 37°C. U-87MG cells were seeded into 4-well chambered coverglass system for 
24 hour before incubated with either the anti-O4 pretreated, the IgM pretreated or the 
untreated liposomes for 1 hour. Cells were washed extensively with ice cold PBS and kept 
in ice cold MEM eagles medium until confocal microscopy observation. The images were 
quantitatively analyzed of the ECM binding of SCLs as described above.  
 
2.2.6. Fluorescent immunochemical detections of TN-C in ECM of glioma cells 
The glioma cells (or been incubated with Rh-PE labeled SCLs for 1 hour) were extensively 
washed, fixed with 3.7% PFA at room temperature, blocked with 5% skim milk (4 °C, 
overnight), and incubated with primary monoclonal antibody binding (1:100), followed by 
secondary Fitc-labeled antibody binding (1:10,000). The samples were observed and 
imaged using laser confocal microscopy. 
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2.2.7. 1, 25-Dihydroxyvitamin D3 (VD3) treatment  
U-87MG cells were treated with up to 1 µM VD3, which is known to inhibit TN-C 
expression in various types of cells (Gonzalez-Sancho 1998; Alvarez-Dolado 1999),  for 24 
hour at 37oC and the expression level of TN-C protein was estimated by Western blotting 
(see below). After washing with PBS, the cells were incubated with RH-PE labeled SCLs 
for 1 hour at 37oC, and quantitative analysis of the binding level of the liposomes was 
conducted as described above. 
 
2.2.8. siRNA preparation and transfection 
 A TN-C specific siRNA duplex corresponding to bases 5209 - 5227 from the open reading 
frame of the human TN-C mRNA was designed and synthesized by Proligo (Singapore): 
5’-  GUG GAG AGC UUC CGG AUU A-dTdT - 3’. A RNA sequence without known 
homology to mammalian genes, which was used as a negative control, was: 5’- UUC UCC 
GAA CGU GUC ACG U-dTdT- 3’. Knockdown of TN-C expression by siRNA was 
carried out according to the manufacturer’s instructions. Briefly, cells were transfected at 
60 - 80% confluence using LipofectamineTM 2000. The final concentration of TN-C siRNA 
and the negative control siRNA used was 0.2 µM. The medium was replaced with fresh 
complete medium 4 h after transfection, and analyses on TN-C knockdown efficiency and 
SCLs binding to the ECM of the cells were conducted at 24 and 72 h after transfection, 
respectively.  
 
2.2.9. Western blotting  
Cells were lysed in the lysis buffer containing 10 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 
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1 mM EDTA (pH 7.4) and various protease inhibitors (Roche, Basal, Switzerland). 
Aliquots of the cell lysate (20 µg of protein) were then resolved by 5% SDS-PAGE and 
electroblotted onto PVDF membranes (Pierce, Rockford, IL) and blocked with 5% skim 
milk for overnight at 4 °C.  TN-C expressions were detected by Western blot analysis using 
the monoclonal antibody against TN-C (1:1000 dilutions). Immunoreactive bands were 
visualized by using a secondary antibody conjugated to horseradish peroxidase (Bio-Rad 
Lab., CA) and the Super Signal enhanced chemiluminescence reagent (Pierce, Rockford, 
IL). 
 
2.2.10. Statistical analysis  
Data were evaluated by either unpaired Student’s t test (two-sided) or one-way ANOVA 
using SPSS 12.0 software (SPSS Inc., Chicago) and presented as means ± SD. All results 




2.3.1. Sulfatides determining the specific SCLs-glioma cell interactions 
Sulfatides are specifically required for binding and uptake of the liposomes by 
human glioma cells. 
Liposomes consisting of various lipids were prepared by extrusion through polycarbonate 
membranes of average pore size of 100 nm (see Materials and Methods for details). The 
mean diameter of such liposomes formed was about 82 nm with a polydispersity of < 0.5, 
as determined by dynamic light scattering (data shown in Chapter 4). 
It was found that effective uptake of Rh-PE (0.5mol%)-labeled liposomes by U-87MG, a 
typical human glioblastoma cell line, relied specifically on the presence of sulfatides 
(Figures 2.1 and 2.2). Similarly, binding of the liposomes to the ECM was observed only 
for sulfatides-containing liposomes (to be further described in later parts of this chapter). It 
was evident that the presence of a galactose group, such as that of GalCer in 
GalCer/dioleoylphosphatidylcholine (DOPC) liposomes and the negative charge carried 
by the constituent lipids, such as that of dioleoylphosphatidylglycerol (DOPG) and 
gangliosides GM1 (GM1) in DOPG/DOPC and GM1/DOPE liposomes, were insufficient 
for effective binding and internalization to occur.  
Increasing the molar ratios of sulfatides in the liposomes formulations resulted in the better 
ECM binding and higher glioma cells uptake (Fig. 2.1 a, k, and i). Increasing the sulfatides 
content in sulfatides/DOPC liposomes from 15% to 30% resulted in a 3.5 fold increasing of 
cellular uptake (Fig.2.2.). It is obvious that the sulfatides play major roles in the binding 
and uptake of liposomes by the glioma cells. 
Meanwhile, optimal ECM binding and cellular uptake was found in cells treated with 
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sulfatide/DOPE (30:70, mol/mol) liposomes. At the same sulfatides content, the uptake of 
sulfatide/DOPE was around 50% higher than those of sulfatide/DOPC liposomes (Fig.2.2). 
The results suggested that using DOPE instead of DOPC as the backbone lipid component 
was desirable for more significant uptake of the liposomes. Similar binding and 
internalization results were also obtained with another human glioblastoma cell line tested 
(CCF-STTG1 cells, data not shown). These data are indicative of existence of specific 
sulfatides receptor(s) on the glioblastoma cell surface which mediated the binding and 












Fig.2.1. Sulfatides are specifically required for the binding and uptake of liposomes 
by glioma cells. U87-MG cells were seeded 24 hour before incubation with the Rh-PE 
labeled liposomes for 1 hour at 37 °C. Representative fluorescence and corresponding 
phase contrast micrographs were shown. Liposomes  formulations (molar ratio) been
used: a: DOPC;  b: DOPG/DOPC (15:85); c: DOPG/DOPC (30:70); d: GalCer/DOPC 
(15:85); e: GalCer/DOPC (30:70); f: GM1/DOPC (15:85); g: GM1/DOPC (30:70); h: 
sulfatide/DOPC (15:85); i: sulfatide/DOPC (30:70); j: sulfatide/DOPE (30:70). The scale 




Fig. 2.2.   Quantitative analysis of liposomes with different formulations been uptake 
by U-87MG cells. U87-MG cells were seeded 24 hour before incubation with the Rh-PE 
labeled liposomes for 1 hour at 37 °C. Liposomes used: DOPC; DOPG/DOPC (15:85,
mol/mol); DOPG/DOPC (30:70, mol/mol); GalCer/DOPC (15:85, mol/mol);
GalCer/DOPC (30:70, mol/mol); GM1/DOPC (15:85, mol/mol); GM1/DOPC (30:70, 
mol/mol); sulfatide/DOPC (15:85, mol/mol); sulfatide/DOPC (30:70, mol/mol); 
sulfatide/DOPE (30:70, mol/mol). Quantitative analysis of the internalization level of 
liposomes by U-87MG cells were carried out (see Materials and Methods for details). The 
uptake level of sulfatide/DOPC (30:70, mol/mol) was set as 100%. Values are mean ± SD 
of three independent experiments. 
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2.3.2. The blocking effect of monoclonal anti-sulfatides antibody on SCLs uptake by 
glioma cells 
In order to further confirm that sulfatides are required for effective liposome binding by the 
glioblastoma cells, the sulfatides-containing liposomes were pretreated with monoclonal 
anti-sulfatides antibody, MAB anti-O4, (100 mg/ml) or mouse IgM (100 mg/ml). Figure 
2.3 shows that treatment with IgM led only to a slight decrease (~ 25%) in ECM binding of 
the liposomes, whereas treatment with anti-O4 under identical conditions resulted in a near 
complete inhibition of the ECM binding of the liposomes, indicating that binding of 
antibody to sulfatide on the outer surface of liposomes has masked the sulfatides-mediated 
interaction with the cells, which is essential for binding and subsequent endocytosis of the 
sulfatide-containing liposomes.  
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Fig.2.3. The effects of anti-O4 antibody pretreatment on SCLs binding and uptake 
by glioma cells. Sulfatide/DOPE/Rh-PE (30:69.5:0.5; mol/mol/mol) liposomes were 
incubated with anti-O4 monoclonal antibody (100 µg/ml) or mouse IgM (100 µg/ml) 
for 30 min at 37°C. U-87MG cells were seeded into 4-well chambered slides for 24 hour 
before incubated with either the untreated(a1-4), the IgM pretreated (b1-4) or anti-O4 
pretreated (c1-4) liposomes for 1 hour at 37 °C . Cells were washed extensively with ice 
cold PBS and kept in ice cold MEM eagles medium until confocal microscopy 
observations. Representative transmited light images (a1, b1 and c1), fluorescent 
images of RH-PE labeled liposomes focus on ECM bindings (a2, b2 and c2), focus on 
cellular uptake (a3, b3, c3) and their cropped images of high magnifications (a4, b4 and 



































Fig.2.4. Effects of monoclonal anti-sulfatides antibody pretreatment on SCLs 
binding and uptake by glioma cells. The images obtained in the anti-O4 pretreatment 
studies were quantitatively analyzed for the ECM binding and cellular uptake of SCLs.
The average ECM binding or cellular uptake level in the control experiments, where 
untreated Rh-PE labeled SCLs were used, was set as 100% respectively. Values are 
means + SD of at least three independent experiments. 
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2.3.3. PEG-DSPE’s sterical shielding effects on SCLs binding and uptake by Glioma 
cells 
U87-MG cells were seeded 24 hour before incubation with the Rh-PE labeled liposomes 
for 1 hour at 37 °C. Representative fluorescence and corresponding phase contrast 
micrographs were shown in Fig.2.5. In these experiments, PEG-DSPE2000 was 
incorporated into SCLs at 3% (molar ratio) of total lipids. The detail of the formulation is: 
PEG-DSPE2000/Sulf/DOPE (3:30:67). Normal SCLs (sulfatides/DOPE (30:70)) and 
PEG-DSPE2000/DOPE (3:97) liposomes were adopted as controls.  The PEG part of the 
PEG-DSPE2000 is a mushroom like formation on the liposome surfaces. The sterical 
shielding effect of the PEG-DSPE2000 in the outer surface of the liposomes is shown in 
the schematic drawings in Fig.2.5.  
DOPE liposomes incorporated with 3% of PEG-DSPE2000 demonstrated no binding and 
uptake by U-87 MG cells (Fig.2.5.a). SCLs incorporated with 3% of PEG-DSPE2000 were 
also found to be unable to bind to the ECM of U-87 MG cells (Fig.2.5.b and d). The cellular 
uptake of PEG-DSPE-SCLs was reduced compared to those of SCLs (Fig.2.5.b and d). The 







Fig.2.5. PEG-DSPE’s sterical shielding effects on the SCLs binding and uptake 
by glioma cells. U87-MG cells were seeded 24 hour before incubation with the Rh-PE 
labeled liposomes for 1 hour at 37 °C. Representative fluorescence and corresponding 
phase contrast micrographs were shown. Liposomes formulations (molar ratio) used: 
a: PEG-DSPE2000/DOPE (3:97); b: PEG-DSPE2000/Sulfatides/DOPE (3:30:67); c: 
sulfatides/DOPE (30:70). High magnificent images were shown: d: 
PEG-DSPE2000/Sulfatides/DOPE (3:30:67); e: sulfatide/DOPE (30:70). The scale bar 
represents 25 µm (yellow, a-c) or 10 µm (green, d and e).  
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2.4. Results Part II: Sulfatides-tenascins interaction mediates binding of SCLs to the 
extracellular matrix of glioma cells 
The bindings of SCLs to the ECM of glioma cells were demonstrated in the above studies. 
The ECM binding is unique to SCLs comparing with liposomes of other compositions. The 
immunological blocking by antibodies and physical shielding with PEG-DSPE2000 
resulted in reduced SCLs binding and uptake by the glioma cells. All these findings 
suggested sulfatides play a major role in the SCLs-Glioma cells interaction.  In the 
following part of this chapter, we will focus on the ECM bindings of the SCLs while in the 
next chapter we will investigate the details of cellular uptake. 
 
2.4.1. The binding of SCLs to the ECM of U-87MG cells does not involved HSPG 
It has been reported that heparin sulfate proteoglycan (HSPG) plays an important role in 
cellular uptake of liposomes (Marty 2004, Sauer 2005). To rule out the possibility that 
binding of SCLs to the ECM of the glioma cells was mediated by HSPG, the cells were 
pretreated with heparinase I (3.0 U/ml, 30 min at 37oC) or the liposomes were incubated 
with the cells in the presence of heparin (100 mg/ml), a HSPG competitor. Such treatments 
affected neither the binding of SCLS to the ECM of the glioma cells, nor the internalization 
rate of the liposomes, suggesting that HSPG was unlikely to be involved in interactions 
between SCLs and the glioma cells.  
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2.4.2. Rh-PE labeled SCLs colocalized with TN-C in ECM of glioma cells 
It has been reported that sulfatides are able to bind to tenascins, in particular, tenascins-c 
(TN-C) (Crossin 1992). TN-C is abundantly expressed in human glioma cell lines 
(Ventimiglia 1992). It was therefore of interest to determine level of this glycoprotein in the 
glioma cell lines we used. Furthermore, whether this glycoprotein is responsible for the 
ECM binding of SCLs will be further examined.  
The fluorescent immunochemical detections of TN-C in U-87 MG cells were performed as 
described in Materials and Methods. TN-C is highly expressed and abundant in the ECM of 
U-87 MG monolayer cell cultures (Figure 2.6.b).   The colocalization study was carried out 
in the cells incubated with the Rh-PE labeled sulfatide/DOPE liposomes. Remarkable 
colocalization of the fluorescent liposomes (red) and TN-C (green) was found (Figure 
2.6.c). Essentially every Rh-PE-positive micro-domain was also TN-C positive.  
Western immunoblot analysis for TN-C protein demonstrated two TN-C protein isoforms 
of 220 and 180 kDa (Fig.2.7.A), which might be due to the expressions of two TN-C 
isoforms of apparent molecular weight of 7.4 and 6.6 kb. (Jones 2002) 
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 Fig.2.6. Immunochemistry study of the Rh-PE labeled sulfatide/DOPE 
liposomes colocalized with TN-C in ECM of glioma cells. The glioma cells were 
incubated with Rh-PE labeled SCLs for 1 hour, followed by extensive washes,
fixation, blocking, primary monoclonal antibody binding (1:100) and secondary 
fluorescence-labeled antibody binding (1:10,000). The samples were observed under 
laser confocal microscopy. The scale bar represents 25 µm for all micrographs. 
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2.4.3. Inhibition of TN-C expressions of glioma cells by VD3 treatment reduced 
binding of SCLs to the ECM of glioma cells 
1, 25-Dihydroxyvitamin D3 (VD3), was reported to be capable of inhibiting TN-C 
expression in various types of cells (Gonzalez-Sancho 1998; Alvarez-Dolado 1999). The 
different drug doses and treatment procedures were compared to achieve the highest level 
of inhibitions of TN-C expression with minimum is crucial to add VD3 in the cell culture 
medium during the seeding procedures (data not shown). The possible reasons are: 1) 
TN-C is among those early response genes during the cell proliferations. Once the 
monolayer of glioma cells was formed, the TN-C would abundantly exist in the ECM.  2) 
The expressions of TN-C are upregulated in U87 MG cells.  
Figure 2.7A shows that TN-C expression was significantly attenuated by VD3 treatment, as 
detected by Western blot with TN-C-specific antibody.   
To confirm the specific interaction between TN-C and the sulfatides containing liposomes, 
VD3 was used to treat the cells for 24 hour before the liposomes were added. 
Correspondingly, binding of the sulfatide-containing liposomes to the ECM of U-87MG 
cells treated with 1mM VD3 for 24 h reduced by ~35% compared with that of the control 
cells (Figure 2.7.B). These results suggest that TN-C, the ECM glycoprotein known to be 
able to bind sulfatides, was indeed involved in binding of the sulfatides/DOPE liposomes 
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Fig.2.7. Effect of VD3 on binding of sulfatides/DOPE (30:70, mol/mol) liposomes to 
the ECM of U-87MG cells. (A) Effect of VD3 on TN-C expression in U-87MG cells as 
examined by immunoblotting with anti-TN-C antibody. β-Actin was used as a loading 
control. The blots are representatives of three independent experiments. Treatment of 
the cells with VD3 attenuated TN-C expression in a dose-dependent manner. (B) 
Binding of Rh-PE-labeled sulfatide/ DOPE (30:70, mol/mol) liposomes to the ECM of 
U-87MG cells was significantly inhibited by VD3 treatment. The concentration of VD3 
used here is 1 mM and higher concentration was found to be toxic to the cells. Values 
are means + SD of at least three independent experiments. *p<0.005, versus the 
non-treated control. 
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2.4.4. Silencing of TN-C expressions by siRNA treatment reduced the binding of 
SCLs to the ECM  
We further confirmed the specific interaction between SCLs and TN-C by transfection of 
the U-87MG cells with a siRNA duplex targeted to the TN-C mRNA.  The siRNA can 
effectively silence TN-C expressions and results in reduced TN-C detections as shown in 
Fig. 2.8.A. 72 hour after the transfection, the TN-C level in the ECM of U87 MG cells 
transfected with TN-C-specific siRNA is only ~20% of those untreated or those transfected 
with a control siRNA of random sequence.  
We next examined whether the knockdown of TN-C expressions would affect the ECM 
binding of SCLs. Figure 2.8.B shows that binding of SCLs to the ECM of TN-C siRNA 
transfected U-87MG cells was reduced by ~50% compared with that in the untreated cells, 
72 hour after cell transfection. Not surprisingly, transfection of cells with the control 
siRNA did not affect the binding of SCLS to the ECM of U-87MG cells.  
Taken together, these results suggest that TN-C, the ECM glycoprotein known to be able to 





Fig.2.8. Effects of TN-C siRNA on TN-C expression in U-87MG cells and ECM 
binding of SCLs. (A) TN-C expression in U-87MG cells following treatment with 
TN-C siRNA and control siRNA for up to 72 h as detected by Western blot analysis. 
The blots are representatives of three independent experiments. β-Actin was used as 
the internal control. (B) Quantitative analysis of TN-C siRNA treatment on ECM 
binding of Rh-PE labeled sulfatide/DOPE (30:70, mol/mol) liposomes by U-87MG 
cells. The average level of ECM binding of untreated liposomes was set as 100%. 
Values are means + SD of three independent experiments. *p<0.001 versus both the 
non-treated control and the control siRNA treated samples. 
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2.5. Discussion 
In this study, we have shown that sulfatides were specifically required for the binding and 
uptake of liposomes by human glioblastoma cells such as U-87MG and CCF-STTG1 cells. 
The binding or targeting motif was demonstrated to be sulfatides, which guided the 
liposomes to, most likely, TN-C, the ECM glycoprotein at the cell surface known to be 
up-regulated during tumorigenesis and correlated with poorer prognosis in various human 
carcinomas (Chiquet-Ehrismann 2003).  
Evidently, the effective binding and uptake of liposomes by the glioblastoma cells were 
attributable largely to sulfatides. When ganglioside GM1 and GalCer were used to prepare 
liposomes, no significant binding and uptake of such liposomes were observed (Figures 2.1 
and 2.2). Uptake of the sulfatides-containing liposomes by the human glioblastoma cells 
was also not due to the charge effects because presence of acidic phospholipids such as 
phosphatidylglycerol in liposomes failed to improve the uptake efficiency (Figures 2.1 and 
2.2).  GalCer becomes sulfatide when its galactose head is sulfated. Liposomes composed 
of GalCer show no propensity to interact with the glioma cells. It is obvious that the 
sulfated galactose moiety of the sulfatides is exclusively requested for the specific 
interaction of SCLs to the glioma cells.  
Interestingly, the molar ratio of sulfatides in the liposomes composition is important for 
efficient liposome-glioma cell interactions. Increasing of sulfatides molar ratio resulted in 
better liposome-glioma cell interaction. It might be due to the increased binding sites for 
the interactions. In the meanwhile, the structural changes of liposomes outer surfaces with 








Fig.2.9. Schematic drawing of liposomes used in the studies.  
(a: lipid bilayer;  b: the symbolic drawings of sulfatides, Rhodamine-DSPE, 
backbone lipids of DOPC and DOPE, and PEG(mw=2000)-DSPE; c: RH-PE 
labeled SCLs; d: the structures of amphiphiles and e: PEG-DSPE-SCLs) 
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The specific requirement for sulfatide has been further confirmed by examining the effect 
of anti-O4 antibody on binding of sulfatide-containing liposomes to the ECM of the cells 
(Figure 2.3). The small reduction in ECM binding caused by IgM could be due to sterical 
hindrance resulted from non-specific binding of IgM at the liposomal surface, which, due 
to its large molecular weight, could affect the interactions between sulfatides and its 
receptors at the cell surface. This postulation was supported by the observation that 
albumin, at a similar or higher concentration, did not affect the binding of the liposomes 
(data not shown).  
Besides the immunological blocking of SCLs, we incorporated PEG-DSPE2000 into SCLs. 
The PEG part of the PEG-DSPE2000 is a mushroom like formation on the liposome 
surfaces (Tirosh, 1998). The sterical shielding effect of the PEG-DSPE2000 in the outer 
surface of the liposomes is shown in the schematic drawings in Fig.2.9.  The incorporated 
PEG-DSPE would be able to sterically shield the binding sites or specific recognition 
structures on outer surface of SCLs. It is noticeable that the ECM bindings were totally 
blocked while the uptake still reach 30% of those normal SCLs. This suggests that the 
intracellular uptake of SCLs is a more complicated process than the ECM bindings of 
SCLs. 
Fluorescence real-time images showed that liposomes bound to the ECM were detachable 
from the cell bodies after the cells were treated with trypsin, while those inside the cells 
were not affected (data not shown). This observation that binding of SCLS to the ECM was 
sensitive to trypsin digestion also supports the involvement of ECM protein components in 
liposomes binding.  
Our results suggest that TN-C is the predominating cell surface receptor for liposomal 
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sulfatides. Firstly, it is well known that TN-C binds specifically to sulfatides but not to 
other gangliosides or GalCer (Crossin 1992), which appeared consistent with what we have 
observed in this work (Figure 2.1). Secondly, our fluorescence microscopy experiments 
demonstrated significant colocalization of Rh-PE labeled sulfatide-containing liposomes 
and essentially all of the TN-C positive sites throughout the ECM (Figure 2.7), which 
provides supporting evidence for a link between liposome binding site and this matrix 
protein. Thirdly, inhibition of TN-C expression by VD3 caused significant reduction in 
binding of sulfatides-containing liposomes to the ECM of the glioblastoma cells (Figure 
2.8). Finally, the expression level of tenascins has been known to be much higher than that 
of other sulfatides-binding ECM proteins like laminin in human glioblastoma cells (Enam 
1998). It has been shown in many studies that expression of TN-C is highly up-regulated in 
many difference cancers (Chiquet-Ehrismann 2003). Sulfatides mediated targeting drug 
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Chapter 3 Sulfatides-Containing Liposomes Internalization Occurs Both 
Clathrin-Dependent and Caveolae /Lipid Rafts Endocytosis Pathways 
3.1. Briefing 
The SCLs binds and are internalized into the glioma cells via the specific interactions of 
sulfatides with the cells. In this chapter, the modes of SCLs endocytosis were studied by 
pharmacological drug treatments, specific tracing markers and expressions of a 
dominant-negative inhibitor of the clathrin-dependent pathway. We could conclude that 
the SCLs were taken up via both clathrin-dependent and caveolae/lipid rafts endocytosis 
pathways.  
 
3.2. Materials and methods 
3.2.1. Chemicals  
Sulfatide (3'-sulfogalactosylceramide), galactosylceramide (GalCer), ganglioside GM1,  
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholera toxin B subunit (CTxB) and 
bodipy-lactosylceramide (Bodipy-LacCer) were obtained from Avanti Polar Lipids, Inc. 
(Alabaster, AL). Lissamine™ rhodamine B 
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine  (Rh-PE) was from Molecular 
Probes (Eugene, OR). Mouse anti-human TN-C monoclonal antibody, anti-O4 monoclonal 
antibody and the IgM negative control were from Chemicon (Temecula, CA). T7•Tag® 
monoclonal antibody was from Merck (Whitehouse Station, NJ). All other chemicals were 
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from Sigma-Aldrich (St. Louis, MO). 
 
3.2.2. Human glioma cell lines and culture conditions  
Human U-87MG glioblastoma cell lines were obtained from American Type Culture 
Collection (Rockville, MD). U-87MG cells were grown in EMEM containing 2mM 
L-glutamine, 2.2 g/l NaHCO3, 110 mg/l sodium pyruvate, and 10% fetal calf serum (FCS). 
Cells were cultured in a humidified atmosphere containing 5% CO2 at 37°C.  
 
3.2.3. Liposome preparation  
All lipids were dissolved in chloroform: methanol (2:1, v/v) except GalCer which was 
dissolved in hot ethanol. Appropriate amounts of lipids were transferred from their 
respective stock solutions into glass tubes and dried by evaporation under a nitrogen stream, 
as described (Shao K 2006). For fluorescence microscopy studies, 0.5 mol % of Rh-PE was 
included. The samples were stored under vacuum for 24 h at 4oC and the thin lipid film 
formed on the wall of the glass tubes was hydrated with PBS, briefly sonicated (1 min), and 
extruded repeatedly through two layers of polycarbonate membranes with a pore size of 
100 nm at room temperature (Avestin, Inc., Canada) (Olson F 1979).    
 
3.2.4. Intracellular uptake of SCL  
The internalization of Rh-PE-labeled SCL were examined by using an inverted microscope 
(Olympus IX71) or a Zeiss laser scanning confocal microscope system (LSM 510), 
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respectively. Cells were seeded into 24-well plates containing glass coverslips for 24 hour 
before co-incubation with the liposomes (final total lipid concentration: 80 µM) for 1 hour. 
The cells were then washed three times with ice-cold PBS and immediately fixed with 
3.7% paraformaldehyde (PFA). The coverslips were thoroughly rinsed with PBS and 
mounted on slides with anti-fade mounting media (Invitrogen, CA) before viewing. Rh-PE 
was excited at 543 nm and the emitted fluorescence was collected using a 560 nm 
long-pass filter. For quantitative analysis, the images were processed with the Image-Pro 
Plus software (version 4.5.1, Media Cybernetics, Inc., USA), where cell contours or the 
ECM areas surrounding the cells for each set of the fields were traced out manually in the 
corresponding phase-contrast images and then used to mask the fluorescence images. The 
fluorescence intensities of 7-10 fields of ~10 cells/field/condition or 5 fields of ~10 ECM 
areas/field/condition were analyzed.  
 
3.2.5. Effects of pharmacological inhibitors/phospholipase on liposome uptake  
Cultured cells were seeded on glass coverslips for 24 h before treatment with various 
pharmacological inhibitors for 1 hour to differentiate clathrin-dependent from 
clathrin-independent internalization of SCLs. The concentration of each reagent used (all 
from Sigma) was 10 mg/ml (2-hydroxypropyl)-β-cyclodextrin (2-HCD) (Wolf 2002), 10 
µg/ml cytochalasin D (Zenni 2000), 5 µM sphingosine (Sofer 1995), 0.5 M hyperosmolar 
sucrose (Heuser 1989) and 0.3 IU/ml phosphatidylinositol-specific phospholipase C 
(PI-PLC) (Ricci 2000, Peters 2002). The treated U-87MG cells were then incubated with 
the Rh-PE-labeled SCL for 1 h for quantitative analysis of the rate of liposome uptake. Cell 
56
viability was >90% for all treatments as judged by trypan blue staining. 
 
3.2.6. Construction and amplifications of T7Hub-pIRES-EGFP plasmid 
Expression of a fragment of clathrin heavy chain, clathrin hub, as a dominant-negative 
inhibitor of clathrin-mediated endocytosis was performed by following the method of Liu 
et al. (Liu 1998), with slight modifications.  
In brief, the cDNA encoding bovine clathrin heavy chain residues 1073-1675 (Liu 1995) 
was cloned into the BamHI and HindIII sites of the vector pET23d (Novagen, Inc.) after the 
T7 gene 10-leader peptide sequence. The polymerase chain reaction (PCR)-amplified 
T7Hub was introduced a Kozak sequence as well as a NotI restriction site at the end of the 
T7-Hub.  
The purified PCR products and pIRES-EGFP plasmids were digested with EcoR V. The 
EcoR V cleaved PCR products were ligated with EcoR V cleaved pIRES-EGFP vectors 
(BD bioscience, NJ) followed by transformation of DH-5α competent cells. The positive 
clones were inoculated to LB medium and incubated overnight. The T7Hub-pIRES-EGFP 
plasmid was extracted, analyzed by enzymatic cleavage. The T7Hub-pIRES-EGFP 
plasmid was amplified in E. coli and finally purified with the DNA Purification Systems 
(Promega). 
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3.2.7. Transfection of U-87MG cells with clathrin-Hub 
U-87MG cells were seeded in plates for 24 hour before transfection with 
Lipofectamine-2000(Invitrogen)/T7Hub-pIRES-EGFP complex according to the 
manufacturer’s protocol. The EGFP expression was detected with the 488 nm laser, which 
was used to indicate the expression of the plasmid. For liposome internalization 
experiments, 48 h after the transfection, U-87MG cells were incubated with Rh-PE-labeled 
SCLs for 1 hour and then viewed and quantified with confocal fluorescence microscopy 
after washing. 
 
3.2.8. Western blotting  
Cells were lysed in the lysis buffer containing 10 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 
1 mM EDTA (pH 7.4) and various protease inhibitors (Roche, Basal, Switzerland). 
Aliquots of the cell lysate (20 µg of protein) were then resolved by 5% SDS-PAGE and 
electroblotted onto PVDF membranes (Pierce, Rockford, IL). After blocking with 5% skim 
milk for 1 h at room temperature, clathrin Hub was detected by Western blot analysis using 
the monoclonal antibody against T7 tags (1:10,000 dilutions). Immunoreactive bands were 
visualized by using a secondary antibody conjugated to horseradish peroxidase (Bio-Rad 
Lab., CA) and the Super Signal enhanced chemiluminescence reagent (Pierce, Rockford, 




3.2.9. Statistical analysis  
 Data were evaluated by either unpaired Student’s t test (two-sided) or one-way ANOVA 
using SPSS 12.0 software (SPSS Inc., Chicago) and presented as means ± SD. All results 




3.3.1. SCLs were internalized via time dependent course and chain like fluorescence 
signals on the plasma membrane. 
The SCLs were taken up by the glioma cells in a time dependent process (Fig. 3.1.A). SCLs 
could be found been internalized as early as 15 minutes after the incubation. In the initial 
stage of the SCLs internalization, signals could be found on the plasma membrane 
(Fig.3.1.A.b, white arrow). The SCLs’ cellular accumulations reached a maximum after 
120 minutes, suggesting a saturation of SCLs uptake (Fig. 3.1. B).    
 
3.3.2. Integrity of sulfatide/DOPE liposomes was retained during internalization.  
To show that the integrity of the sulfatides/DOPE liposomes during uptake and early 
intracellular delivery is maintained, FITC-dextran was encapsulated in Rh-PE labeled 
sulfatide/DOPE (30:70, mol/mol) liposomes. Upon endocytosis of these liposomes by 
U-87MG cells, both the Rh-PE red fluorescence (Figure 3.2.A) and the FITC green 
fluorescence (Figure 3.2.B) were monitored with the confocal microscope (Olympus 
FluoView 300). Figure 3.2.C shows that large numbers of the membrane marker (Rh-PE) 
and the internal space marker (FITC-dextran) of the liposomes were colocalized after a 
total of 5 h incubation at 37oC, indicating that liposomes were delivered into the cytoplasm  


















Fig.3.1. SCLs Were Internalized Via Time Dependent Course and Chain Like 
Fluorescence signals on the plasma membrane. U87 MG cells were incubated with 
RH-PE labeled SCLs for 15, 30, 45, 60 and 120 minutes. A. Relative SCLs 
internalizations (the SCLs signals of 120 minutes’ incubation set as 100%) B. 
Representative fluorescence images were shown: a: 15; b: 30; c: 45; d: 60 and e: 120 
minutes after incubation with SCLs.  Arrows: the chain like fluorescence signal on 
plasma membrane. Scale bar=20 µm. 
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Fig. 3.2. Extensive colocalization of the membrane marker (Rh-PE, A) and the
internal space marker (FITC-dextran, B) of SCLS indicates that the integrity of
liposomal structure was maintained during early internalization. C. 
Representative superimposed image of the liposomal Rh-PE and FITC-dextran. 
These images were obtained after U-87MG cells had been cultured with the 
liposomes (total lipid concentration: 80 µM in EMEM) for 1 h, followed by 4-h 
incubation in the absence of liposomes at 37 °C. Scale bar=10 µm. 
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3.3.3. Macropinocytosis pathway is not involved in the cellular uptake of SCLs 
After binding of the liposomes to the target cells, the route of their internalization becomes 
very important for optimal therapeutic effects. For example, strategies may need to be 
developed for endosomal escape of the drugs to avoid subsequent degradation by 
lysosomal enzymes if the drug delivery system enters the cell via the clathrin-dependent 
pathways. In order to identify the pathway(s) responsible for uptake of the 
sulfatides-containing liposomes, we first tried to exclude the possibility of 
macropinocytosis as a major pathway for liposomal internalization by pretreatment of the 
cells with cytochalasin D. It is well known that this mode of internalization requires a 
functional actin cytoskeleton while cytochalasin D destabilizes the actin filaments (Zenni 
2002, Swanson 1995). Pre-treatment of the cells with cytochalasin D (10 mg/ml) had no 
effect on the internalization of the sulfatides-containing liposomes (data not shown), 
suggesting that macropinocytosis is unlikely to be an important mode of uptake of the 
liposomes. 
 
3.3.4. Cholesterol depletion of the plasma membrane inhibit the cellular uptake of 
SCLs 
The chain-like fluorescence signals found on the plasma membrane during the SCLs 
internalization suggested that plasma membrane associated structures may play important 
roles.  
It has been well-established that various types of endocytosis may co-exist and some, such 
as caveolae- and clathrin mediated endocytosis, are affected by depletion of cholesterol of 
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the cell plasma membranes (Rodal 1999, Rejman 2004). We therefore examined if the 
internalization of sulfatides/DOPE liposomes by the human glioma cells was susceptible to 
cholesterol depletion. Cyclodextrin treatment can effectively deplete the plasma membrane 
cholesterol. In our studies, (2-hydroxypropyl)-β-cyclodextrin (2-HCD) treatments could 
effectively remove ~40% of total cholesterol from the U 87 MG cells (Figure 3.3. A.). 
When the cells are pre-treated with 2-HCD, an approximately 75% decrease in 
internalization of the fluorescence labeled sulfatides/DOPE liposomes was observed 
(Figure 3.3. B.), suggesting that the internalization of such liposomes is clearly 
cholesterol-dependent. However, since both caveolae- and clathrin-dependent endocytosis 
have been known to be affected by cholesterol depletion, further experiments were thus 
conducted to ascertain either or both of these pathways contributed to the uptake of the 
sulfatides-containing liposomes. In the following studies, markers for caveolae- and 
clathrin-dependent endocytosis (Rejman 2004, Puri 2001, Singh 2003), cholera toxin B 















































Fig.3.3 Cholesterol depletion and its effects on SCLs internalizations. U-87MG cells 
treated with 2-HCD, PI-PLC, sucrose and sphingosine on the internalization of 
sulfatide/DOPE (30:70, mol/mol) liposomes. The cells were pretreated with 1% (w/v) 
2-HCD (A), 0.3 IU/ml PI-PLC (B), 0.5 M sucrose (C) or 5 µM sphingosine (D), 
respectively, for 1 h at 37oC before the liposomes were introduced. Control cells were 
treated with vehicle and the uptake of Rh-PE-labeled liposomes by control cells was set 
as 100% (not shown in the figure). Values are mean ± SD of at least three independent 
experiments. *p<0.01 versus the uptake levels of both CTxB and transferrin. 
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3.3.5. Caveolae-mediated endocytosis was responsible for uptake of SCLs: the effects 
of PI-PLC pretreatment.  
We first checked if caveolae-mediated endocytosis was responsible for uptake of the 
liposomes. To this end, the cells were pre-treated with PI-PLC, a well-established 
procedure to remove GPI-anchored proteins from the cell surface (Ricci 2000, Peters 2003). 
Figure 3.4 shows that PI-PLC treatment caused a 30% reduction in the uptake of the 
fluorescence labeled liposomes compared with the untreated control cells, a clear 
indication that perturbation to caveolae did affect the internalization of the 
sulfatide-containing liposomes.  
This was supported further by experiments in which the cells were pretreated by nystatin, a 
drug known to perturb the structure and function of caveolae but not clathrin-coated pits, 
actin filaments, or other membranous structures (Deckert 1996, Skretting 1999, Rothberg 
1992). U-87MG cells treated with nystatin (40mg/ml) before addition of liposomes 























Fig.3.4 Effects of pretreatment of U-87MG cells with PI-PLC on the 
internalization of sulfatide/DOPE (30:70, mol/mol) liposomes. U-87 MG cells 
were pretreated with 0.3 IU/ml PI-PLC (B) for 1 hour at 37oC before the liposomes 
were introduced. Control cells were treated with SCLs and the uptake of 
Rh-PE-labeled liposomes by control cells was set as 100% (not shown in the figure). 
Values are mean ± SD of three independent experiments.  *p<0.01 versus the uptake 
levels of both CTxB and transferrin. 
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3.3.6. SCLs were internalized via Clathrin-dependent endocytosis. 
We next investigated whether the sulfatide-containing liposomes could be internalized by 
the clathrin-mediated pathway. It is well-known that hypertonic sucrose inhibits 
clathrin-mediated endocytosis by disrupting formation of clathrin-coated pits (Heuser 
1989, Lakkaraju 2002). The human glioma cells were treated with 0.5 M sucrose before the 
uptake of liposomes was studied. It was found that such treatment decreased the 
internalization of sulfatides-liposomes by as much as 70% compared with the control cells 
(Figure 3.5). This implied that uptake of sulfatides-containing liposomes was also 
clathrin-mediated.  
This conclusion was verified by examining the uptake of the sulfatides-containing 
liposomes after treatment of the cells with 5 mM sphingosine, a cationic amphiphilic drug 
known to interrupt assembly-disassembly of clathrin from coated pits and endosomes 
(Wang 1993, Sofer1995). Figure 3.6. shows that sphingosine exhibited similar inhibition 
effects shown by hypertonic sucrose. The internalization of the SCLs was reduced by 40% 
























Fig.3.5 Hypertonic sucrose treatment effects on SCLs internalizations. 
U-87MG cells treated with 0.5 M sucrose for 1 h at 37oC before the incubation with
liposomes. Control cells were treated with EMEM and the uptake of Rh-PE-labeled 
liposomes by control cells was set as 100% (not shown in the figure). Values are 
mean ± SD of at least three independent experiments. *p<0.01 versus the uptake 






















 Fig.3.6 Sphingosine pretreatment and its effects on SCLs internalizations. 
U-87MG cells treated with 5 µM sphingosine for 1 hour at 37oC before the
incubations with RH-PE labeled SCLs. Control cells were pre-treated with 
EMEM and the uptake of Rh-PE-labeled liposomes by control cells was set as 
100% (not shown in the figure). Values are mean ± SD of at least three 




3.3.7. Expressions of a dominant-negative hub fragment of clathrin in U-87MG cells 
inhibits SCLs uptake 
It was reported that expression of a dominant-negative hub fragment of clathrin could 
perturb clathrin-mediated endocytosis (Liu 1998, Altschuler 1999, Bennett 2001). To 
obtain further support for a mechanism that would involve clathrin-mediated endocytosis, 
we therefore investigated whether expressing the hub in U-87MG cells will affect SCLs 
internalizations. 
 
3.3.7.1 The plasmid containing T7-hub was cloned into pIRES-EGFP vector.  
The Hub DNA was a gift from Prof. Yoram Altschuler (Hebrew University of Jerusalem, 
Israel). Two primers were designed to PCR amplify the T7Hub and introducing kozak sequence as 
well as a Not I enzymatic site at the ends of the T7Hub.  
Sense Primer: T7tag 
5’-CCGCCATG GCT AGT ATG ACT GGT GGA CAG -3’ 
       kozak + T7 tag 
Antisense primer: HubRev 
5’- CT GGC TTT GGG TAC AGC ATG TGA GCGGCCGC -3’                                                  
 C terminal of Clathrin Hub   Stop     Not I 
Reverse complement 
5’- GCGGCCGC TCA CAT GCT GTA CCC AAA GCC AG -3’ 
        Not I             Stop   C terminal of Clathrin Hub 
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The PCR products were ligated with EcoR V and Not I cleaved pIRES-EGFP vectors 
followed by transformation of DH-5 α competent cells. Clones were analyzed with 
enzymatic digestion and confirmed by DNA sequencing. 
 
Fig. 3. 7 T7HUB-pIRES-EGFP plasmid map.  The T7HUB sequence was inserted 
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Fig.3.8. T7HUB-pIRES-EGFP plasmid construction and verification. T7HUB 
sequence was inserted in the EcoR V and Not I cleaved pIRES-EGFP vector. Sense 
T7HUB-pIRES-EGFP vector were verified with EcoR I and Pst I digestions and 




3.3.7.2. Transfection of U-87 MG Cells with T7Hub-pIRES-EGFP. 
Clathrin hub expression was detected, using anti-T7 epitope antibody, 24 hour after 
transfection and reached its maximum 48 hour after transfection (Figure 3.9.A). The 
uptake of the sulfatides containing liposomes by the U87 MG cells was examined 48 hours 
after the transfection. The representative images were shown in Figures 3.10 to 3.12. There 
were no significant differences of the SCLs uptake between pIRES-EGFP positive cells 
and control cells. There was significant attenuation of SCLs uptake in those hub 
expressions positive cells (Fig. 3.12.). It was found the SCLs uptake was attenuated even in 
U 87 MG cells which the EGFP signal were very weak (Fig. 3.12, yellow arrow pointed 
cells). Quantitative analyzing of those images shows that clathrin hub expression inhibits 
approximately 50% liposomal endocytosis with p value < 0.01. Taken together, these data 
are consistent with the notion that both caveolae and clathrin were involved in the 
internalization of the sulfatide-containing liposomes. 
74
A 




























   * 
Fig3.9. Effect of expression of clathrin hub on internalization of sulfatide/DOPE 
(30:70, mol/mol) liposomes by U-87MG cells. A. Expression of clathrin hub in 
U-87MG cells as detected by Western blot with anti-T7 epitope antibody. The blots are 
representatives of three independent experiments performed. β-Actin was used as a 
loading control. B. Internalization of Rh-PE–labeled sulfatide/DOPE (30:70, mol/mol) 
liposomes was studied in U-87MG cells 48 h after clathrin hub transfection. Values are 
mean ± SD of at least three independent experiments. *p<0.01 versus the 
non-transfected control and the vector-transfected. cells. 
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 Fig. 3.10. The effects of expression HUB in gliomas cells on SCLs internalizations.
U87 MG cells incubated with RH-PE labeled SCLs for 1 hour. Representative images of 
fluorescence (a) and transmit (b) light were shown. Bar=20 µm. 
 
Fig. 3.11. pIRES –EGFP transfection in gliomas cells and the effects on SCLs 
internalizations. U87 MG cells transfected with pIRES-EGFP were incubated with RH-PE 
labeled SCLs for 1 hour. Representative images of fluorescence (a: Rhodamine ; b: FITC; c: 
overlap of Rhodamine and FITC;) and transmit (d) light were shown. Arrows to the cells: 
white: EGFP expression cells; blue: no EGFP expression. Scale bar=20 µm. 
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 Fig. 3.12. T7HUB-pIRES –EGFP transfection in gliomas cells  and the effects on 
SCLs internalizations. U87 MG cells transfected with T7HUB-pIRES-EGFP were 
incubated with RH-PE labeled SCLs for 1 hour. Representative images of 
fluorescence (a: Rhodamine; b: FITC; c: overlap of Rhodamine and FITC;) and 
transmit (d) light were shown. Arrows to the cells: white: EGFP expression cells; 
yellow: EGFP weak expression; blue: no EGFP expression. Scale bar=20 µm. 
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3.4. Discussion 
The binding and internalization of sulfatides-containing liposomes by U-87MG cells were 
well defined sequential events. Fluorescence real-time images showed that liposomes 
bound to the ECM were detachable from the cell bodies after the cells were treated with 
trypsin, while those inside the cells were not affected (data not shown). The trypsin 
sensitivity also suggests the involvement of ECM protein components in liposome binding. 
It is clear that both caveolae and clathrin-mediated endocytosis contributed to the uptake of 
the sulfatide-containing liposomes. Since the particle size affects the route of its 
internalization, an explanation for such a dual entry mechanism could be due to the 
intrinsic heterogeneous size distribution of the liposomes (Rejman 2004). This does not 
rule out the possibility that independent internalization machinery did exist for caveolae- 
and clathrin-dependent endocytosis of the SCLs. The clathrin-dependent and caveolae 
pathways of SCLs endocytosis could lead to effective delivery of the drug bypassing the 
P-GP mediated multiple drug resistance. 
For effective intracellular drug and/or gene delivery, an early release of the cargo is always 
desirable in order to avoid lysosomal degradation in clathrin-mediated endocytosis. 
Presence of DOPE definitely reduces the chance of lysosomal degradation as the 
liposomes would become unstable in endosomes under acidic pH (Wu 1996, Wu1999). It 
is interesting to note that a significant portion of the sulfatides-containing liposomes was 
internalized via the clathrin independent pathway, in which the internalized caveolae may 
fuse with caveosomes, and the caveosomes then deliver their contents into other 
non-lysosomal subcellular compartments. Bypass of the acidic and harmful milieu is 
considered as a major advantage, among others, for drug delivery via the caveolar pathway 
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over the clathrin-dependent pathway (Carver 2003, Gumbleton 2003, Bathori 2004). 
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Chapter 4 SCLs as Drug Delivery Systems:  in vitro studies  
4.1. Briefing 
The SCLs were found to bind to the ECM of glioma cells via the specific interactions 
between sulfatides and TN-C. The SCLs were effectively internalized the glioma cells via 
both caveolae and clathrin-dependent endocytosis pathways. In this chapter, we further our 
studies to test whether SCLs can be applied as drug delivery systems. The size distribution 
and surface potential of the SCLs were studied. Doxorubicin was chosen to be 
encapsulated in SCLs, and the encapsulation efficiency and stability of drug in SCLs was 
studied. In vitro studies of drug accumulation, distribution and cytotoxicity of SCL-DOX 
were carried out using glioma cell lines. 
 
4.2. Materials and Methods 
4.2.1. Human glioma cell lines and culture conditions.  
Human U-87MG and CCF-STTG1 glioblastoma cell lines were obtained from American 
Type Culture Collection (Rockville, MD). U-87MG cells were grown in EMEM containing 
2mM L-glutamine, 2.2 g/l NaHCO3, 110 mg/l sodium pyruvate, and 10% FCS. 
CCF-STTG1 cells were maintained in DMEM supplemented with 10% FCS. Cells were 
cultured in a humidified atmosphere containing 5% CO2 at 37°C and were passaged 
following treatment with trypsin (0.05%)/EDTA (0.02%). For tumor cell implantation into 
nude mice, cells were treated with trypsin/EDTA, neutralized with complete medium, spun 
down, and washed twice with serum-free medium. 
 
4.2.2. Liposome preparation.  
81
All lipids were dissolved in chloroform:methanol (2:1, v/v) except GalCer which was 
dissolved in hot ethanol. The lipid thin films of various formulations were prepared as 
described by Shao and Li (Shao 2006) and were hydrated with PBS or other buffers as 
indicated, followed by extrusion through polycarbonate membranes with a pore size of 100 
nm (Avestin, Inc., Canada) (Olson 1979). For fluorescence microscopy studies, 0.5 mol % 
of Rh-PE was added to the lipid mixture.  
 
4.2.3. Size distribution and zeta potential of the SCLs 
Particle size measurements were performed using a Zetasizer 3000 (Malvern Instruments, 
UK). All measurements were carried out at 25°C with the following system: count rate, 50 
~75 kilo counts per second; detector angle, 90.00; wavelength, 633.0 nm; and analysis 
mode, automatic continuous. 
The zeta potentials were determined with a laser electrophoretic mobility instrument 
Zetasizer (model 4; Malvern Instruments) in PBS.  
 
4.2.4. Drug encapsulation 
For liposomes used for encapsulation of DOX, each batch consisting of 10 µmol total 
lipids was hydrated in 250 mM ammonium sulfate (pH 8.5), followed by vigorous 
vortexing and brief sonication (1 minute). Liposomes were formed by extruding repeatedly 
through two layers of 100 nm polycarbonate membranes at room temperature (MacDonald 
1991). Extruded liposomes were dialyzed extensively against a 100-fold volume of 10% 
sucrose (25 mM Trizma at pH 8.5), four changes over 24 hour at 4°C. DOX dissolved in 
the above buffer was actively loaded into the liposomes through establishment of 
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ammonium sulfate gradient (Haran 1993, Ishida 2001). Non-entrapped DOX was removed 
after incubation at 55°C for 1 hour by passing the liposomes through a Sephadex G-50 
column equilibrated with degassed PBS. DOX concentrations were determined by 
measurement of fluorescence intensity of the drug ( λex = 480 nm, λem = 550 nm) and the 
encapsulation efficiency was generally greater than 90%, with a drug to phospholipids ratio 
of approximately 0.2 µmol/µmol. 
 
4.2.5. In vitro stability of the SCL-DOX.  
The stability of liposomes containing doxorubicin was examined in PBS, cell culture 
medium and fetal bovine serum. Briefly, liposomes are prepared by membrane extrusion 
and drugs are loaded in the same day when the stability study is carried out. 70 µl of 
liposomes solution is added into 630 µl of PBS, cell culture medium and fetal bovine serum, 
respectively. The mixture is vortexed, and 50 µl of the mixture is to be taken out for drug 
concentration assay, another two of 50 µl of the mixtures are added to G50 spin column for 
liposomal drug assay. All mixtures are incubated at 37 C, and at time 1, 4, 18 and 24 hour, 
two of 50 µl samples are taken for the liposomal drug assay. The concentrations of 
liposomal drug are then compared with the initial liposomal drug concentration. 
 
4.2.6. Cellular and nuclear distribution of DOX.  
To investigate quantitatively the delivery of DOX to the nucleus, cell fractionations were 
performed according to published methods (Goren 2000, Kirchmeier 2001) with 
modifications. In these experiments, CCF-STTG1 and U87-MG cells were seeded at a 
density of 20,000/cm2 in T75 plastic flask (NUNC) in 95% humidified air and 5% CO2 at 
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37°C for 3 days (80-90% confluence). Free DOX and DOX encapsulated in 
sulfatide/DOPE (30:70, mol/mol) liposomes (SCL-DOX) were added into RPMI1640 
medium to a final drug concentration of 10 µM. The cells were exposed to free DOX or 
SCL-DOX for 1, 4, 12 and 24 h at 37°C. The treated cells were then washed twice with 
chilled PBS, and detached by trypsinization. The cells were centrifuged at 300 x g for 3 
min and the pellets were washed twice with chilled PBS and re-suspended at a 
concentration of 5x106 cells/ml in TEA buffers(10 mM Tris buffer (pH 7.4) containing 100 
mM NaCl, 1 mM EDTA, and 1 % Triton X-100) for 10 min at 4°C. The suspension was 
then centrifuged at 800xg for 15 min and the precipitate of cell nuclei was separated from 
the supernatant. The fluorescence intensity of the cytosol fraction (the supernatant) was 
detected at λex = 480 nm, λem = 550 nm. The drug concentration was calculated according 
to a standard curve of DOX vs. its fluorescence intensity. The nucleus fraction was washed 
once with TEA, then added with 0.75 ml of TEA,  5 µl of digitonin (25 mg/ml) and 5 µl of 
MgCl2 (57 mg/ml) followed by vortex and brief sonication. Twenty-five microliters of 
DNase 1 (Sigma) solution (3 mg/ml) was added and the suspension was vortexed and 
allowed to stand at room temperature for 2 h. The samples were centrifuged at 3,000 g for 5 
min, and the fluorescent intensity of the supernatant was measured at the excitation and 
emission wavelength for DOX.  
 
4.2.7. Cytotoxicity studies. 
The viabilities of treated and untreated cells were determined by the quantitative 
colorimetric MTT assay which measures the mitochondrial conversion of MTT to 
formazan as detected by the change of optical density at 570 nm (Mosmann 1983). To 
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evaluate the cytotoxicity of free DOX and liposomal DOX, U-87MG cells (10×105 cells/ml) 
in 100 µl aliquots were plated in 96-well flat-bottomed microtiter plates and cultured for 24 
h at 37°C. The medium was then replaced with serum-free and antibiotics-free medium 
containing various concentrations of free or liposomal DOX. The cells were further 
cultured for 4 h at 37°C under 5% CO2. After a thorough rinse with ice-cold PBS, 
DOX-free complete medium was added and the incubation was continued for 72 h before 
the cells were washed and 0.5 mg/ml MTT (100 µl) in complete medium (without phenol 
red) was added to each well and the cells were incubated for another 4 h at 37°C. The 
reaction was stopped by removing the MTT solution and the cells were then solublized in 
150 µl DMSO before the absorbance at 570 nm was measured with a plate reader (Spectra 
Fluor, Tecan Group Ltd., Mannedorf, Switzerland). 
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4.3. Results 
4.3.1. The size distribution and zeta potential of SCLs 
For liposomes containing DOPE/sulfatides used in our studies, the liposomes were 
prepared by membrane extrusion methods. Liposomes were passed through two layers of 
polycarbonate membranes with pore size (50, 100 nm) for 13 times. The size distribution 
was analyzed with Zetasizer 2000/3000 (Malvern Instruments). Fig. 4.1 shows that the size 
distribution of liposomes prepared appears to follow normal distribution. The average size 
of SCLs is about 42.9 and 80.6 nm respectively. Liposomes with average size less than 100 
nm are considered suitable for our further study.   
Size distribution(s)










Fig 4.1 The size distribution of SCLs: SCLs with two different sizes were 
prepared. SCLs were prepared by passed through two layers of polycarbonate 
membranes with pore size (50, 100 nm) for13 times. The size distribution of SCLs was 
analyzed by the zetasizer 2000/3000 (Malvern Instruments). 
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In our studies, the zeta potential of liposomes is correlated to the molar ratio of sulfatides 
incorporated into the liposomes (Fig.4.2). The zeta potential became more negative at 
higher sulfatide concentrations, reaching -50mV at 30 mol% sulfatides. The anionic 








0 10 20 3











Fig. 4.2 Zeta potential (surface charge) of  SCLs composed with different
content of sulfatides. Sulfatides containing liposomes composed with different 
sulfatides content (molar ratio) DOPC (100%), Sulf:DOPC(10%: 90%), Sulf:DOPC 
(20%:80%) and Sulf:DOPE(30%:70%) were prepared. The zeta potential those 
different SCLs was analyzed by the zetasizer 2000/3000 (Malvern Instruments).  
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4.3.2 Drug encapsulation 
 
 
Fig.4.3 Schematic illustrations of active drug loading.  Briefly, liposomes were 
prepared in (NH4)2SO4 solution. (NH4)2SO4 was then removed by extensive dialysis. 
Active drug loading was accomplished after incubating the liposomes with DOX at 55 oC 
for 60 minutes. During the incubation, the liposome bilayers are permeable to neutral 
DOX. Once the DOX reaches the interior aqueous phase of the liposomes, it will form a 
gel like precipitate with (NH4)2SO4.  The drug/ liposomes solutions were passed through a 
gel filtration column to remove the not encapsulated or outer surface attached drugs if 
there was any. 
Doxorubicin is widely used to treat solid tumors such as AIDS-related Kaposi’s sarcoma, 
ovarian cancer and metastatic breast cancer (Northfelt 1996, Gill 1995, Cowens 1993). 
Efficient "active loading" encapsulation procedures result in high internal concentrations 
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of drug that can remain sequestered within circulating liposomes and undergo deposition in 
tumors as the liposomes extravasate.  
There are maybe some biophysical obstacles while loading the drug to SCLs: the high 
negative surface charge of the liposome and the pH sensitivity of DOPE. We have 
optimized the loading protocols to achieve high DOX loading efficiency. 






















Fig. 4.4 DOX quantifications: standard curve of DOX vs. its fluorescence 
intensity.  The standard curve of fluorescence intensity of DOX was detected at λex = 
480 nm, λem = 550 nm.  
 The resulting SCL-DOX and PEGL-DOX was analyzed with a drug/lipid ratio of about 
0.17 (mol/mol). For DOPE/sulfatide (70:30, mol/mol) liposomes, the DOX encapsulation 
efficiency was about 92.4%. For PEG(MW2000)-DSPE/DOPE/sulfatide (3:67:30, 
mol/mol) liposomes, the DOX encapsulation efficiency was about 90.7%. There are no 
significant differences in the drug encapsulation efficiency between different liposomes 
formulations used in the studies. It was also noted that the DOPE/sulfatide liposomes had 
higher drug encapsulation efficiency compared to egg PC/sulfatide liposomes at similar 
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phospholipids to sulfatide ratio (data not shown). 
 
4.3.3. Stability of SCL-DOX: in vitro release of DOX in different medium 
The stability of several liposomal drug systems were studied and compared by incubating 
those liposomes in different solutions of PBS, EMEM and 50% fetal bovine serums in PBS 
at 37 oC. The drugs retained in the liposomes after 1, 4, 16 and 24 hour incubation were 
determined and compared to drug concentration at 0 hour. There was negligible release of 
DOX in the first four hours of incubation for all formulations in all media tested (Fig. 4.5 
and Fig. 4.6.).  
Table 4.1 shows the amounts of DOX retained in the liposomes after 24 h incubation. It is 
clear that liposomes were more stable in the cell culture medium and FBS than in PBS. 
However, even in the latter case, there were about 63% DOX remaining in the liposomes. 
Furthermore, incorporation of 3 mol% PEG-DSPE to liposomes did slightly improve the 
stability of liposomes containing 30 mol% of sulfatides (Table 4.1).   
SCL-DOX PEGL-DOX 
Incubating 
Solutions Drug retaining 
After 24 hour 
Drug release 
% per hour Drug retaining 
Drug release % 
per hour 
PBS 62.70% 1.63% 70.50% 1.23% 
EMEM 72.60% 1.05% 84% 0.72% 
50% FBS 73.80% 1.14% 81.10% 0.94% 
Table 4.1. in vitro release of DOX from liposome.  SCL-DOX (DOPE:Sulfatide=70:30) 
and PEGL-DOX (DOPE:SULF:PEG-DSPE=67:30:3) were incubated in different 
solutions of PBS, EMEM and 50% fetal bovine serum in PBS at 37 oC. The drugs retained 
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in the liposomes after 24 hour incubation were determined and compared to drug 
concentration at 0 hour. Drug release rate of liposomal DOX were shown. 
 
4.3.4. Intracellular distribution SCL-DOX.   
To study the uptake of the free doxorubicin and SCL-DOX by glioma cells, we quantify the 
accumulation of drugs in the cells as well as the subcellular distribution of the drugs. 
4.3.4.1. Cellular fractions and DOX quantification 
Doxorubicin was found to penetrate the cell and subsequently concentrate in the nucleus 
where it intercalation with chromosomal DNA which inhibits the DNA replication. The 
tight intercalation of Drug-DNA reduces the fluorescence of the drug. The effective of 
intracellular delivering and nuclei accumulation of the drug are highly desirable to achieve 
better antitumor efficacy. After the DOX treatment, we first separated the cytosolic 
fraction and nuclei fraction. The drug concentration of the cytosol fraction was detected in 
presence of 1% Triton X-100. The Triton X-100 can effectively disrupt the cell plasma 
membrane and releases the cytosolic drug from any possible aggregation while keeping the 
nuclear membrane relatively intact.  To release the nuclear fraction drugs, digitonin was 
used to permeablize the nuclear membrane, followed by brief sonication. DNase I was used 
to breaks DNA into a complex mixture of monomers and small oligomers (Vanecko 1961) 
with release of DXR and fluorescence de-quenching (Andersen 1994, Danjani 1995). 
DNase I was used to cleave the DNA and release the drugs. Time course study showed that 
2 hour’s DNase I digestion is crucial for maximum release of the drug, further digestion 





















































































Fig 4.5.  in vitro release of DOX from SCL-DOX. The stability of SCL-DOX was 
studied incubating SCL-DOX in different solutions of: A) PBS, B) EMEM and C) 50% 
fetal bovine serums in PBS at 37 oC. The drugs retained in the liposomes after 1, 4, 16 





















































































Fig 4.6. in vitro release of DOX from PEGL-DOX. The stability of PEGL-DOX was 
studied incubating PEGL-DOX in different solutions of: A) PBS, B) EMEM and C) 50% 
fetal bovine serums in PBS at 37 oC. The drugs retained in the liposomes after 1, 4, 16 and 
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Fig. 4.7. DNase I digestion and nuclei DOX quantifications. The nucleus fraction 
was washed once with TEA, then added with 0.75 ml of TEA,  5 µl of digitonin (25 
mg/ml) and 5 µl of MgCl2 (57 mg/ml) were added followed by vortexing and a brief 
sonication. Twenty-five microliters of DNase I solution (3 mg/ml) was added and the 
suspension was vortexed and allowed to stand at room temperature for up to 160 
minutes. The samples were centrifuged at 3,000 g for 5 min, and the fluorescent 
intensity of the supernatant was measured at the excitation and emission wavelength 
for DOX The fluorescence intensity was detected at λex = 480 nm, λem = 550 nm. The 
optimal DNase I digestion time was 120 minutes, and thus was used for further studies.
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4.3.4.2. Intracellular distribution of DOX 
Intracellular accumulation and distribution of free and liposomal DOX were examined 
using the human glioma cell lines, CCF-STTG1 and U87-MG11 cells, with methods 
modified from published references (Goren 2000, Kirchmeier 2001). Figure 4.8 A shows 
that the entry of free DOX into the cells was much faster than that of SCL-DOX. The 
nuclear drug concentration reached its maximum after 4 hour incubation at 37oC when the 
cells were loaded with free DOX. In contrast, the nuclear drug gradually increased and 
reached a maximum only after 12 hour incubation when SCL-DOX was used. More 
interestingly, nuclear delivery of free DOX seemed to be reversible when incubation was 
prolonged from 4 hour to 24 hour. This was not shown by SCL-DOX during the same 
period. At 24 hour incubation, approximately 80% of the intracellular SCL-DOX was 
accumulated in the nuclei, where it is supposed to exert its cytotoxic effect. However, in 
the case of free DOX, only ~55% of the drug inside the cells remained in the nuclei. 
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DOX distribution in CCF-STTG1 cells
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DOX distribution in U87-MG cells
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Fig. 4.8 Accumulation and intracellular distribution of DOX in cells of U87-MG 
and CCF-STTG1. Accumulation of DOX in the nuclei and cytosol of both cells after 




4.3.5. In vitro cytotoxicity study 
The cytotoxicity of SCL-DOX was then compared with that of free DOX and PEGL-DOX. 
U-87MG cells were exposed to free or liposomal DOX (SCL-DOX and PEGL-DOX) for 4 
hours, washed and further incubated for 72 h in fresh medium before the MTT assay was 
performed. The growth inhibition curves derived from treatment were shown in Fig.4.9. It 
was found that SCL-DOX was slightly less toxic than free DOX, but clearly superior 
(~6-fold drop in IC50) to that of PEGL-DOX. The higher cytotoxicity of SCL-DOX 
compared with PEGL-DOX is consistent with the key role of sulfatides in mediating  




















Fig.4.9. The in vitro cytotoxicity of DOX in different formulations. The cytotoxicity 
of SCL-DOX was then compared with that of free DOX and PEGL-DOX. U-87MG 
cells were exposed to free or liposomal DOX for 4 hours, then washed and further 
incubated for 72 h in fresh medium before the MTT assay was performed. Values are 




Liposomes of a defined size are readily prepared by extrusion of lipid suspensions through 
filters containing pores of a defined size (Olson F 1979). The size of liposomes could affect 
the effective loading of the drugs via the different inner aqueous volumes. The size of the 
liposome could also affect the pharmacokinetics of the liposomal drugs. The general trend 
for liposomes of similar composition is that increasing size translates into more rapid 
uptake by the RES (Abra 1981, Senior 1987). At the same time, the size of liposomes will 
also affect the accumulations in the tumor area by the passive accumulations due to the 
enhanced permeability and retention (EPR) effects.  The liposomes prepared in our lab 
have defined size distributions of either 43 nm or 81 nm, which are suitable in most studies 
as drug delivery systems. 
The effect of liposome surface charge on liposome clearance kinetics has been studied by 
many groups. Gabizon et al. reported on the effect of surface charge on liposome clearance 
in mice using liposomes containing different anionic phospholipids (Gabizon 1992). The 
experiments showed that the inclusion of anionic lipids such as ganglioside GM1 or 
phosphatidylinositol resulted in longer circulation lifetimes.  
Doxorubicin is widely used to treat solid tumors. Efficient "active loading" encapsulation 
procedures result in high internal concentrations of drug that can remain sequestered within 
circulating liposomes and undergo deposition in tumors as liposome extravasate.  There 
maybe some obstacles while loading the drug to SCLs: the high negative surface charge of 
the liposome and the pH sensitivity of DOPE. We have optimized our loading protocols to 
achieve high loading efficiency. With the active loading method, the drug is likely to form 
a gel precipitant when it goes into the inner aqueous phase of the liposomes. It is possible 
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that in our case most of the drug is in such a state since the drug encapsulated in the 
liposomes exceeds its solubility in the solvent. There should be equilibrium between the 
drugs in the gel state and those bound to the sulfatides in the inner surface of the liposomes. 
Yagi et al. showed that drug molecules do bind to the inner surface of liposomes containing 
sulfatides (Yagi 1989). Compare to Yagi et al, we have applied the active loading methods 
in SCLs with some optimizations of the loading methods and achieve the high loading 
efficiency.  However, the effect of interactions between lipids and DOX on the drug 
encapsulation efficiency is a complicated issue and interactions between the lipids may 
also affect such efficiency. 
The in vitro release of DOX from the liposomes was studied in different media. The 
releasing of DOX from the liposomes in EMEM and 50% FCS were chosen for the ease of 
further studies carried out in cells and animal models. It was found that the incorporations 
of PEG-DSPE into SCLs may increase the stability of the liposomes which results in 
slower release of DOX from liposomes when incubated in all media tested (Table 4.1.).  
The liposomes have been observed to remain intact for hours after uptake by the 
glioblastoma cells (Figure 3.2). Apparently, free DOX could readily enter the cells and 
accumulate quickly in the nuclei. Under the conditions used in this study, the nuclear DOX 
concentration reached a maximum 4 hour after free drug was added into the cell culture, 
but began to decay thereafter, apparently due to active efflux of the drug by transporters 
such as P-glycoprotein and the multidrug resistance-associated proteins found in the 
nuclear membranes (Baldini 1995, Bradshaw 1998). In contrast, nuclear DOX 
concentration was maintained at its maximal level for at least 12 hour when SCL-DOX was 
used, albeit its initial entry rate was slower than that of free DOX (Figure 4.8 A). This is  
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probably due to continuous internalization of liposomes from the ECM, or slow release of 
the entrapped DOX from the liposomes or both. The apparent failure of the efflux 
transporters to pump out liposomal DOX from the nuclei might also be due to the sustained 
supply of SCL-DOX, as total intracellular liposomal DOX kept on increasing for 12 hour 
following addition of SCL-DOX to the cells (Figure 4.8 A). The inability of cells to pump 
out liposomal DOX has been observed before (Goren 2000), where it was postulated that 
this might be due to the presence of liposomal DOX in aggregated states when loaded by 
the methods of ammonium sulfate-generated gradient (Li X 1998, Price 1999). We cannot 
rule out this possibility in the current system.  
The differences in cytotoxicity exhibited by the different drug formulations may be due to 
the different intracellular distribution of drug. The nucleus is the target site for the drug to 
exert cytotoxicity on the tumor cells. The total intracellular DOX delivered by SCLs was 
slightly less (about 20%) than that by the free drug. However, the in vitro cytotoxicity of 
the liposomal DOX was comparable to free DOX and much higher than the PEG-DSPE 
incorporated liposomal DOX (Figure 4.9). This could be adequately explained by early 
findings such as the reduced ECM bindings and intracellular uptake as well as reduced 
releasing rate of the DOX from the liposomes caused by the incorporation of PEG(MW 
2000)-DSPE into SCLs.   
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Chapter 5 In Vivo Study of SCL-DOX in Balb/C mice and a Subcutaneous Tumor 
Xenografts Animal Model  
5.1. Briefing 
The antitumor drug of doxorubicin can be effectively encapsulated in 
sulfatides-containing liposomes. The stability, intracellular distributions and in vitro 
cytotoxicity were examined in previous chapter. This chapter detailed studies in 
animals of normal mice of Balb/c and athymic mice bearing subcutaneous (s.c.) 
tumors were used to test the anti-tumor efficacy of SCL-DOX.  
 
5.2. Materials and methods 
5.2.1. Cell culture (details in previous chapters) and animals 
Twelve-week-old male Balb/c mice were provided and housed by he animal holding 
unit of National University of Singapore. Five-week-old male athymic nude mice 
(Animal Resources Center, Australia) were imported and acclimatized for one week in 
the animal holding unit of National University of Singapore. All animal experiments 
were performed in accordance with the guidelines of the Institutional Animal Care 
and Use Committee (IACUC) of the National University of Singapore. Mice were 
bred under specified pathogen-free conditions at 25°C, 70% relative humidity, and a 
12-hour light/12-hour dark cycle. They were fed ad libitum with a 
breeding/maintenance diet (Animal Resources Center, Australia) and sterile water. 
 
5.2.2. Preparation of plasma and tissues.  
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Balb/c mice (i.v. injected of SCL-DOX or controls) were anesthetized with an 
intraperitoneal injection (100 µl) of a ketamine/xylazine mixture (160 and 20 mg/kg, 
respectively). Whole blood was collected via cardiac puncture and immediately placed 
in EDTA-coated Falcon tubes. Plasma was subsequently prepared by centrifugation at 
1500 × g for 10 min.  
Tissues of liver, spleen and heart were collected, weighed and homogenized into a 
10% homogenate (w/v in H20) with a homogenizer. 
 
5.2.3. Sample treatment  
Briefly, tissue homogenates of 10% w/v were prepared in acidified isopropanol (0.75 
N HCl). Plasma 25% in water (200 ul) was placed in a 2-ml micro-centrifuge tube, 
and 100 ul of 10% (v/v) Triton X-100, 200ul of water, and 1,500 ul of acidified 
isopropanol (0.75 N HCl) were added. All samples were mixed thoroughly, and the 
doxorubicin and doxorubicin metabolites (if any) were extracted overnight at -20°C. 
The next day, the tubes were warmed to room temperature, vortexed for 5 min, 
centrifuged at 15,000g for 20 min, and subjected to analysis as described below.  
 
5.2.4. Doxorubicin quantifications 
Doxorubicin was quantified fluorometrically (excitation: 470 nm and emission: 590 
nm) with a Perkin Elmer LS50 B Luminescence Spectrometer. To correct for 
nonspecific background fluorescence, the samples were analyzed using a standard 
curve containing blood or tissue extracts derived from drug-free mice. The data 
represent the mean + S.D. of triplicate aliquots from 3 ~ 4 mice and are expressed as 
doxorubicin microequivalents per milliliter of plasma or per gram of tissue, as this 
assay does not discriminate between doxorubicin and any fluorescent metabolites that 
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may have similar excitation and emission profiles. 
 
5.2.5. Tumor implantation 
U-87 MG human glioma cells from exponential cultures were detached with trypsin 
EDTA, neutralized with completed medium and washed twice with EMEM, and 
brought to a concentration of 4 x 107cells/ml. Cell suspension (4 x 106/0.1 ml) was 
inoculated s.c. at the right flank of 6-week-old male BALB/c athymic nude mice. 
Xenograft sizes were determined three times weekly by measuring tumor dimensions 
using a caliper. Tumor volume (V) was determined by the equation V=LxW2x0.5, 
where L is the length and W is the width of the xenograft.  
 
5.2.6. Stage, treatment and evaluation.  
At day 16 post tumor implantation, the mice were staged and randomized to groups 
followed by drug and control treatments. For the nude mice, all i.v. treatments were 
performed via lateral tail vein injection. Free DOX, SCL-DOX, PEG- modified 
liposome-DOX and PEG-modified SCL-DOX, free DOX + empty SCLs were 
administered i.v. at 3.0 mg dox/kg/dose every week for 2 weeks, for a total DOX dose 
of 6 mg/kg. The corresponding lipid dose was typically 1 µmol of lipid per dose and 
2.0 µmol total. Additional treatment groups were included as indicated in the text. 
Saline was administered i.v. in the saline control group at the same injection volume 
and schedule as liposomes. Empty liposomes were administered i.v. at the same lipid 
dose as SCL-DOX and by the same weekly schedule. 
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 5.2.7. Statistical analysis.  
Data are presented as mean values plus or minus SEM and were evaluated by 
one-way ANOVA using SPSS 12.0.  
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5.3. Results 
5.3.1. Plasma SCL-DOX concentrations                          
Doxorubicin encapsulated in sulfatides-containing liposomes (SCL-DOX) was 
injected i.v. to 6 weeks old male BALB/c mice through the lateral tail vein at a dose of 
10mg/kg. Blood samples and tissues were taken 0.5, 1, 2, 5, 10, 24 and 48 hours post 
i.v. administrations. Two phases of SCL-DOX levels decreases in the plasma were 
found. The plasma drug level decreased very fast in the first 5 hours, from 4.05 to 
~0.32 µg/mL. From 5 hours to 48 hours, the plasma drug levels decrease very slowly 



























Fig. 5.1 SCL-DOX plasma concentration-time profiles in Balb/C mice following 
the i.v. injections of SSL-DOX at dose of 10mg/kg. SCL-DOX was injected i.v. to 6 
weeks old male BALB/c mice through the lateral tail vein at dose of 10mg/kg. Blood 
samples were taken 0.5, 1, 2, 5, 10, 24 and 48 hours post the injections.  
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 5.3.2. Distributions of the SCL-DOX in tissues. 
The distributions of DOX in the tissues were studied. Two major RES tissues, liver 
and spleen, were dissected and analyzed. Hearts from the mice were isolated and 
analyzed because they are tissues where DOX may exert adverse effect. 
 
Time Heart (µg/g) Spleen(µg/g) Liver (µg/g) 
(hour) aver std aver std aver std 
0.5 4.96 0.30 32.18 4.51 44.55 5.05 
1 5.82 0.84 35.86 2.89 50.17 2.01 
2 5.27 1.45 39.90 3.48 51.36 5.21 
5 1.34 0.23 45.67 4.15 49.86 3.58 
10 0.71 0.23 41.64 4.48 42.50 4.95 
24 0.66 0.19 34.25 5.34 31.52 3.48 
48 1.02 0.27 27.34 7.60 19.44 1.04 
Table 5.1 Distribution of SCL-DOX in BALB/c mice tissues (µg/g). SCL-DOX 
was injected i.v. to 6 weeks old male BALB/c mice through tail vein at dose of 
10mg/kg. Tissue samples were taken 0.5, 1, 2, 5, 10, 24 and 48 hours post the 
injections.  
 
For the liver, DOX reached the highest level 2 hours after injection and slowly 
reduced to 19.44 µg /g in the liver 48 hours later. In the spleen, the maximum DOX 
levels of 45.67 µg /g were found at 5 hours post injections followed by a slow 




























Fig. 5.2. Tissue distribution of SCL-DOX in Balb/c mice (µg/g). SCL-DOX was 
injected i.v. to 6 weeks old male BALB/c mice through the lateral tail vein at dose of 
10mg/kg. Tissue samples were taken 0.5, 1, 2, 5, 10, 24 and 48 hours post the 
injections. 
 
A modest SCL-DOX distribution to the heart was found. The highest drug levels were 
5.8 µg /g , 1 hour post injection. The SCL-DOX levels in the heart decreased very fast 
in the first 5 hour post injection. Nearly 80% of the drug was removed from the heart 
by 4 hours post injection. 
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5.3.3. Antitumor efficacy of SCL-DOX in s.c. tumor model compared with other 
liposomal drug and free drug 
To determine whether SCLs could be used to improve the therapeutic effects of 
anticancer drugs, we encapsulated DOX, one of the most frequently used anticancer 
drugs, in sulfatide/DOPE (30:70, mol/mol) liposomes and treated nude mice bearing 
subcutaneous tumors derived from human U-87MG glioblastoma cells. Six week old 
male athymic mice were inoculated subcutaneously (s.c.) with U87-MG cells at 4x10 
6 cells per mouse. The mice were randomized at day 16 post tumor inoculation when 
tumors had been fully established and treatments were initiated immediately thereafter. 
Mice were injected i.v. at a DOX dose of 3mg/kg/dose via the tail vein and a second 
dose was given one week later. The body weight and tumor size were measured three 
times weekly.  
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 Table5.2. The drug treatment groups of the s.c. tumor model studies. Six week 
old male athymic mice were inoculated s.c. with U87-MG cells at 4x10 6 cells per 
mouse, and randomized at 16 days after inoculation followed by weekly treatment, 
table 5-2. Drug dose is 3mg/kg x 2 weekly, i.v. The details of treatment for each group 
such as drug form (liposome formulations) and number of animals were shown. 
Group , drug form and liposomes formulations  Animal number (n=) 
Saline 3 
Empty SCLs, DOPE/SULF (70:30, molar ratio) 3 
Free doxorubicin 5 
Free doxorubicin +  Empty SCLs 3 
Sulf/DOPE-DOX ( SCL-DOX ), with liposomes formulation: 
DOPE/SULF (70:30) 
5 
PEG-DSPE/DOPE-DOX (PEGL-DOX),  with liposomes 
formulation: DOPE/SULF/PEG-DSPE 2000(67:30:3) 
6 
 
5.3.4. Effective inhibition of tumor growth by DOX. 
It was found that DOX treatment inhibited the growth of established tumors. Both the 
free DOX and SCL-DOX treatment resulted in the inhibitions of tumor growth. (Table 
5.3) After the second treatment, the tumor size of SCL-DOX treatment group was 
around 39%-50% of that of control groups while a reduction of 40% was considered 
effective (Chen 2001). 
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Day (post tumor 
innoculation) 
21 23 26 28 
Relative tumor Volume 
SCL –DOX treated 74.2 71.7 43.1 39.2 
Relative tumor Volume 
Free DOX 91.3 82.4 46.6 40.2 
Table 5.3. The relative tumor volume (% relative to saline control (100%)) of 
treated groups. Six week old male athymic mice were inoculated s.c. with U87-MG 
cells at 4x10 6 cells per mouse, and randomized at 16 days after inoculation followed 
by weekly treatment (details in table 5-2). Drug dose is i.v. injections at 3mg/kg, 2 
weekly administrations. Xenograft sizes were determined three times weekly by 
externally measuring tumors in two dimensions using a caliper. Tumor volume (V) 
was determined by the equation V=LxW2x0.5, where L is the length and W is the 
width of the xenograft (Duguay 2002). The relative tumor volume of SCL-DOX and 
free DOX treatment group were shown (the VOL of saline groups set as 100%). 
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5.3.5. Tumor growth profiles of different treatment groups 
Mice that received SCL-DOX (n = 5) showed clearly retarded tumor growth (Figure 
5.3.) compared with those animals treated with empty sulfatide/DOPE (30:70, 
mol/mol) liposomes (n = 5), a mixture of DOX and blank liposomes (n = 3) and 
PEGL-DOX (n = 6). The effect of SCL-DOX on the rate of tumor growth was 
comparable to that of free DOX (n = 5). However, marked ulceration and tumor 
necrosis appeared in most of the mice (3 out of 5) treated with free DOX towards the 
end of the experiment, while this was not observed in the animals treated with 
SCL-DOX. It is evident that tumor-bearing mice treated with SCL-DOX had slower 
tumor growth than that of the control animals (Figure 5.3). 
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 Fig.5.3 Efficacy of treatments on tumor growth. Six week old male athymic mice 
were inoculated s.c. with U87-MG cells at 4x10 6 cells per mouse, and randomized at 16 
days after inoculation followed by weekly treatment (details in table 5-2). Drug dose is 
i.v. injections at 3mg/kg, 2 weekly administrations. The arrows indicate the time for 
drug administration (day 16 and 23 post tumor inoculations). Xenograft sizes were 
determined three times weekly by externally measuring tumors in two dimensions using 
a caliper. Tumor volume (V) was determined by the equation V=LxW2x0.5, where L is 
the length and W is the width of the xenograft. Values are mean ± S.D. (n=5– 6). 
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5.3.6. Kaplan-Meier survival analysis: increasing of life spans. 
To sacrifice mice as necessary in accordance with humane principles and practices, in 
our study, the mice are held until (1) the tumor reaches 10% of the body weight 
(~2000 mm3); (2) the tumor becomes ulcerated/ necrotic; or (3) 2 weeks since the last 
treatment with no evidence of tumor growth delays, whichever comes first. 
Kaplan-Meier survival analysis was carried out using software of SPSS 12.0.  The 
analyzed results showed that the increasing of life span (ILS%) of the mice treated 
with SCL-DOX was 33.3% compared to control animals injected with empty 
liposomes (P < 0.01). The survival difference between animals treated with free DOX 
(ILS% of 6.7%) and with SCL-DOX (ILS% of 33.3%) was also significant (P <0.05). 
Although free DOX might be able to inhibit tumor growth (Figure 5.4), only 









Increasing of life span% 
(ILS% )* 
saline     3 33(0)
empty SCLs 5 33(1) 31-35  
free DOX + empty SCLs 3 33   
free-DOX     
    
     
5 35(1) 33-37 6.7
SCL-DOX 5 44（2） 40-48 33.3
PEGL-DOX 6 35(1) 33-37 6.7
Table.5.4. Kaplan-Meier survival analysis of animals received different drug treatments. Six week old male athymic mice were 
inoculated s.c. with U87-MG cells at 4x10 6 cells per mouse, and randomized at 16 days after inoculation followed by weekly treatment 
(details in table 5-2). Drug dose is i.v. injections at 3mg/kg, 2 weekly administrations. The median of survive of each treatment groups 
were shown. Data are presented were evaluated by one-way ANOVA using SPSS 12.0. * ILS%: increasing of life span% was 
comparing to those of saline (100%).  **: p value: p<0.05: SCL-DOX vs. Free-DOX; free-DOX vs. saline; PEGL-DOX vs. saline; 
p<0.001: SCL-DOX vs. PEGL-DOX; SCL-DOX vs. saline. 
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Fig.5.4. Kaplan–Meler (KM) survival analysis of tumor-bearing nude mice 
after various treatments. Six week old male athymic mice were inoculated s.c. 
with U87-MG cells at 4x10 6 cells per mouse, and randomized at 16 days after 
inoculation followed by weekly treatment (details in table 5-2). Drug dose is i.v. 
injections at 3mg/kg, 2 weekly administrations. The KM survive curves were 
drawn by using SPSS 12.0.  
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5.3.7. Comparison of in vivo subacute toxicity.  
The body weights of athymic mice that received weekly i.v. injections of SCL-DOX 
(3 mg/kg) or equivalent of empty SCLs shows no difference between the saline 
control groups throughout the entire course.  Histological examinations of organs 
obtained from mice treated with saline, empty SCLs and SCL-DOX were also 




The plasma drug concentration and tissue distributions were studied for SCL-DOX. 
The reticuloendothelial system (RES) uptake of SCL-DOX is one of the intrinsic 
characters for liposomes. Fast clearance of SCL-DOX from the heart is a favorable 
alteration of drug distributions comparing to free doxorubicin. The heart 
accumulations of the free drug could lead to the severe side effects on heart. The two 
phase plasma drug concentrations distributions suggested a two-compartment model, 
which may be confirmed by future pharmacokinetics studies. To achieve better 
antitumor efficacy of SCL-DOX, detailed studies on the drug dose, schedule of 
administrations, tissue and tumoral distributions of SCL-DOX are highly desired.  
The subcutaneous tumor xenograft animal model has many advantages such as: easy 
and fast inoculation procedures, ease of monitoring of tumor growth and providing 
the human tumor growths in immune-deficient small animals. The s.c xenografts 
model has been adopted by many others studies (Price 1999, Lakka 2002, Szereday 
2002). We have therefore used this animal model to investigate the therapeutic 
efficacy of SCL-DOX. 
The treatment schedule was chosen deliberately to mimic the clinical situation of 
advanced-stage cancerous patients when the tumors become palpable. The dose of 
DOX administered was 3 mg/kg weekly for 2 weeks, which was on the lower side of 
the dose allowed for nude mice (Fiebig 1990, Arap 1998), because we expected 
SCL-DOX to be more effective than the free drug. In our case, the first dose of DOX 
was given 16 days after tumor inoculation, much later than the first treatment in most 
of the studies using DOX to treat xenograft tumors (Mayer 1989, Park 1995, Sugano 
2000, Sapra 2002, Pastorino 2003, Lee 2004).  
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The efficacy of SCL-DOX was evaluated in terms of the rate of tumor growth and 
increase in life span. It is evident that treatment with SCL-DOX, but not with the PEG 
grafted SCL-DOX (PEGL-DOX), effectively retarded the growth rate of the tumors 
(Figure 5.3). It is likely that both liposomes could reach the interstitum surrounding 
the tumor cells through the leaky endothelium of the tumor microvasculature and the 
impaired lymphatic drainage (Jain 1987, Huang 1992, Jain 1996, Hashizume 2000, 
McDonald 2002). From the in vitro experimental results obtained in this study, it is 
most likely that SCLs would bind to the ECM of the tumor cells via the specific 
sulfatides-TN-C interactions and then be internalized by the tumor cells via both 
clathrin-independent and -dependent pathways to exert the therapeutic effect of DOX. 
However, sterically stabilized liposomes do not interact directly with tumor cells in 
vitro or in vivo (Horowitz 1992). In our earlier studies, the incorporations of 
PEG(MW 2000)-DSPE to SCLs masks the binding of SCLs to the ECM (Fig. 2.6.). It 
is plausible that the steric shielding effects of PEG could partially inhibit the 
SCLs-tumor interactions as we have shown in earlier studies. 
On the other hand, the effect of free DOX on retardation of tumor growth might have 
been overestimated because considerable skin ulceration and tumor necrosis were 
observed towards the end of the experiment. As far as the increase in life span, which 
is the ultimate goal of all anticancer therapy, is concerned, treatment with SCL-DOX 
extended the life span of the mice with tumor xenograft by approximately 33% 
compared with controls treated with free DOX and PEGL-DOX. Considering the 
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Chapter 6. The Accumulation of SCLs in the Brain Tumor Xenograft Animal 
Model 
6.1. Briefing 
The previous studies revealed that the sulfatides-containing liposomes are able to pass 
through the blood brain barrier and accumulate in the animal brain (Chen 1993 A, 
Chen 1993 B, Sakamoto 1993). However, all these studies were carried out in normal 
animals. To better understand the targeting and accumulation effect of 
sulfatides-containing liposomes, a brain-tumor animal model study is highly desired. 
In this part of study, an orthotopic tumor xenograft animal model was established. 
Liposomes were fluorescence labeled and the accumulations of liposomes after i.v. 
injections were studied by confocal laser microscopy inspections of brain cryosections. 
SCLs were found effectively accumulated in the brain tumor compared to other 
liposome formulations without sulfatides in the composition. The compromised blood 
brain barrier (BBB) of tumor bearing animals enables the delivery of liposomes with a 
smaller size distribution. SCLs were found accumulated in tumor in a time dependent 
pattern. The diffusion of SCLs in the whole volume of the tumor after the first burst 
accumulation suggests the strong interactions of the SCLs-Glioma could overcome 
the high interstitial fluid pressure in the tumor volume. The immumohistochemistry 
studies show that TN-C was overexpressed in the tumor volume and normal brain 
area adjacent to the tumor. The colocalization of SCLs and TN-C immunostaining 
suggest the interactions between sulfatides and TN-C play important roles in the 
liposomes targeting effect to the gliomas.  
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6.2. Materials and Methods 
6.2.1. Animals.  
In the orthotopic xenograft animal model studies, 8 weeks old male Balb/c nu/nu mice 
were imported from ARC (Animal Research Center, Australia) and acclimatized for 
four weeks in the animal holding unit of National University of Singapore. All animal 
experiments are performed in accordance with the guidelines of the Institutional 
Animal Care and Use Committee (IACUC) of the National University of Singapore. 
Mice were bred under specified pathogen-free conditions at 25°C, 70% relative 
humidity, and a 12-hour light/12-hour dark cycle. They were fed ad libitum with a 
breeding/maintenance diet (ARC) and water.  
 
6.2.2. Tumor cell preparation.  
Human U-87MG glioblastoma cell lines were obtained from American Type Culture 
Collection (Rockville, MD). U-87MG cells were grown in EMEM supplemented with 
2mML-glutamine, 2.2 g/L NaHCO3, 110 mg/L sodium pyruvate, and 10% fetal calf 
serum (FCS). Cells were cultured in a humidified atmosphere containing 5% CO2 at 
37 °C. For orthotopic xenograft animal model study, U-87 MG cells were seeded in 
T175 flasks at 4.5x106 cells per flask for 3 days. The cells from exponential cultures 
were detached with trypsin EDTA, neutralized with completed medium and washed 
with EMEM for twice, and brought to a concentration of 1 x 108cells/ml. Cells were 
kept at 4 °C before inoculations and used within 2 hours. 
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6.2.3. Surgical procedure.  
Stereotaxic surgery was performed under sterile conditions using a stoelting 
stereotaxic instrument for mice as described below. The 12 weeks old (mean body 
weight 25 g) mice were anesthetized with xylazine (15mg/kg i.p.) and ketamine 
(80mg/kg i.p.). They were then placed on a stereotaxic apparatus and a midline scalp 
incision was made with a scalpel. The parietal bone was drilled through (with a 
1-mm-diameter bit) 2 mm on the right-hand side of the sagittal line and 2 mm rostral 
of the coronal line. A Hamilton syringe was then slowly lowered 3mm deep into the 
right striatum over a time of 3 minutes. The U87-MG cells (10 µl, 106 cells) were then 
injected over a time period of fifteen minutes with the microdialysis syringe pump. 
Three minutes after the injection, the syringe was withdrawn slowly (1mm/minute). 
The skull hole was blocked with wax and the wound closed with surgical cement. The 
animals were then placed on a heating pad until they recovered from anesthesia.  
 
6.2.4. Histochemistry 
Tumor formation was checked by hematoxylin and eosin (H&E) staining. Animals 
were killed at day 21 and perfused with ice cold 4% PFA. Brains were removed and 
fixed in Bouin’s solution for 3 days, dehydrated, and embedded into paraffin. Serial 
5-µm coronal sections were prepared for every 200 µm starting and ending 1.5 mm 




6.2.5. Liposomes accumulation in Balb/c mice.  
6.2.5.1. Liposome preparation and i.v. injection 
Rhodamine-phosphotidylethanolamine (Rh-PE) labeled liposomes were prepared as 
described earlier. Liposomes with different size distributions were ٛ repared by 
passing through polycarbonates membranes with different pore size. RH-PE labeled 
liposomes of different size (50 or 100 nm) were i.v. injected (60µmol lipid/ kg body 
weight) via the lateral tail vein of 12 week old male Balb/c mice.  
 
6.2.5.2. Brain cryosections and confocal microscopy investigations  
Mice were euthanatized 15 minutes, 1, 2, 4 and 24 hours post injections (10 groups, 3 
mice per group). Brains were removed without perfusion or post-fixation and 
embedded in OCT compound (Sakura) and froze in liquid nitrogen. The samples were 
kept at -80 °C. Serial 5-µm coronal cryosections were prepared every 200 µm starting 
from caudal approach of the region of tumor cell implantation with a Cryostat (Leica). 
The sections were dried at room temperature in the dark, mounted in anti-fade 
mounting media and covered with cover slips. The slices were observed with a 
confocoal microscope (Zessis LSM510). 
 
6.2.6. Liposomes accumulation in tumor bearing nude mice.  
For liposome accumulation studies, the tumor bearing mice were kept for 20 days 
after the tumor implantation. Rhodamine-PE labeled liposomes with different 
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formulations or size were i.v. injected (60µmol lipid/ kg body weight) via the lateral 
tail vein. Mice were euthanatized at particular time points post injection (n=3). Brain 
cryosections slices were prepared for confocal microscoy investigations as described 
in 6.3.5.2. At least three sections of tumor central areas were observed with confocoal 
microscope (Zessis LSM510). The images were analyzed with the software 
Image-Pro-Plus. 
 
6.2.6.1. The accumulation of SCLs with different size distributions in tumor 
bearing nude mice. 
SCLs were prepared as previously described. SCLs with different size distributions 
were achieved by passing through polycarbonate membranes with different pore size, 
50 and 100 nm respectively. Mice were euthanatized 1 hour post injection (n=3), 
followed with further inspections mentioned. 
 
6.2.6.2. The accumulation of SCLs (50 nm) in tumor bearing nude mice a time 
course study. 
In this part of study, SCLs (50 nm) were i.v. injected via lateral the tail vein. Mice 
were euthanatized 0.5, 1, 2, 4, 12 and 24 hours post injection (n=3), and followed with 
further inspections as drescribed earlier. 
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6.2.6.3. The accumulation of SCLs (50 nm) in tumor bearing nude mice: 
comparisons between different liposome formulations.  
Liposomes with different formulations were prepared and were i.v. injected via the 
lateral tail vein to tumor bearing mice. Mice were euthanatized 1 hour post injection 
(n=3), and followed with further inspections as described. 
 
6.2.7. Immunohistochemistry.  
To examine whether the sulfatides-containing liposomes bind directly to TN-C, some 
of the dried cryosections of the brain were fixed with 4% PFA following PBS 
washing. Nonspecific binding was prevented by preincubation in 16% goat serum 
(Invitrogen, CA) over night at 4 °C. Primary monoclonal anti-human TN-C antibody 
(Chemicon, CA) was diluted 1:100 with 16% goat serum in PBS. After incubation 
with primary antibody overnight at 4°C, the cover slips were washed 5 times with 
PBS (15 min each at room temperature) and treated with the secondary antibody 
(FITC-conjugated goat anti-mouse, Molecular Probes, OR) for 5 min at room 
temperature. The sections were then washed 5 times in PBS (15 min each at room 
temperature) and mounted in anti-fade mounting media (Invitrogen, CA) and viewed 
with the Zeiss confocal microscope (LSM 510).  
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6.3. Results  
6.3.1. The H&E staining the brain of tumor bearing mice 
H&E stained visible light micrographs of the mouse brain containing the malignant 
glioma are shown in Figs. 6.1 a-e. In the micrographs (Figs. 6.1a and b) of a left brain, 
various anatomical structures can be readily identified, such as, the cortex, the 
caudoputamen, the corpus callosum, the septal nucleus and the anterior commissure. 
In the brain section of the tumor–bearing animal the primary tumor site within the 
caudoputamen is clearly visible in the right hemisphere. As a consequence of the 
tumor growth, the brain morphology is distorted. Histologically, the tumor was 
composed of cells with severer nuclear pleomorphism (Figs. 6.1. d-e). The tumor edge 
is very smooth (Figs. 6.1.a, c-d). Areas of necrosis were not found (Figs. 6.1. d). 
 
6.3.2. Rh-PE labeled SCLs in the normal brain of Balb/C mice 
Rh-PE labeled sulfatides containing liposomes (RH-SCLs) with two different size 
distributions were prepared. The brain accumulation of RH-SCLs after i.v. injections 
were studied in Balb/c mice. No fluorescence signal could be found in the mice brain 
i.v. injected with RH-SCLs with size of 100 nm (RH-SCLs (100 nm)) (data not 
shown). However, some weak fluorescence signals could be found in the brains of 
mice that received i.v. injections of RH-SCLs 50 nm in size (RH-SCLs (50 nm)). The 
fluorescence signals could be found in the mice brains 15 minutes after liposomes 
injection (fig.6.2.b.). Highest intensity of fluorescence signals could be found in the 
brains from the mice which were euthanized 1 hour after the injection (fig.6.2.c.). 
Fluorescence signals could be also found in those brains from mice euthanized 4 to 24 
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 injections (fig.6.2. f). Fluorescence signals found in mice brains received RH-SCLs 
(50 nm) injections, but the signal intensity is very weak.  
Fig.6.1. H&E staining of mice brain (coronal section slice).  Twelve weeks old 
male athymic mice were inoculated with 106 u87-MG cells in the right cortex. 21 
days after the inoculation, the mice were euthanized followed by perfusion. The 
brains were fixed in boilin’s solution for 3 days, and embedded in paraffin and 
microsectioned coronally followed by H&E staining. a) section of the brain; b) the 
contralateral part of brain; c) the tumor edge; d) the tumor edge, high magnification , 
the arrow towards tumor; e) the center of tumor xenograft, high magnification.  
Scale bars: b-c: 100 µm, d-e: 10 µm 
  
Fig.6.2. Confocal microscopy imaging of RH-SCLs in the healthy mice brains.  
Twelve weeks old male Balb/C mice were i.v. injected with RH-SCLs at dose of 
60µmol lipid/ kg body weight. Mice were euthanatized at 15 minutes, 1, 2, 4 and 24 
hours post injections (10 groups, 3 mice per group). Serial 5-µm coronal 
cryosections were prepared and observed with a confocoal microscope (Zessis 
LSM510). Representative fluorescent images of brain slices from Balb/c mice after 
receiving RH-SCLs (50nm) (size of 50nm) or RH-SCLs (100nm) (size of 100nm) i.v. 
injection were shown: a,d) no injection; b) RH-SCLs (100nm) 1hr; c) RH-SCLs (50nm) 1 
hr; e) RH-SCLs (100nm) 24 hour and f) RH-SCLs (50nm) 24 hour. Arrow: point to 
fluorescent signals observed. Scale bar = 100 µm. 
6.3.3. The size dependent accumulation of Rh-SCLs in the brain of tumor 
bearing nude mice. 
To study the effect of liposome size on tumoral uptake, the tumor bearing nude mice 
(n=3) were i.v. injected with RH-SCLs prepared by passing through either 100 nm or 
50 nm polycarbonate membranes. 1 hour after the injection, the brains were removed 
and cryosections were prepared followed by confocal microscopy imaging. The 
fluorescent signals in the brain were quantified with Image-Pro Plus.  
We found that the both RH-SCLs could reach in the brain of tumor bearing mice. 
RH-SCLs could be found accumulated in the tumor area. SCLs with smaller size 
could accumulate more effectively in the tumor than bigger ones. The fluorescence 
intensity of smaller RH-SCLs (50 nm) in the tumor is 11.5 fold higher than those of 





























Fig.6.3 SCLs of different sizes accumulated differently in the brain of tumor 
bearing mice. The size dependent Rh-SCLs (50 nm and 100 nm) accumulation in the 
brain of tumor bearing nude mice (n=3) were studied by i.v. injected with RH-SCLs 
and kept for 1 hour. The brains were removed and cryosections slides were prepared 
followed by confocal microscopy observations. The fluorescent signals in the brain 
were calculated with Image-Pro Plus. 
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6.3.4. The accumulation of RH-SCLs (50 nm) in the brain of tumor bearing mice 
The tumor accumulation of the RH-SCLs (50 nm) is a time dependent process. The 
fluorescence intensity could be detected 30 minutes after the i.v. injection and reached 
the highest level 60 minutes after the injection, but could be detected even after 12 
hours of the injection. The uneven distributions of SCLs in the first 30 minutes 
suggested a fast accumulation in certain parts of the tumor followed by a slower 
diffusion of the SCLs in the whole tumor volume. Most importantly, the SCLs were 
found in the whole tumor volume during the first 12 hours after injection. (Fig. 6.4.)  
 
There were also some RH-SCLs signals in the contralateral hemisphere of the brain 
(Fig.6.4. b2, the left brain images, 1 hour after the injection). However, the levels of 
RH-SCLs signals of contralateral hemisphere were only 1/9 of those of tumor area. 
(Fig. 6.5) Quantified profiles of SCLs in the brain of tumor bearing mice are shown in 
Fig. 6.5. It is clear that SCLs found in the brain contralateral to the tumor site was 




Fig.6.4 The accumulation of Rh-SCL in tumor bearing mice brain time 
profiles. The time dependent Rh-SCLs (50 nm) accumulation in the brain of 
tumor bearing nude mice (n=3) were studied by i.v. injected with RH-SCLs and 
kept for 0.5, 1, 2, 4, 12 and 24 hours. The brains were removed and cryosections 
slides were prepared followed by confocal microscopy observations. 
Representatives images were shown: a: 0.5 hour, b1:1 hour, c: 2 hour, d: 4 hour, 
e: 12 hour and f: 24 hour. Scale bar = 200 µm.  
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Fig.6.5 The accumulation of RH-SCLs in tumor bearing mice brain time 
profiles. The time dependent Rh-SCLs (50 nm) accumulation in the brain of tumor 
bearing nude mice (n=3) were studied by i.v. injected with RH-SCLs and kept for 
0.5, 1, 2, 4, 12 and 24 hours. The brains were removed and cryosections slides 
were prepared followed by confocal microscopy observations. The fluorescent 
signals in the brain were quantified with Image-Pro Plus 
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6.3.5. The Sulfatides determined the accumulations of liposomes in the brain of 
tumor bearing mice  
The degree of accumulation of different liposomes formulations (DOPC (100%), 
DOPG/DOPC, GalCer/DOPC, GM1/DOPC and Sulf/DOPE (all at 30:70 molar ratio) 
in the brain of tumor bearing mice were studied. The tumor bearing nude mice (n=3) 
were i.v. injected with RH-SCLs and kept for 1 hour. The brains were removed and 
cryosections slides were prepared followed by confocal microscopy observations. The 
fluorescent signals in the brain were calculated with Image-Pro Plus.  
It was found only sulfatides containing liposomes could effectively accumulate in the 
tumor. The levels of SCLs tumor accumulation were 12 to 24 folds higher than other 



























Fig 6.6 The brain accumulation of different liposomes (50 nm) formulations in 
tumor bearing mice. The accumulation of different liposomes formulations 
(DOPC (100%), DOPG/DOPC, GalCer/DOPC, GM1/DOPC and Sulf/DOPE (all at 
30:70 molar ratio) were studied. The brain tumor bearing nude mice (n=3) were i.v. 
injected with RH-PE labeled liposomes and kept for 1 hour. The brains were 
removed and cryosection slides were prepared followed by confocal microscopy 
observations. The fluorescent signals in the brain were calculated with Image-Pro 
Plus. 
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 6.3.6. The detection of human TN-C and colocalization of SCLs of liposomes in 
the brain of tumor bearing mice 
The brains of RH-SCLs (50 nm) injected mice were removed 1 hour after the 
injection, cryosectioned and fixed for immunohistochemistry studies. The RH-SCLs 
(50 nm) fluorescence signals were largely reduced after the sample processing during 
immunohistochemistry preparations with the extensively blocking and washing 
(Fig.6.7 column a.). TN-C were well expressed in the whole volume of the tumor and 
highly expressed at the tumor edges (Fig.6.7 column b of A-B). TN-C was also found 
outside the main body of the tumor (Fig.6.7 A(b) ). It was found that the RH-SCLs 






Fig. 6.7. TN-C imunostaining and colocalization with Rh-SCLs. The brains of 
Rh-SCL injected mice were taken out 1 hour after the injection. Cryosectioned and 
fixed with PFA and blocked with BSA followed by anti-TN-C (1:100) and FITC 
conjugated secondary antibody (1:1000). The tissues were observed under confocal 
microscopy Zeiss LSM 510. Row A: the tumor edge area, B: the tumor center area; C: 
the left hemisphere. Images are taken: column a) TRITC (Rhodamine); b) FITC; c) 




Liposomes containing sulfatides were reported be able to pass through the blood brain 
barrier and accumulate in animal brain (Chen 1993 A, Chen 1993 B, Sakamoto 1993). 
All these previous studies were carried out in normal animal. In our studies, we using 
confocal microscopy to study the brain/tumor accumulations of Rhodamine labeled 
liposomes in both normal mice and tumor bearing mice. The confocal studies are 
much less sensitive compared with radio-labeling studies used in the above mentioned 
studies. However, confocal microscopy could provide the details of RH-SCLs 
distribution in brains of mice bearing tumor. In addition, the images of confocal 
microscopy could also be further quantified with the right softwares . 
In the Balb/c mice studies, only RH-SCLs with smaller sizes could be found in brains. 
The RH-SCLs (50nm) were found in the mice brains after i.v. injections, in a time 
range of 15 minutes to 24 hours. These results suggested that RH-SCLs (50nm) could 
pass through the blood brain barrier and reach the brain. It is obvious that the majority 
of those RH-SCLs (50nm) introduced into the circulation was blocked by the BBB of 
those normal mice.  
The applications of drug delivery systems in the central nervous systems are largely 
limited due to the blood-brain-barrier. The BBB could be compromised in certain 
pathological states such as glioma. It was reported that in tumor bearing mice, the 
BBB is leaky, with a cut off pore size ranging from 40-70 nm. In our studies, this 
notion is confirmed by the accumulations of SCLs in the tumor. The cut off effects of 
blood brain barrier limit the passage of SCL particles of larger size. In our studies, 
SCLs with smaller size (prepared extrusion through polycarbonate membrane with 
pore size of 50 nm) were found to accumulate more effectively in the tumor compared 
to those prepared by membranes with pore size of 100 nm. 
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achieved by modifying the liposomes formulation and size distribution. The special 
interactions of liposomal sulfatides to the brain tumor proteins such as TN-C enable 
the fast accumulation, wide diffusions and retentions of SCLs in the tumor. SCLs 
could therefore be effectively used as novel delivery systems to the brain tumor or 
applied to the brain tumor imaging studies.  
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Chapter 7 Conclusions and Future Directions  
7.1 Conclusions 
Malignant gliomas represent a difficult therapeutic challenge due to the vigorous invasive 
nature of the tumor and limited tumoral delivery of therapeutic agents. In this study, we 
aimed to design novel nano-sized sulfatides containing liposomes (SCLs) as a glioma 
drug delivery system, which targets gliomas by specific liposomes-gliomas interactions. 
The SCLs are efficiently taken up by receptor mediated endocytosis, capable of 
bypassing the blood brain barrier and could accumulate in the tumor after systemically 
administration. 
In the first part of this study, the gliomas cell uptake of liposomes with different 
formulations indicated that liposomes composed of sulfatides could be effectively taken 
up by the glioma cells, when compared to liposomes composed with DOPG, 
galactosylceramides (GalCer) or GM1. The uptake of SCLs was affected by the molar 
ratio of the sulfatides in the liposomes. The perturbations by anti-sulfatides monoclonal 
antibodies and incorporations of PEG-DSPE on the liposome surface would eliminate the 
SCLs taken up by gliomas cells. this suggested that the sulfatides on the SCLs plays a 
major role in liposome-gliomas cells interactions. 
The down regulation of tenascin-C (an extracellular matrix (ECM) protein overexpressed 
in the gliomas cells) expressions by either chemical treatment or siRNA silencing, greatly 
attenuated the SCLs-glioma cell interaction and resulted in reduced uptake of SCLs by 
the glioma cells. These results suggested that SCLs bind to the glioma cells by the 
specific recognition and interactions of sulfatides to tenascin-C. 
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SCLs were found to be effectively internalized in the glioma cells comparing with 
liposome with other formulations. Pre-treatment of the glioma cells with cytochalasin D 
(10 mg/ml) had no effect on the internalization of the SCLs, suggesting that 
macropinocytosis is unlikely to be involved in uptake of the liposomes.  Cholesterol 
depletions and PI-PLC pretreatment caused 75% and 30% reduction in the uptake of the 
SCLs in gliomas respectively suggesting caveolae/lipid rafts endocytosis are involved in 
the internalization. Sucrose and sphingosine pretreatments resulted in ~60% reduction in 
the SCLs uptake, suggesting that SCLs could be internalized by glioma cells via clathrin-
dependent endocytosis pathways. This was further confirmed by the overexpression of a 
dominant-negative Hub fragment of clathrin in the glioma cells. It was clear that SCLs 
were internalized in the gliomas cells by both clathrin-dependent and caveolae/lipids 
rafts-dependent pathways.  
In the second part of this study, doxorubicin (DOX), a widely used antitumor drug, was 
adopted to investigate the capability of SCLs as an effective glioma targeted delivery 
system. DOX was loaded into the SCLs to form the liposomal drug SCL-DOX. The 
intracellular delivery of SCL-DOX was studied. SCL-DOX could be effectively 
accumulated in the nuclei of glioma cells with a different pattern compared to those of 
free drug. The in vitro cytotoxicity studies showed SCL-DOX clearly superior (~6-fold 
drop in IC50) to that of DOX encapsulated with other liposome formulation of (PEG-
DSPE/Sulf/DOPE). In the s.c. xenografts animal model, SCL-DOX could effectively 
inhibit tumor growth, increased the life span by 33% compared to control groups 
(Kaplan-Meier survival analysis)  
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In the last part of this study, an orthotopic tumor xenograft animal model was established. 
The compromised blood brain barrier (BBB) of tumor-bearing animals enables the 
delivery of liposomes with smaller size distribution. SCLs were found to be effectively 
accumulated in the brain tumor compared to other liposome formulations without 
sulfatides. SCLs accumulated in the brain tumor site in a time- dependent manner, and 
exhibited a fast accumulation and diffusion followed by a slow dissipation. The diffusion 
of SCLs in the whole volume of the tumor after the first burst accumulation suggests the 
strong interactions of the SCLs-glioma had overcome the high interstitial fluid pressure. 
The colocalization of SCLs and TN-C immunostaining suggest the interactions between 
sulfatides and TN-C might play important roles in the diffusion and retention of SCLs in 
the tumor. 
 
7.2 Future Directions 
In this study, we have developed SCLs as novel liposome-base, drug delivery systems 
targeting gliomas. The SCLs could interact specifically with gliomas cells and TN-C 
interactions may play an important role. TN-C was reported to be overexpressed in other 
cancers such as breast cancer and melanoma. This highly specific sulfatides-mediated 
tumor targeting drug delivery may thus be useful in therapeutics for treatment of a 
spectrum of cancers other than gliomas. 
There are several other molecules overexpressed in glioma which could interact 
specifically with sulfatides, such as brevican and midkine. The contributions of those 
molecules in the SCL-gliomas interactions and the efficacy of SCL-mediated drug 
delivery would of great interest.  
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We have shown that SCLs are internalized by the glioma cells via both caveolae/lipid 
rafts and clathrin-dependent endocytosis pathways. However, the details of the cell 
surface receptors and adaptors involved in the endocytosis are unclear. Further studies on 
the mechanism underlying SCLs internalization will help to improve the development of 
more effective carrier systems. 
Our studies showed that SCLs are good as drug delivery systems for doxorubicin. The 
SCL-DOX effectively inhibits glioma cells growth both in vitro and in vivo. To achieve 
better antitumor effects, a detailed toxicity and pharmacokinetics study of SCL-DOX in 
animals is highly desired. Since the reduced liposome size makes it possible for 
substantial accumulation of SCLs in the brain tumor in the orthotopic tumor xenografts 
animal model, the antitumor efficacy of SCL-DOX study is of high expectations. As an 
effective brain tumor delivery system which could bypass the blood brain barrier, the 
applications of SCLs as carriers for other therapeutic agents of CNS disorders or injury 
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Abstract
We described here a liposomal carrier system in which the targeting ligand was sulfatide, a glycosphingolipid known to bind several
extracellular matrix (ECM) glycoproteins whose expression was highly up-regulated in many tumors. In vitro experiments with human glioma cell
lines demonstrated that robust intracellular uptake of the liposomes depended specifically on the presence of sulfatide as the key liposomal
component. Significant amount of the liposomes remained largely intact in the cytoplasm for hours following their internalization. When
anticancer drug doxorubicin (DOX) was encapsulated in such liposomes, most of the drug was preferably delivered into the cell nuclei to exert its
cytotoxicity. Use of this drug delivery system to deliver DOX for treatment of tumor-bearing nude mice displayed much improved therapeutic
effects over the free drug or the drug carried by polyethylene glycol (PEG)-grafted liposomes. Our results demonstrate a close link between
effective intracellular uptake of the drug delivery system and its therapeutic outcome. Moreover, the sulfatide-containing liposomes (SCL) may
represent an interesting ligand-targeted drug carrier for a wide spectrum of cancers in which sulfatide-binding ECM glycoproteins are expressed.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
Liposomes have attracted considerable attention as one of
the most promising drug delivery systems [1]. Despite many
existing pharmaceutical agents and newly synthesized biolog-
ical macromolecules such as nucleic acids, proteins and
peptides have the potential of being encapsulated in liposomes
to serve as liposomal drugs, their in vivo efficacy depends
largely on how they are delivered to the right sites of action,
which are often located inside the cells. Efficient intracellular
drug delivery relies on specific interactions between the drug
carriers and the diseased cells. For example, ligand-targeted
liposomes may specifically bind to their receptors and be
internalized by receptor-mediated endocytosis [2], whereas
sterically stabilized long-circulating liposomes may not directly
interact, at least in vitro, with certain tumor cells such as ovarian
carcinoma cells [3] and gliomas [4]. In the latter case, the
therapeutic effect of the liposomal drug appears to depend on
the perivascular accumulation of the liposomes, in addition to
the cytotoxic effect of the drug carried in them [5].
An obvious strategy to enhance cellular binding and uptake of
liposomal drugs is to incorporate in the drug carrier a ligand that
would bind to its receptor on the cell surface or in the extracellular
matrix (ECM) of the cells [2,6–8]. Since the ECM composition
surrounding the tumor cells is very different from that of their
normal counterparts and certain ECM glycoproteins such as
tenascin-C (TN-C) are highly up-regulated in many different
cancers including breast cancer, ovarian cancer, prostate cancer
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and gliomas [9], it is therefore possible to formulate a liposome
containing a ligand specifically interacts with the ECM of the
tumor cells. To this end, we have focused on a sulfatide-con-
taining liposomal system as the potential carrier for anticancer
drugs. Sulfatide has been found in a number ofmammalian tissues
and is involved in a variety of biological processes such as cell
adhesion, platelet aggregation, cell growth, protein trafficking,
signal transduction, neuronal plasticity, cell morphogenesis and
disease pathogenesis [10–12]. It has been found that the incor-
poration of sulfatide into phospholipids such as 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) vesicles greatly
enhances the stability of the liposomes formed, even in the
presence of plasma, presumably due to the hydration of the
negatively charged sulfate headgroup of the glycosphingolipid
[13]. More interestingly, sulfatide is known to bind several ECM
glycoproteins including particularly TN-C [14]. Based on this
information, sulfatide-containing liposomes (SCL) are expected
to interact directly with the targeting tumor cells that express
sulfatide-binding ECMglycoproteins. It is hypothesized that such
liposome-cell interactions would facilitate the intracellular drug
delivery and thus improve the therapeutic outcome of the
liposomal drugs.
In this study, we examined the internalization of SCL by the
human glioma cells in vitro, the intracellular drug distribution
following uptake of the liposomal doxorubicin (DOX) and the
consequent cytotoxicity of the drug. The in vivo therapeutic
properties of SCL with encapsulated DOX were evaluated in
nude mice xenografts of the human glioma cells. Our results
show that the sulfatide-containing liposomal drug was more
potent than free DOX and DOX encapsulated in nontargeted
liposomes in terms of inhibition of tumor growth and extension
of the survival time of the tumor-bearing animals.
2. Materials and methods
2.1. Chemicals
Sulfatide (3′-sulfogalactosylceramide), galactosylceramide
(GalCer), ganglioside GM1 (GM1), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (poly-ethylene glycol)-2000]
(PEG-DSPE), DOPE and other phospholipidswere obtained from
Avanti Polar Lipids, Inc. (Alabaster, AL). Lissamine™ rhoda-
mine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine
(Rh-PE) was from Molecular Probes (Eugene, OR). All other
chemicals were from Sigma-Aldrich (St. Louis, MO).
2.2. Human glioma cell lines and culture conditions
Human U-87MG and CCF-STTG1 glioblastoma cell lines
were obtained from American Type Culture Collection (Rock-
ville, MD). U-87MG cells were grown in EMEM containing
2mML-glutamine, 2.2 g/L NaHCO3, 110mg/L sodium pyruvate,
and 10% fetal calf serum (FCS). CCF-STTG1 cells were
maintained in RPMI 1640 medium supplemented with 10%
FCS. Cells were cultured in a humidified atmosphere containing
5% CO2 at 37 °C and were passaged following treatment with
trypsin (0.05%)/EDTA (0.02%).
2.3. Liposome preparation
All lipids were dissolved in chloroform:methanol (2:1, v/v)
except GalCer that was dissolved in hot ethanol. The lipid thin
films of various formulations were prepared as described by Wu
and Li [13]. For fluorescence microscopy studies, 0.5 mol% of
Rh-PE was included in the lipid mixture that was hydrated with
PBS. For liposomes used for encapsulation of DOX, each batch
consisting of 10 μmol total lipids was hydrated in 250 mM
ammonium sulfate (pH 8.5), followed by vigorous vortex and
brief sonication (1min). The liposomes were formed by extrusion
19 times through two stacked polycarbonate membranes with a
defined pore size of 100 nm at 25 °C (Avestin, Inc., Canada) [15].
The extruded liposomes were then dialyzed extensively against a
100-fold volume of 10% sucrose (in 25 mM Trizma at pH 8.5),
four changes over 24 h at 4 °C. DOXdissolved in the above buffer
was actively loaded into the liposomes through establishment of
ammonium sulfate gradient [16]. Nonentrapped DOX was
removed by passing the liposomes through a Sephadex G-50
column equilibrated with degassed PBS. DOX concentrations
were determined by measurement of the fluorescence intensity of
the drug (kex=480 nm, kem=550 nm) against a standard curve
and the encapsulation efficiency was generally greater than 90%,
with a drug to phospholipid ratio of approximately 100 μg/μmol.
2.4. Fluorescence microscopy
Cells were examined by using an inverted microscope
(Olympus IX71) and a Zeiss laser scanning confocal microscope
system (LSM510). Cells were seeded in 24-well plates containing
glass coverslips for 24 h before co-incubated with the liposomes
(total lipid concentration: 80 μM) for up to 1 h. The cells were
then washed three times with ice-cold PBS and fixed with 3.7%
paraformaldehyde (PFA) (1 h at 25 °C). The coverslips were
thoroughly rinsed with PBS and mounted on slides with anti-fade
mounting media (Invitrogen, CA) before viewing. For experi-
ments on uptake of liposomes, Rh-PE was excited at 543 nm and
the emitted fluorescence was collected using a 560 nm long-pass
filter. For quantitative analysis, the images were processed with
the Image-Pro Plus software (Media Cybernetics, Inc., USA),
where cell contours for each set of fields were traced out manually
in the corresponding phase-contrast images and then used tomask
the fluorescence images. The fluorescence intensities of 7–10
fields of ∼10 cells/field/condition were analyzed.
2.5. Colocalization studies
To investigate whether the integrity of SCL was maintained
after internalization, fluorescein isothiocyanate (FITC)-dextran
loaded liposomes were prepared by adding 1 ml FITC-dextran
in PBS (45 mg/ml) to the Rh-PE-labeled lipid films [17]. The
lipid dispersion was briefly sonicated and then extruded through
the polycarbonate membranes as described above. A Sephadex
G-50 (Sigma) gel filtration column (15 cm×1.5 cm) was used to
remove the un-encapsulated FITC-dextran. Lipid concentration
of the eluted liposomes was estimated with the colorimetric
method by Stewart [18]. To the cultured U-87MG cells,
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liposomes (final lipid concentration was adjusted to 80 μMwith
EMEM) were added and incubation was carried out for 1 h at
37 °C. The cells were thoroughly washed with PBS followed by
incubation with liposome-free culture medium for 4 h at 37 °C
before fixed with 4% PFA. Both Rh-PE (kex=543 nm,
kem=560 nm long-pass filter) and FITC (kex=488 nm,
kem=510–540 nm band-pass filter) fluorescence were ob-
served by confocal fluorescence microscopy. Quantitative
analysis of the colocalized areas was performed by using the
Image-Pro Plus software (Media Cybernetics, Inc., USA).
2.6. Cytosolic and nuclear DOX
To investigate quantitatively the delivery of DOX to the
nucleus, cell fractionations were performed according to the
published methods [19,20] with slight modifications. In these
experiments, the human glioma cells were seeded at a density of
20,000/cm2 in T75 plastic flask (NUNC) in 95% humidified air
and 5%CO2 at 37 °C for 3 days (80–90% confluence). Free DOX
and DOX encapsulated in sulfatide/DOPE (30:70, mol/mol)
liposomes (SCL-DOX) were introduced at a final drug concen-
tration of 10 μM. The cells were exposed to free DOX or SCL-
DOX for 1, 4, 12 or 24 h, respectively, at 37 °C. The treated cells
were then washed twice with ice-cold PBS and detached by
trypsinization. The cells were spun at 300 ×g for 3 min and the
pellets were washed twice with ice-cold PBS and re-suspended at
a concentration of 5×106 cells/ml in a 10mMTris buffer (pH 7.4)
containing 100mMNaCl, 1mMEDTA, and 1%Triton X-100 for
10min at 4 °C. The suspension was then centrifuged at 800 ×g for
15 min and the precipitate of cell nuclei was separated from the
supernatant. The fluorescence intensity of the cytosolic fraction
(the supernatant) was detected at λex=480 nm, λem=550 nm.
The drug concentration was calculated according to a standard
curve of DOX concentration vs. its fluorescence intensity. The
nuclear fraction was washed once with TEA, then added with
0.75 ml of TEA, 5 μl of digitonin (25 mg/ml) and 5 μl of MgCl2
(57 mg/ml) followed by vortex and brief sonication. Twenty-five
microliter of DNase 1 (Sigma) solution (3 mg/ml) was added and
the suspension was vortexed and allowed to stand at room
temperature for 2 h. The sampleswere centrifuged at 3000 rpm for
5 min, and the fluorescent intensity of the supernatant was
measured at the excitation and emission wavelength for DOX.
2.7. Cytotoxicity studies
The viabilities of treated and untreated cells were determined
by the quantitative colorimetric MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay which mea-
sures the mitochondrial conversion of MTT to formazan as
detected by the change of optical density at 570 nm [21]. To
evaluate the cytotoxicity of free DOX and liposomal DOX, U-
87MG cells (10×105 cells/ml) in 100 μl aliquots were plated in
96-well flat-bottomed microtiter plates and cultured for 24 h at
37 °C. The medium was then replaced with serum-free and
antibiotic-free medium containing various concentrations of
free or liposomal DOX. The cells were further cultured for 4 h at
37 °C under 5% CO2. After thorough rinse with ice-cold PBS,
DOX-free complete medium was added and the incubation was
continued for 72 h before the cells were washed and MTT
(0.5 mg/ml, 100 μl) in complete medium (without phenol red)
was added to each well and the cells were incubated for another
4 h at 37 °C. The reaction was stopped by removing MTT and
the cells were then solubilized in 150 μl DMSO before the
absorbance at 570 nm was measured with a plate reader (Spectra
Fluor, Tecan Group Ltd., Mannedorf, Switzerland).
2.8. Tumor implantation, treatment and evaluation
Five-week-old male BALB/c athymic nude mice (Animal
Resources Center, Australia) were imported and acclimatized
for one week in the Animal Holding Unit of National University
of Singapore. All animal experiments were performed in ac-
cordance with the guidelines of the Institutional Animal Care
and Use Committee of National University of Singapore. Mice
were kept under pathogen-free conditions at 25 °C, 70% relative
humidity, and a 12-h light/12-h dark cycle. They were fed ad
libitum with a standard breeding/maintenance diet (Animal
Resources Center, Australia). U-87MG cells from exponentially
growing cultures were detached by trypsin/EDTA, neutralized
with completed medium, washed with EMEM twice and
brought to a concentration of 4×107 cells/ml. Cell suspension
(0.1 ml) was inoculated s.c. at the right flank. At day 16 post
tumor implantation, the mice were staged and randomized to
groups before drug and placebo treatments, which were per-
formed via lateral tail vein injections. Free DOX, SCL-DOX,
DOX encapsulated in PEG-grafted liposomes (PEGL-DOX), at
a weekly dose of 3.0 mg DOX/kg, and the controls (vehicles)
were administered i.v. for 2 weeks. All treatments (0.1 ml) were
filtrated through 0.2 μm filters immediately before injection.
Xenograft sizes were determined three times weekly by
measuring externally the tumors in two perpendicular dimen-
sions using a caliper. Tumor volume (V) was determined by the
equation V=0.5L×W2, where L is the largest superficial
diameter and W the smallest superficial diameter of the
xenograft. Mice were monitored routinely for weight loss.
Tumor growth retardation and elongation of survival time were
recorded as the main criteria for determining treatment efficacy.
2.9. Statistical analysis
Results are presented as mean±S.D. and were evaluated by
either unpaired Student's t-test (two-sided) or one-way
ANOVA using SPSS 12.0 software (SPSS Inc., Chicago). All
of the in vitro data were derived from at least three independent
experiments.
3. Results
3.1. Sulfatide is specifically required for internalization of
liposomes by human glioma cells
Liposomes consisting of various lipid components were
prepared by extrusion through polycarbonate membranes of
average pore size of 100 nm (see Materials and methods for
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details). The mean diameter of the liposomes thus formed was
∼82 nmwith a polydispersity of b0.5, as determined by dynamic
light scattering (data not shown). It was found that effective
uptake of Rh-PE(0.5 mol.%)-labeled liposomes by U-87MG, a
typical human glioblastoma cell line, relied specifically on the
presence of sulfatide (Fig. 1A and B). Similarly, binding of
liposomes to the ECM of the cells was also only detectable for
SCL (data not shown). It was evident that presence of a galactose
group, such as that ofGalCer inGalCer/dioleoylphosphatidylcho-
line (DOPC) liposomes and negative charge carried by the
constituent lipids, such as that of dioleoylphosphatidylglycerol
(DOPG) and GM1 in DOPG/DOPC and GM1/DOPC liposomes,
were insufficient for effective binding and internalization of the
liposomes to occur. In addition, higher sulfatide concentration, as
seen in sulfatide/DOPC (30:70, mol/mol) liposomes compared
with sulfatide/DOPC (15:85, mol/mol) liposomes, and use of
DOPE instead of DOPC as the second lipid component were
desirable for more significant uptake of the liposomes (Fig. 1A
and B). Similar binding and internalization results were also
obtainedwith the other human glioblastoma cell line tested (CCF-
STTG1 cells, data not shown). These data are indicative of
existence of specific sulfatide receptor(s) on the glioblastoma cell
surface that would facilitate the binding and uptake of SCL.
3.2. Integrity of SCL was retained during internalization
To examine whether the integrity of SCL during uptake and
early intracellular delivery is maintained, FITC-dextran was
encapsulated in Rh-PE-labeled SCL. Upon internalization of
Fig. 2. Extensive colocalization of the membrane marker (Rh-PE, A) and the
internal space marker (FITC-dextran, B) of SCL indicates that the integrity of
liposomal structure was maintained during early internalization. C. Represen-
tative superimposed image of the liposomal Rh-PE and FITC-dextran. These
images were obtained after U-87MG cells had been cultured with the liposomes
(total lipid concentration: 80 μM in EMEM) for 1 h, followed by 4-h incubation
in the absence of liposomes at 37 °C. Bar=100 μm.
Fig. 1. Sulfatide is specifically required for uptake of liposomes by U-87MG
cells. A. Fluorescence and corresponding phase contrast micrographs of U-
87MG cells after incubation with Rh-PE-labeled liposomes for 1 h at 37 °C.
Liposomes used: (left panel, from top to bottom) DOPC; DOPG/DOPC (15:85,
mol/mol); DOPG/DOPC (30:70, mol/mol); GalCer/DOPC (15:85, mol/mol);
GalCer/DOPC (30:70, mol/mol); (right panel, from top to bottom) GM1/DOPC
(15:85, mol/mol); GM1/DOPC (30:70, mol/mol); sulfatide/DOPC (15:85, mol/
mol); sulfatide/DOPC (30:70, mol/mol); sulfatide/DOPE (30:70, mol/mol). The
scale bar represents 25 μm for all micrographs. B. Quantitative analysis of the
internalization level of liposomes (see Materials and Methods for details) by U-
87MG cells. The uptake level of sulfatide/DOPC (30:70, mol/mol) was set as
100%. Values are mean±SD of at least three independent experiments.
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these liposomes by U-87MG cells, both the Rh-PE red
fluorescence (Fig. 2A) and the FITC green fluorescence (Fig.
2B) weremonitored with the confocal microscope. Fig. 2C shows
that large numbers of the membrane marker (Rh-PE) and the
internal space marker (FITC-dextran) of the liposomes were
colocalized after a total of 5-h incubation at 37 °C. Quantitative
analysis of the colocalized areas with the Image Pro® Plus
software (Media Cybernetics, Inc., USA) showed that the overlap
coefficient was approximately 80%, suggesting that liposomes
were delivered into the glioblastoma cell cytoplasm and majority
of the liposomes remained intact during this period.
3.3. Intracellular distribution and cytotoxicity of SCL-DOX
Intracellular accumulation and distribution of DOX were
examined by using both U-87MG and CCF-STTG1 cells. Fig. 3A
shows that the entry of free DOX into U-87MG cells was initially
at a slightly higher rate compared with SCL-DOX. In both case,
however, the nuclear drug concentration reached its maximum
after 12 h incubation at 37 °C and approximately 80% of the
intracellular DOX was accumulated in the nuclei, where it is
supposed to exert its typical cytotoxic effect. Similar intracellular
DOXdistributionwas observedwhenSCLwas used to deliver the
drug into CCF-STTG1 cells (data not shown).
The cytotoxicity of SCL-DOXwas then compared with that of
freeDOXand PEGL-DOX.U-87MGcellswere exposed to free or
liposomalDOX for 4 h, thenwashed and further incubated for 72 h
in fresh medium before theMTTassay was performed. As seen in
Fig. 3B, the growth inhibition curve derived from treatment by
SCL-DOXwas only slightly less toxic than free DOX, but clearly
superior (∼6-fold drop in IC50) to that of PEGL-DOX. The higher
cytotoxicity of SCL-DOX compared with PEGL-DOX is
consistent with the notion that pegylated liposomes, unlike SCL,
might not interact directly with the tumor cells [3,4].
Fig. 3. Accumulation and intracellular distribution of DOX and its cytotoxicity
in human glioblastoma cells. A. Accumulation of DOX in the nuclei and cytosol
of U-87MG cells after exposure to free DOX and SCL-DOX. B. Cytotoxicity of
DOX delivered to U-87MG cells as free DOX, SCL-DOX or nontargeted
PEGL-DOX. Values are mean±S.D. of at least three independent experiments.
Fig. 4. Efficacy of treatments for nude mice bearing U-87MG-derived
subcutaneous tumors. A. Effect of various treatments on tumor growth. The
arrows indicate the time for drug administration. Values are mean±S.D. (n=5–
6). B. Survival time of tumor-bearing nude mice after various treatments. The
Kaplan–Meler survival curve shows a significant improvement (approximately
30%) in life span when the mice were treated with SCL-DOX.
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3.4. In vivo therapeutic studies
To determine whether SCL could be used to improve the
therapeutic effects of anticancer drugs,we encapsulatedDOX, one
of the most frequently used anticancer drugs, in SCL and treated
the nude mice bearing subcutaneous tumors derived from human
U-87MG glioblastoma cells. Themice were randomized at day 16
post tumor inoculation when tumors had been fully established
and treatments were initiated immediately thereafter. Mice were
injected i.v. at a DOX dose of 3 mg/kg/dose via the tail vein and a
second dose was given one week later. Such a DOX dose is
considered at the lower side of the commonly used DOX dose in
nude mice with human xenografts (2.5–10 mg/kg/week) [22].
Mice receiving SCL-DOX (n=6) showed retarded tumor growth
(Fig. 4A) compared with those animals treated with vehicle (n=3,
data not shown), blank sulfatide/DOPE (30:70, mol/mol)
liposomes (n=5), a mixture of DOX and blank liposomes (n=3,
data not shown) and PEGL-DOX (n=6). The effect of SCL-DOX
on retardation of the rate of tumor growth was comparable to that
of free DOX (n=5). However, marked ulceration and tumor
necrosis appeared in most of the mice (3 out of 5) treated with free
DOX towards the end of the experiment, while this was not
observed in the animals treated with SCL-DOX.
It is evident that tumor-bearing mice treated with SCL-DOX
outlived the control animals (Fig. 4B). Kaplan–Meier survival
analysis showed that the life span of the mice treated with SCL-
DOX was increased by 33.3% compared to control animals
injected with blank liposomes (Pb0.01, one-way ANOVA).
The survival difference between SCL-DOX-treated animals and
those treated with free DOX (6.7% increase in life span
compared to control animals), whose effect was comparable to
that of PEGL-DOX, was also significant (Pb0.05, one-way
ANOVA). Although free DOX might be able to inhibit tumor
growth (Fig. 4A), only SCL-DOX could effectively increase the
life span of the treated animals.
4. Discussion
In this study, we have shown that sulfatide was specifically
required for robust uptake of liposomes by human glioblastoma
cells such as U-87MG and CCF-STTG1 cells. It is likely that
sulfatide served as the binding or targeting motif which would
guide the liposomes to the ECM of the tumor cells by interacting
with ECM glycoproteins like TN-C. It is unclear what inter-
nalization machinery was involved at this stage. Nevertheless,
DOX encapsulated in SCL could be delivered into the
glioblastoma cells to exert cytotoxicity. Use of this drug delivery
system to deliver DOX for treatment of tumor-bearing nude mice
exhibited much improved therapeutic effects over the free drug or
the drug carried by PEG-grafted liposomes.
Evidently, the key component of the liposomes which facili-
tated the effective binding and subsequent uptake of the drug
carrier by the glioblastoma cells was sulfatide. When gang-
lioside GM1 and GalCer, both are structurally related to
sulfatide, were used to prepare liposomes, no significant
binding and uptake of such liposomes were observed (Fig. 1).
Uptake of SCL by the human glioblastoma cells was also not
due to the charge effects because presence of acidic phospho-
lipids such as phosphatidylglycerol in liposomes failed to
improve the uptake efficiency (Fig. 1). We would like to pro-
pose TN-C as the potential cell surface receptor for liposomal
sulfatide. Firstly, it is well known that TN-C binds specifically
to sulfatide but not to other gangliosides or GalCer [14], which
appeared consistent with what we observed in this work
(Fig. 1). Secondly, the expression level of tenascins is known
being much higher than that of other sulfatide-binding ECM
proteins like laminin in human glioblastoma cells [23]. Thirdly,
fluorescence real-time images showed that liposomes bound to
the ECM were detachable from the cell bodies following treat-
ment with trypsin, while those inside the cells were not affected
(data not shown). This observation suggested the involvement
of ECM protein components in binding of SCL. Further exper-
iments, aimed at elucidating the nature of the sulfatide receptor
(s) in the ECM of tumor cells and the mechanism of sulfatide-
mediated intracellular uptake of liposomes, are currently under
way.
The SCL have been found to remain intact for hours after
uptake by the glioblastoma cells (Fig. 2). Apparently, free DOX
could readily enter the cells and accumulate quickly in the
nuclei. Under the conditions used in this study, the nuclear
DOX concentration reached the maximum 12 h after free drug
was added into the cell culture. Similarly, nuclear DOX con-
centration also reached its maximal level 12 h after SCL-DOX
was used, albeit the initial entry rate was slightly lower than that
of free DOX (Fig. 3A), probably due to the interactions bet-
ween SCL and the ECM of the tumor cells which was expected
to delay the entry of SCL-DOX. Since the total intracellular
DOX, as well as its nuclear and cytosolic distribution, was
similar when the drug was introduced as SCL-DOX or in its
free form, as a result, the in vitro cytotoxicity of SCL-DOXwas
comparable to that of its free counterpart but much higher than
that of the nontargeted PEGL-DOX (Fig. 3B), most likely due
to the fact that PEG-grafted liposomes do not interact directly
with the tumor cells [3,4].
The human glioma cell line U-87MG was implanted sub-
cutaneously in the BALB/c athymic nude mice, a model of
tumor xenograft adopted also by others [24,25], for our
investigation into the therapeutic efficacy of SCL-DOX. The
treatment schedule was chosen deliberately to mimic the
clinical situation of advanced-stage cancerous patients when
the tumors become palpable. The dose of DOX administered
was 3 mg/kg weekly for 2 weeks, which was on the lower side
of the dose allowed for nude mice [22], because we expected
SCL-DOX to be more efficient than the free drug as the former
would be able to target the ECM of the tumor cells. In our
case, the first dose of DOX was given 16 days after tumor
inoculation, much later than the first treatment in most of the
studies using DOX to treat xenograft tumors [26–28]. The
efficacy of SCL-DOX was evaluated in terms of the rate of
tumor growth and increase in life span. It is evident that
treatment with SCL-DOX, but not with the nontargeted PEGL-
DOX, effectively retarded the growth rate of the tumors (Fig.
4A). It is likely that both liposomes could reach the interstitum
surrounding the tumor cells through the leaky endothelium of
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the tumor microvasculature and the impaired lymphatic
drainage [29–31]. Based on the in vitro experimental results
obtained in this study, it is postulated that SCL might bind to
the ECM of the tumor cells and be internalized by the latter to
exert the therapeutic effect of DOX. However, sterically
stabilized liposomes do not interact directly with tumor cells
[3,4], which may render the inability of PEGL-DOX in
delaying tumor growth. On the other hand, the effect of free
DOX on retardation of tumor growth might have been
overestimated because considerable skin ulceration and
tumor necrosis were observed towards the end of the
experiment. As far as the increase in life span, which stands
for the ultimate goal of all anticancer therapy, is concerned,
treatment with SCL-DOX had extended the life span of the
mice with tumor xenograft by approximately 30% compared
with controls treated with free DOX and PEGL-DOX (Fig.
4B). The improved therapeutic effect of SCL-DOX over free
DOX implied that SCL might indeed target the ECM of glioma
cells in vivo. Considering the treatment conditions employed
in this study, an increase in life span of 30% should be
considered as a remarkable achievement.
5. Conclusion
We have demonstrated a tumor-targeted drug delivery system
which can effectively enhance the therapeutic index of DOX
chemotherapy in experimental animals. It may therefore provide
a particularly potent and useful treatment for cancers that involve
overexpression of sulfatide-binding proteins such as TN-C.
Because expression of TN-C is highly up-regulated in many
different cancers, use of this natural lipid guided liposomal
formulation of DOX has the clinical potential to markedly im-
prove the treatment, with reduced side effects, for these cancers.
In addition, this drug carrier system may also have broad
utilization for delivery of other anticancer drugs and/or other
substances like imaging agents into the target tumor cells.
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Abstract. Tenascin-C is an extracellular matrix glyco-
protein, whose expression is highly restricted in
normal adult tissues, but markedly up-regulated in a
range of tumors, and therefore serves as a potential
receptor for targeted anticancer drug or gene delivery.
We describe here a liposomal carrier system in which
the targeting ligand is sulfatide. Experiments with
tenascin-C-expressing glioma cells demonstrated that
binding of liposomes to the extracellular matrix relied
essentially on the sulfatide-tenascin-C interaction.
Following binding to the extracellular matrix, the
sulfatide-containing liposomes were internalized via
both caveolae/lipid raft- and clathrin-dependent path-
ways, which would ensure direct cytoplasmic release
of the cargoes carried in the liposomes. Such natural
lipid-guided intracellular delivery targeting at the
extracellular matrix glycoproteins of tumor cells thus
opens a new direction for development of more
effective anticancer chemotherapeutics in future.
Keywords. Ligand-targeted drug delivery, liposomes, sulfatide, tenascin-C, extracellular matrix.
Introduction
Tumor-targeted drug delivery relies on specific inter-
actions between the ligands associated with the drug
carriers and the antigens or receptors either uniquely
expressed or overexpressed on the tumor cells [1]. The
most frequently used ligands for the purpose of
targeted drug delivery to tumor cells are antibodies
or their fragments that recognize the tumor-associated
antigens ([1, 2] and references therein). Although this
approach possesses a high level of specificity to the
targeted tissues, its applications might be limited by
problems such as immunogenicity and low percentage
of tumors that express any given antigen. Therefore,
design of new drug delivery systems based on alter-
native and yet highly specific ligand-receptor inter-
actions could have important implications for the
development of novel anticancer therapeutics.
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The extracellular matrix (ECM) surrounding tumor
cells is very different from that surrounding normal
cells. In particular, tenascin-C (TN-C), a multifunc-
tional ECM glycoprotein, is highly up-regulated in
many different cancers such as glioma, breast cancer,
ovarian cancer and prostate cancer ([3] and references
therein). Under normal circumstance, TN-C is only
expressed during the early stages of development and
is absent or much reduced in developed tissues [4].
Since the reappearance of TN-C is closely associated
with pathological conditions like carcinogenesis and
usually indicative of poor prognosis [3], it makes an
attractive target for ligand-targeted therapeutic strat-
egies, similar to other ECM-associated targets such as
integrins andED-B fibronectin [5–7]. In principle, any
molecule that specifically binds this tumor-specific
ECM glycoprotein has the potential to be exploited in
the development of novel drug carrier systems to
improve the therapeutic outcomes and/or reduce the
systemic toxicity of anticancer drugs.
Sulfatide has been found in a number of mammalian
tissues and is involved in a variety of biological
processes such as cell adhesion, platelet aggregation,
cell growth, protein trafficking, signal transduction,
neuronal plasticity, cell morphogenesis and disease
pathogenesis [8–10]. More interestingly, sulfatide
binds several ECM glycoproteins including specially
TN-C [11–14]. In other words, sulfatide, a natural
acidic glycosphingolipid consisting of a hydrophobic
ceramide and a hydratable galactose residue sulfated
at the C3 position, is a promising candidate as the
ligand of targeted carriers to deliver anticancer drugs
to tumor cells via binding to TN-C. In fact, sulfatide
had been chosen previously as a minor lipid compo-
nent in liposomes preparation [15–17]. It was found
that incorporation of sulfatide into phospholipids such
as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE) vesicles greatly enhanced the stability of
the liposomes formed, even in the presence of plasma,
presumably due to hydration of the negatively charg-
ed sulfate headgroup of the glycosphingolipid [17].
In this study, we examined the molecular mechanisms
involved in binding and subsequent internalization of
sulfatide-containing liposomes (SCL) by human glio-
ma cells. The results demonstrate a ligand-targeted
intracellular delivery system based on interaction
between a glycosphingolipid and a tumor-specific
ECM glycoprotein, which may lead the way for
formulation and development of novel chemothera-
peutics to treat a wide spectrum of cancers.
Materials and methods
Chemicals. Sulfatide (3-sulfogalactosylceramide), galactosylcera-
mide (GalCer), ganglioside GM1, 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phospho-
choline (DOPC), cholera toxin B subunit (CTxB) and bodipy-
lactosylceramide (Bodipy-LacCer) were obtained from Avanti
Polar Lipids, Inc. (Alabaster, AL). Lissamine rhodamine B 1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine (Rh-PE) was
from Molecular Probes (Eugene, OR). Mouse anti-human TN-C
monoclonal antibody, anti-O4 monoclonal antibody and the IgM
negative control were from Chemicon (Temecula, CA). T7*Tag
monoclonal antibody was from Merck (Whitehouse Station, NJ).
All other chemicals were from Sigma-Aldrich (St. Louis, MO).
Human glioma cell lines and culture conditions. Human U-87MG
and CCF-STTG1 glioblastoma cell lines were obtained from
AmericanTypeCultureCollection(Rockville,MD).U-87MGcells
were grown in Eagles minimum essential medium (EMEM)
containing 2 mM L-glutamine, 2.2 g/l NaHCO3, 110 mg/l sodium
pyruvate, and 10% fetal calf serum (FCS). CCF-STTG1 cells were
maintained in Dulbeccos modified Eagles medium (DMEM)
supplemented with 10% FCS. Cells were cultured in a humidified
atmosphere containing 5% CO2 at 378C.
Liposome preparation. All lipids were dissolved in chloroform:-
methanol (2:1, v/v) except GalCer, which was dissolved in hot
ethanol.Appropriate amounts of lipids were transferred from their
respective stock solutions into glass tubes and dried by evaporation
under a nitrogen stream, as described byWu and Li [17]. The ratio
of sulfatide to phospholipid was chosen such that liposomes would
be formed with the optimal stability [16, 17]. For fluorescence
microscopy studies, 0.5 mol%of Rh-PEwas included. The samples
were stored under vacuum for 24 h at 48C and the thin lipid film
formed on the wall of the glass tubes was hydrated with phosphate-
buffered saline (PBS), briefly sonicated (1 min), and extruded
repeatedly through two layers of polycarbonate membranes with a
pore size of 100 nm at room temperature (Avestin, Inc., Canada)
[18].
ECM binding and intracellular uptake of SCL. ECM binding and
internalization of Rh-PE-labeled SCL were examined using an
inverted microscope (Olympus IX71) or a Zeiss laser-scanning
confocal microscope system (LSM 510), respectively. Cells were
seeded into 24-well plates containing glass coverslips for 24 h
before co-incubation with the liposomes (final total lipid concen-
tration: 80 mM) for 1 h. The cells were thenwashed three timeswith
ice-cold PBS and immediately fixed with 3.7% paraformaldehyde
(PFA). The coverslips were thoroughly rinsed with PBS and
mountedon slideswith anti-fademountingmedia (Invitrogen, CA)
before viewing. Rh-PE was excited at 543 nm and the emitted
fluorescence was collected using a 560-nm long-pass filter. For
quantitative analysis, the images were processed with the Image-
Pro Plus software (version 4.5.1, Media Cybernetics, Inc., USA),
where cell contours or the ECM areas surrounding the cells for
each set of the fieldswere traced outmanually in the corresponding
phase-contrast images and then used to mask the fluorescence
images. The fluorescence intensities of seven to ten fields of
~10 cells/field/condition or five fields of ~10 ECM areas/field/
condition were analyzed to quantitate the cellular uptake or the
ECM binding, respectively, of the liposomes.
Antibody perturbation. Sulfatide/DOPE/Rh-PE (30:69.5:0.5; mol/
mol/mol) liposomes were incubated with anti-O4 monoclonal
antibody (100 mg/ml) or mouse IgM (100 mg/ml) (Chemicon, CA)
for 30 min at 378C. U-87MG cells were seeded into 4-well
chambered coverglass system for 24 h before being incubated
with either the anti-O4-pretreated, the IgM-pretreated or the
untreated liposomes for 1 h, followed by quantitative analysis of
the ECM binding of SCL as described above.
1,25-Dihydroxyvitamin D3 treatment. U-87MG cells were treated
with up to 1 mM 1,25-dihydroxyvitamin D3 (VD3), which is known
to inhibit TN-C expression in various types of cells [19, 20], for 24 h
at 378C and the expression level of TN-C protein was estimated by
Western blotting (see below). After washing with PBS, the cells
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were incubated with Rh-PE-labeled SCL for 1 h at 378C and
quantitative analysis of the binding level of the liposomes was
conducted as described above.
Small interfering RNA preparation and transfection. A TN-C-
specific small interfering RNA (siRNA) duplex corresponding to
bases 5209–5227 from the open reading frame of the human TN-C
mRNA was designed and synthesized by Proligo (Singapore): 5-
GUGGAGAGCUUCCGGAUUA-dTdT- 3. The RNA sequence
without knownhomology tomammalian genes, whichwas used as a
negative control, was: 5-UUCUCCGAACGUGUCACGU-
dTdT-3. Knockdown of TN-C expression by siRNA was carried
out according to themanufacturers instructions. Briefly, cells were
transfected at 60–80%confluence usingLipofectamineTM2000. The
final concentration of TN-C siRNA and the negative control
siRNA used was 0.2 mM. The medium was replaced with fresh
complete medium 4 h after transfection, and analyses on TN-C
knockdown efficiency and SCL binding to the ECM of the cells
were conducted at 24 and 72 h after transfection, respectively.
Western blotting. Cells were lysed in the lysis buffer containing
10 mMTris-HCl, 150 mMNaCl, 1%NP-40, 1 mMEDTA (pH 7.4)
and various protease inhibitors (Roche, Basal, Switzerland).
Aliquots of the cell lysate (20 mg protein) were then resolved by
5% SDS-PAGE and electroblotted onto polyvinylidene difluoride
(PVDF) membranes (Pierce, Rockford, IL). After blocking with
5% skim milk for 1 h at room temperature, TN-C and the clathrin
hub were detected by Western blot analysis using the monoclonal
antibody against TN-C (1 :1000 dilution) and clathrin hub (1:10 000
dilution), respectively. Immunoreactive bands were visualized
using a secondary antibody conjugated to horseradish peroxidase
(Bio-Rad, CA) and the SuperSignal enhanced chemiluminescence
reagent (Pierce, Rockford, IL).
Effects of pharmacological inhibitors/phospholipase on liposome
uptake. Cultured cells were seeded on glass coverslips for 24 h
before treatment with various pharmacological inhibitors for 1 h to
differentiate clathrin-dependent from clathrin-independent inter-
nalization of SCL. The concentration of each reagent used (all from
Sigma) was 10 mg/ml (2-hydroxypropyl)-b-cyclodextrin (2-HCD)
[21], 10 mg/ml cytochalasin D [22], 5 mM sphingosine [23], 0.5 M
hyperosmolar sucrose [24] and 0.3 IU/ml phosphatidylinositol-
specific phospholipase C (PI-PLC) [25, 26]. The treated U-87MG
cells were then incubated with the Rh-PE-labeled SCL for 1 h for
quantitative analysis of the rate of liposome uptake. Cell viability
was >90% for all treatments as judged by trypan blue staining.
Transfection of U-87MG cells with clathrin hub. Expression of a
fragment of clathrin heavy chain, clathrin hub, as a dominant-
negative inhibitor of clathrin-mediatedendocytosis was performed
by following themethod of Liu et al. [27], with slightmodifications.
In brief, the cDNA encoding bovine clathrin heavy chain residues
1073–1675 was cloned into the BamHI and HindIII sites of the
vector pET23d (Novagen, Inc.) after the T7 gene 10-leaderpeptide
sequence. The PCR-amplified T7Hub introduced a Kozak se-
quence as well as a NotI restriction site at the end of the T7Hub.
ThePCRproducts digestedwithEcoRVwere ligatedwithEcoRV-
cleavedpIRES-EGFP (whereEGFP is enhanced green fluorescent
protein) vectors (BDbioscience,NJ) followedby transformation of
DH-5a competent cells. The positive clones were inoculated to LB
medium and incubated overnight. The T7Hub-pIRES-EGFP
plasmid was extracted, analyzed by enzymatic cleavage and
amplified in E. coli and finally purified with the DNA Purification
Systems (Promega). The U-87MG cells were seeded in plates for
24 h before transfection with Lipofectamine-2000 (Invitrogen)/
T7Hub-pIRES-EGFP complex according to the manufacturers
protocol. The EGFP expression was detected with the 488-nm
laser, which was used to indicate the expression of the plasmid. For
liposome internalization experiments, U-87MG cells were incu-
bated, 48 h after transfection, with Rh-PE-labeled SCL for 1 h and
then viewed and quantitated with confocal fluorescence micro-
scopy after washing.
Statistical analysis. Data were evaluated by either unpaired
Students t-test (two-sided) or one-way ANOVA using SPSS 12.0
software (SPSS Inc., Chicago) and presented as means  SD. All
results were derived from at least three independent experiments.
Results
Sulfatide was required for binding of liposomes to the
ECM of human glioma cells. Liposomes consisting of
GM1, GalCer or sulfatide as the minor component
(30 mol%) and either DOPC or DOPE as the major
component (70 mol%) were prepared by extrusion
through polycarbonate membranes of average pore
size 100 nm (see Materials and methods for details).
The mean diameter of such liposomes formed was
~82 nm with a polydispersity of <0.5, as determined
by dynamic light scattering (data not shown). It was
found that presence of sulfatide was essential for
effective binding of the Rh-PE (0.5mol%)-labeled
liposomes to the ECM of U-87MG, a typical human
glioblastoma cell line (Fig. 1Aa–d).
Evidently, presence of a galactose group, such as that
of GalCer in GalCer/DOPC liposomes, or a complex
oligosaccharide headgroup, such as that of ganglio-
sides GM1 in GM1/DOPC liposomes, was insufficient
for effective ECM binding to occur. In addition,
DOPE significantly enhanced the ECM binding of
SCL by approximately twofold compared with that of
sulfatide/DOPC liposomes (Fig. 1B). Similar effects
of sulfatide on binding of SCL to the ECM of another
human glioblastoma cell line, CCF-STTG1 cells, were
also observed (data not shown).
To further confirm that sulfatide is required for
effective binding by the glioblastoma cells, SCL were
pretreated with monoclonal anti-sulfatide (anti-O4)
antibody (100 mg/ml) or mouse IgM (100 mg/ml).
Figure 2 shows that treatment with IgM led only to a
slight decrease (~25%) in ECM binding of the lip-
osomes, whereas treatment with anti-O4 under iden-
tical conditions resulted in a near complete inhibition
of ECM binding of the liposomes, indicating that
binding of antibody to sulfatide on the outer surface of
liposomes had prevented it from interacting with its
receptor(s) in theECMof the cells. These data suggest
that sulfatide plays an essential role in mediating the
binding of liposomes to the ECM of the glioma cells.
TN-C was involved in binding of SCL to the ECM of
human glioma cells. It has been reported that heparan
sulfate proteoglycan (HSPG) plays an important role
in cellular uptake of liposomes [28, 29]. To rule out the
possibility that binding of SCL to the ECM of the
glioma cells was mediated by HSPG, the cells were
pretreated with heparinase I (3.0 U/ml, 30 min at
378C) or the liposomeswere incubatedwith the cells in
the presence of heparin (100 mg/ml), a HSPG com-
petitor. Such treatments affected neither the binding
of SCL to the ECM of the glioma cells nor the
internalization rate of the liposomes, suggesting that
HSPG was unlikely to be involved in interactions
between SCL and the glioma cells. On the other hand,
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sulfatide is known to be able to bind tenascins, in
particular, TN-C [11], which is abundantly expressed
in human glioma cell lines [30]. It was therefore of
interest to ascertain if this glycoprotein is responsible
for theECMbinding of SCL. Therefore,VD3was used
to treat the cells for 24 h to inhibit the expression of
TN-C before the liposomes were introduced. Fig-
ure 3A shows that TN-C expression was significantly
attenuated by VD3 treatment, as detected byWestern
blot with TN-C-specific antibody. Correspondingly,
binding of SCL to the ECM of U-87MG cells treated
with 1 mM VD3 for 24 h reduced by ~35% compared
with that in the control cells (Fig. 3B). We further
confirmed the specific interaction between SCL and
TN-C by transfection of the U-87MG cells with a
siRNA duplex targeted to the TN-C mRNA. Fig-
ure 4A shows the immunoblots probed for TN-C
protein in U-87MG cells 24 or 72 h after transfection.
TN-C expression was knocked-down by ~80% 72 h
after transfection with TN-C-specific siRNA com-
pared with that in untreated cells and cells transfected
with a control siRNA of random sequence. We next
examined whether the knockdown of TN-C would
affect the ECM binding of SCL. Figure 4B shows that
binding of SCL to the ECM of TN-C siRNA trans-
fected U-87MG cells was reduced by ~50% 72 h after
cell transfection compared with that in the untreated
cells. Not surprisingly, transfection of cells with the
control siRNAdid not affect the binding of SCL to the
ECM of U-87MG cells. Taken together, these results
suggest that TN-C, theECMglycoprotein known to be
able to bind sulfatide, was indeed involved in binding
of SCL to the ECM of the human glioma cells.
Figure 1. Sulfatide is specifically required for binding of phospholipid liposomes to the ECM of U-87MG cells. (A) Fluorescence and
corresponding phase-contrast micrographs of U-87MG cells after incubation with Rh-PE-labeled liposomes for 1 h at 378C. Liposomes
(total lipid concentration: 80 mM) used: a and a, GM1/DOPC (30:70, mol/mol); b and b, GalCer/DOPC (30:70, mol/mol); c and c,
sulfatide/DOPC (30:70, mol/mol) and d and d, sulfatide/DOPE (30:70, mol/mol). The scale bar represents 50 mm. The boxed regions in c
and d and their corresponding regions in c and d are enlarged by approximately threefold in the insets to show typical ECMbinding of the
liposomes. (B)Quantitative analysis of the binding level of liposomes by the ECMofU-87MGcells. The average binding level represented
by the fluorescence intensity of Rh-PE-labeled sulfatide/DOPE (30:70, mol/mol) liposomes was set as 100%. Values are mean SD of at
least three independent experiments.
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SCL were internalized via both clathrin-dependent
and -independent endocytosis. After binding of the
liposomes to the target cells, the route of their
internalization becomes important for optimal ther-
apeutic effects. For example, strategiesmay need to be
developed for endosomal escape of the drugs to avoid
actions by lysosomal enzymes if the drug delivery
system enters the cell via the clathrin-dependent
pathway. To identify the pathway(s) responsible for
uptake of SCL, we first tried to exclude the possibility
of macropinocytosis as the major pathway for lip-
osomal internalization by pre-treatment of the cells
with cytochalasin D. It is known that this mode of
internalization requires a functional actin cytoskele-
ton while cytochalasin D destabilizes the actin fila-
ments [22, 31]. Pre-treatment of the cells with
cytochalasin D (10 mg/ml) had no effect on the
internalization of SCL (data not shown), suggesting
that macropinocytosis is unlikely to be involved in
uptake of the liposomes. It has been well-established
that various types of endocytosis may co-exist and
some, such as caveolae/lipid raft- and clathrin-medi-
ated endocytosis, are affected by depletion of choles-
terol of the cell plasma membranes [32, 33]. We then
examined whether the internalization of SCL by the
human glioma cells was susceptible to cholesterol
depletion.When the cells are pre-treatedwith 2-HCD,
an approximately ~70% decrease in internalization of
the fluorescence-labeled SCLwas observed (Fig. 5A),
suggesting that the endocytic pathways of SCL were
cholesterol dependent. However, since both clathrin-
dependent and -independent endocytosis may be
affected by cholesterol depletion, further experiments
were needed to ascertain that either or both of these
pathways had contributed to the uptake of SCL. In
these experiments, markers internalized almost ex-
clusively via caveolae-dependent pathway (CTxB and
Bodipy-LacCer) or clathrin-dependent pathway (flu-
orescein-conjugated transferrin)were used as controls
[33–35].
We first examined whether caveolae/lipid raft-medi-
ated endocytosis was responsible for uptake of the
liposomes. The cells were pre-treated with PI-PLC, a
well-established procedure to remove glycosylphos-
phatidylinositol(GPI)-anchored proteins from the cell
surface [25, 26]. Figure 5B shows that PI-PLC treat-
Figure 2. Effect of pretreatment of sulfatide/DOPE (30:70, mol/
mol) liposomes with anti-O4 antibody or IgM on their binding to
the ECM of U-87MG cells. The average ECM binding level in the
control experiments, where untreated Rh-PE-labeled SCL were
used, was set as 100%. Values are mean  SD of at least three
independent experiments.
Figure 3.Effect of VD3 on binding of sulfatide/DOPE (30:70, mol/
mol) liposomes to the ECMofU-87MGcells. (A) Effect of VD3 on
TN-C expression inU-87MGcells as examined by immunoblotting
with anti-TN-C antibody. b-Actin was used as a loading control.
The blots are representatives of three independent experiments.
Treatment of the cells with VD3 attenuated TN-C expression in a
dose-dependent manner. (B) Binding of Rh-PE-labeled sulfatide/
DOPE (30:70, mol/mol) liposomes to the ECM of U-87MG cells
was significantly inhibited by VD3 treatment. The concentration of
VD3 used here is 1 mM and higher concentration was tested to be
toxic to the cells. Values are mean  SD of at least three
independent experiments. *p<0.005 versus the non-treated con-
trol.
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ment caused a ~55% reduction in the uptake of the
fluorescence-labeled liposomes compared with the
untreated control cells, a clear indication that pertur-
bation to caveolae/lipid rafts did affect the internal-
ization of SCL. However, it is likely that clathrin-
dependent endocytosis was also involved, as the
internalization rate of SCL was significantly higher
than that of CTxB. The situation became more
complicated as treatment by PI-PLC also disturbed
somehow the uptake of transferrin, a typical marker
for clathrin-mediated endocytosis.
We next investigated whether SCL could be internal-
ized by the clathrin-mediated pathway. It is well-
known that hypertonic sucrose inhibits clathrin-medi-
ated endocytosis by disrupting formation of clathrin-
coated pits [24]. The human glioma cells were treated
with 0.5 M sucrose before uptake of liposomes was
allowed to take place. It was found that such treatment
decreased the internalization of SCL by as much as
70% compared with that in the control cells (Fig. 5C).
This implies that uptake of SCL was indeed also
mediated by clathrin. This conclusion was verified by
examining the uptake of SCL following treatment of
the cells with 5 mMsphingosine, a cationic amphiphilic
drug known to interrupt assembly-disassembly of
clathrin from coated pits and endosomes [23]. Fig-
ure 5D shows that sphingosine had similar effects to
hypertonic sucrose and internalization of SCL was
reduced by ~60%, suggesting that SCL were internal-
ized, at least partly, by the clathrin-mediated path-
ways.
To obtain further support for a mechanism that would
involve clathrin-mediated endocytosis, we then ex-
pressed a dominant-negative hub fragment of clathrin
by transfection of U-87MG cells, which has been
known to perturb clathrin-mediated endocytosis [27,
Figure 4. Effects of TN-C siRNA on TN-C
expression in U-87MG cells and ECM binding
of sulfatide/DOPE (30:70, mol/mol) liposomes.
(A) TN-C expression inU-87MG cells following
treatment with TN-C siRNA and control siRNA
for up to 72 h as detected by Western blot
analysis. The blots are representatives of three
independent experiments. b-Actin was used as
the internal control. (B) Quantitative analysis of
TN-C siRNA treatment on ECM binding of Rh-
PE-labeled sulfatide/DOPE (30:70, mol/mol)
liposomes by U-87MG cells. The average level
of ECM binding of untreated liposomes was set
as 100%. Values are mean SD of at least three
independent experiments. *p<0.001 versus both
the non-treated control and the control siRNA-
treated sample.
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36]. Clathrin hub expression was detected, using anti-
T7 epitope antibody, by 24 h and reached itsmaximum
48 h after transfection (Fig. 6A), at which time uptake
of SCL by the transfected cells was examined.
Figure 6B shows that clathrin hub expression inhib-
ited ~50% liposomal endocytosis. Taken together,
these data are consistent with the notion that both
clathrin-dependent and -independent (or caveolae/
lipid raft-dependent) pathways are involved in the
internalization of SCL by the glioblastoma cells.
Discussion
In this study, we have shown that sulfatide was
specifically required for effective binding of phospho-
lipid liposomes to the ECM of human glioblastoma
cells such as U-87MG and CCF-STTG1 cells. In
contrast, when ganglioside GM1 and GalCer were
used to formulate the liposomes, no detectable bind-
ing of such liposomes were observed (Fig. 1A, B). The
specific requirement for sulfatide has been further
confirmed by examining the effect of anti-O4 anti-
body on binding of SCL to the ECM of the glioblas-
Figure 5.Effects of pretreatment ofU-87MGcells with 2-HCD, PI-PLC, sucrose and sphingosine on the internalization of sulfatide/DOPE
(30:70, mol/mol) liposomes. The cells were pretreated with 1% (w/v) 2-HCD (A), 0.3 IU/ml PI-PLC (B), 0.5 M sucrose (C) or 5 mM
sphingosine (D), respectively, for 1 h at 378C before the liposomeswere introduced. Control cells were treatedwith vehicle and the uptake
of Rh-PE-labeled liposomes by control cells was set as 100% (not shown in the figure). Values aremean SDof at least three independent
experiments. *p<0.01 versus the uptake levels of both CTxB (or Bodipy-LacCer) and transferrin.
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toma cells (Fig. 2). The small reduction in ECM
binding caused by IgM could be due to sterical
hindrance resulting from nonspecific binding of IgM
at the liposomal surface, which, due to its large
molecular weight, would affect the interactions be-
tween sulfatide and its receptor(s) at the cell surface.
This postulation was supported by the observation
that albumin, at a similar concentration, did not affect
the binding of the liposomes (data not shown). We
hypothesize that TN-C, the ECM glycoprotein, plays
an essential role in mediating the binding of SCL.
Firstly, it is well known that TN-C binds specifically to
sulfatide but not to other gangliosides or GalCer [11],
which is consistent with our observations in this work
(Fig. 1). Secondly, inhibition to TN-C expression by
VD3 caused significant reduction in binding of SCL to
the ECM of the glioblastoma cells (Fig. 3B). Thirdly,
knockdown of TN-C by specific TN-C siRNA pro-
vided supporting evidence for a link between this
matrix protein and SCL binding (Fig. 4B). Finally, the
expression level of tenascins is known to be much
higher than that of other sulfatide-binding ECM
proteins like laminin in human glioblastoma cells
[37]. In addition, expression of TN-C is highly up-
regulated in many different cancers (reviewed in [3]).
Hence, a targeted liposomal drug delivery system
mediated by specific sulfatide-TN-C interactions may
hold the promise of development of new therapeutics
for treatment of a wide spectrum of cancers.
The binding and internalization of SCL by U-87MG
cells are well-defined sequential events. Fluorescence
real-time images showed that liposomes bound to the
ECM were detachable from the cell bodies after the
cells were treated with trypsin, while those inside the
cells were not affected (data not shown). This
observation that binding of SCL to the ECM was
sensitive to trypsin digestion also supports the involve-
ment of ECM protein components in binding of the
liposomes. It is still unclear what the internalization
machinery is at this stage. Nevertheless, it has been
demonstrated that both clathrin-dependent and –
independent endocytosis contributed to the uptake of
SCL (Figs 5 and 6). Since the particle size affects the
route of its internalization [33], a simple explanation
for such a dual entry mechanism could be the intrinsic
heterogeneous size distribution of the liposomes.
However, this does not rule out the possibility that
distinguishable internalization machineries exist for
clathrin-dependent and -independent endocytosis of
the liposomes. For effective intracellular drug and/or
gene delivery, early release of the cargo is always
desirable to avoid lysosomal degradation in clathrin-
mediated endocytosis. Presence of DOPE definitely
reduces the chance of lysosomal degradation as the
liposomes would become unstable in endosomes with
an acidic pH [16, 17]. Moreover, it is advantageous to
have a significant portion of SCL internalized via the
clathrin-independent pathway, e.g. , internalization
mediated by caveolae/lipid rafts in which the caveo-
somes could deliver their contents into other non-
lysosomal subcellular compartments. Bypassing the
acidic and harmfulmilieu is always considered amajor
advantage, among others, for drug delivery via the
clathrin-independent pathway over the clathrin-de-
pendent pathway [38, 39].
In conclusion, we have demonstrated, at least theo-
retically, a potential targeted drug delivery system
utilizing sulfatide as the binding or targeting motif,
which should markedly improve the targeting effi-
ciency of drug delivery, and thus treatment effect for
cancers that involve overexpression of sulfatide-bind-
ing proteins like TN-C. Because expression of TN-C is
known to be highly up-regulated in many different
types of cancers, use of this natural lipid-guided
liposomal formulation of anticancer drugs thus pos-
sesses promising clinical potential, and preliminary
therapeutic effects of SCL with encapsulated doxor-
ubicin have recently been evaluated in vitro in nude
Figure 6. Effect of expression of clathrin hub on internalization of
sulfatide/DOPE (30:70, mol/mol) liposomes by U-87MG cells. (A)
Expression of clathrin hub inU-87MGcells as detected byWestern
blot with anti-hub antibody. The blots are representatives of three
independent experiments performed.b-Actinwas used as a loading
control. (B) Internalization of Rh-PE–labeled sulfatide/DOPE
(30:70, mol/mol) liposomes was studied in U-87MG cells 48 h after
clathrin hub transfection. Values are mean  SD of at least three
independent experiments. *p<0.01 versus the non-transfected
control and the vector-transfected cells.
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mice xenografts of human glioma cells [40]. Further-
more, as the stability of this drug delivery system is pH
sensitive [16, 17] and its internalization by cells
involves both clathrin-dependent and –independent
pathways, it may have broad applications for delivery
of substances such as imaging agents, therapeutic
proteins and peptides directly into the cytoplasm of
the target tumor cells. All these warrant further
exploration.
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SCLs accumulated quickly in the tumor area in the first 60 minutes. At the same time 
point, mice received i.v. injection of other liposome formulations with similar size 
distributions (50 nm) showed little accumulation in the tumor and the brain 
contralateral to the tumor. This result is consistent with our previous findings in cell 
culture studies (Shao 2006). Those liposomes composed of GM1, DOPG and GalCer 
with DOPC were not effectively taken up by glioma cells (Chapter 2). Given the same 
size distribution which enables the permeable of liposomes to the compromised BBB, 
the superior accumulations of SCLs in the brain tumor could be attributed to the 
specific sulfatides-glioma interactions. 
 
SCLs could be found evenly diffused in the whole volume of the tumor mass 
suggested that SCLs could overcome of the interstitial fluid pressure in the tumor 
mass. Interstitial fluid pressure is a big obstacle for cancer therapy which prevents the 
therapeutic reagents to reach the tumor center and results in incomplete killing of the 
tumor cells and tumor reoccurrences. We have previously shown that SCLs could bind 
to the ECM of glioblastoma through the interactions between the TN-C and sulfatides 
in in vitro cell culture studies (Shao 2006, Shao 2007). In the orthotopic glioma 
xenografts animal model studies, TN-C were well expressed in the whole volume of 
the tumor and highly expressed at the tumor edges. (Fig.6.7. column b of A-B). TN-C 
was also found in outside the main body of the tumor (Fig.6.7. A(b) ). It was found 
that the SCLs coexist well with TN-C in the tumor volume. High TN-C levels were 
found in those normal brain areas adjacent to the tumor body. It is most probably due 
to those invading tumor cells which over-expressing the TN-C..  
In this part of our studies, we found that SCLs could pass through the BBB especially 
when the animals bearing a tumor. Optimal tumor accumulations of SCLs could be 
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